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Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a heterogeneous cancer 
at the genetic and cellular levels. Whole exome-sequencing studies have identified 
inactivating mutations in NOTCH1 in 11-15% of SCCHN. It was the aim of this 
research to correlate genetic changes in NOTCH1 expression with changes in cell 
behaviour. 
 
A human oral SCC line harbouring two truncating NOTCH1 mutations was rescued 
via lentiviral transduction of the NOTCH intracellular domain (NICD). In vitro assays 
provided evidence to suggest that expression of NICD was able to inhibit proliferation, 
clonogenicity and cell migration into a scratch wound. At high expression levels, 
NICD also promoted differentiation. Microarray data supported the in vitro findings 
and further associated NOTCH1 expression with increased cell death and decreased 
angiogenesis. SERPINE 1 was highlighted as a potential regulator of NICD-mediated 
changes in cell behaviour. A high number of histone related genes were also found to 
be down-regulated in response to increased NICD expression. These findings were not 
explored further in this thesis but are of interest for future work.   
 
Microarray analysis also identified SPANXA1/2 as the most up-regulated gene in 
response to NICD expression. The fold change increase of SPANXA1/2 was 3x that 
of any other gene. In order to investigate the functional consequence of SPANXA1/2 
expression, a shRNA system was used to knockdown SPANXA1/2 in the NICD-
rescued cell line. Primary findings provide evidence to associate the expression of 
SPANXA1/2 with a potential increase in cell proliferation, increased cell migration 
into a scratch wound and a change in cell morphology.  Current literature suggests that 
changes in cell morphology may be associated with the inhibition of epithelial to 
mesenchymal transition (EMT) and the induction of mesenchymal to epithelial 
transition (MET). However, data is preliminary and further studies are required to 
confirm this association. 
 
A murine xenograft model was established to assess tumour formation in vivo. The 
expression of NICD resulted in significantly larger tumours. However, no difference 
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in proliferation was recorded over the two hour period prior to sacrifice. Histological 
observations also suggest that the expression of NICD may be associated with reduced 
keratin pearl formation and increased areas of what pathologically presents as comedo-
type necrosis. Finally, the expression of NICD was not found to give rise to any 
significant difference in angiogenesis. Together, these findings suggest a tumour 
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The aim of this thesis is to explore the functional consequence of changes in NOTCH1 
expression in Squamous Cell Carcinoma of the Head and Neck (SCCHN). This chapter 
provides a general overview of SCCHN, NOTCH signalling and what is currently 
understood about the role of NOTCH1 in SCCHN.  
 
 
1.1 Squamous Cell Carcinoma of the Head and Neck 
 
1.1.1 Epidemiology  
 
Each year, there are over 550,000 new cases of head and neck cancer and 
380,000 deaths attributed to the disease worldwide. The disease most commonly 
presents in the 5th-7th decade of life and males are significantly more affected than 
females, with the ratio ranging from 2:1 to 4:1 (Fitzmaurice, et al., 2017).  
Squamous cell carcinomas (SCCs) are the most common malignant tumours of 
the head and neck region, accounting for more than 90% of all head and neck cancers. 
Squamous Cell Carcinoma of the Head and Neck (SCCHN) is currently recognised as 
the sixth most common cancer by incidence worldwide and, despite preventative 
measures, rates are projected to continue to increase (Jemal, et al., 2007; Union for 
International Cancer Control, 2014).  
 
1.1.2 Risk Factors  
 
SCCHN can be categorised into clinically distinct human papillomavirus 
(HPV) positive and negative cases. Approximately 25% of all SCCHN and 90% of 
oropharyngeal cancers are as a result of infection with the HPV virus, in particular 
HPV-16 (Gillison, et al., 2000). Tobacco use and moderate alcohol consumption are 
the most prevalent risk factors and act synergistically as causative agents in the 
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development of non-viral SCCHN. It is predicted that abstinence from these 
substances could reduce incidence by up to 90% (Rousseau & Badoual, 2012).  
To a lesser extent, diet, occupational exposure to substances such as 
formaldehyde or asbestos, infection with the oral microflora candida, allergies, a 
weakened immune system, infection with the Epstein-Barr virus and poor oral health 
have also been demonstrated to increase risk. Prolonged U.V. exposure has also been 
associated with cancers of the lip (Khalesi, 2016). In addition, a number of inherited 
genetic conditions, such as Fanconi Anemia and Bloom’s Syndrome, are known to 
predispose individuals to SCCHN (Kutler, et al., 2003).  
 
1.1.3 Classification  
 
Several histological variants of SCCHN are recognised, some of which are 
associated with unique risk factors and have different prognoses. For example, 
verrucous carcinomas are well-differentiated, locally destructive SCCs that rarely 
metastasise, whereas basaloid SCCs are a highly aggressive variant. Conventional 
SCC is the most commonly diagnosed neoplasm (Pereira, et al., 2007) 
Non-viral tumours are the most frequent SCCHN, making up 85% of cases. At 
a molecular level, non-viral tumours have a significantly increased mutational 
landscape compared to those associated with the HPV or Epstein-Barr virus. HPV-
related tumours are more often associated with tumours at the back of the oral cavity, 
oropharynx, hypopharynx and larynx rather than tumours of the tongue or lip (Gillison, 
et al., 2000; Shah, et al., 2014). 
SCCHN encompasses a number of pathologically distinct diseases that can be 
characterised by the sub-location of the primary tumour: (1) oral cavity and tongue, 
(2) nasal cavity and paranasal sinuses, (3) nasopharynx, oropharynx and hypopharynx, 
and (4) larynx (Figure 1.1) (National Cancer Institute, 2013). Non-viral conventional 
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1.1.4 Squamous Epithelium  
 
 SCCHN begins with the malignant transformation of the squamous cells that 
make up the epithelial lining of the mucosal surfaces of the upper aero-digestive tract. 
The epithelial linings of the body protect underlying tissues from damage by forming 
an effective barrier against environmental stresses. The moist linings of the body, such 
as those lining the oral cavity, nasal passage and pharynx, are mucous membranes. In 
the oral cavity, this lining is called the oral mucosa. The skin is the dry covering of the 
body exterior and is continuous with the oral mucosa. The skin and oral mucosa share 
structural similarities and much of what is understood about the structure and function 
of the oral mucosa has been learnt from skin and vice versa (Squier & Brogden, 2010).  
This squamous epithelium can be sub-divided into three types of sub-mucosa: 
(1) the masticatory mucosa, which is a stratified squamous keratinized epithelium (e.g. 
gingiva), (2) the lining mucosa, a non-keratinized epithelium (e.g. inner lining of the 
cheeks and oesophagus), and (3) the specialised mucosa, a non-keratinized epithelium 
Figure 1 1: Common primary tumour sites of squamous cell carcinomas of the head and neck. Figure 
adapted from the National Cancer Institute, 2013 (National Cancer Institute, 2013). 
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that contains nerve endings for taste perception (e.g. dorsal and lateral surfaces of the 
tongue) (Nanci, 2013). Keratinized epithelium resembles the epidermis of the skin and 
lines areas that are subject to mechanical force. Conversely, non-keratinized 
epithelium lines regions that require more flexibility (e.g. for chewing or swallowing) 
(Squier & Brogden, 2010; Papagerakis, et al., 2014). Figure 1.2 details the anatomic 



















 The human epithelium is made up of stratified layers. During normal 
homeostasis, the epithelium is maintained by stem cells in the basal layer. As the cells 
progress towards terminal differentiation, they migrate upwards through the 
suprabasal layers until they are eventually sloughed off at the epithelial surface. 
Normally, the rates of cell proliferation and cell loss are balanced and form a ‘steady 
state’ (Mackenzie & Fusenig, 1983; Calenic, et al., 2015). The human skin is made up 
of interfollicular epidermis as well as structures such as sebaceous glands and hair 
follicles. Evidence suggests the existence of multiple stem cell pools that, although 
able to differentiate into all epidermal lineages, are lineage-restricted as a result of 
Masticatory Mucosa 
Lining Mucosa 
Specialised Mucosa  
 
Figure 1 2: The anatomic location of the three types of sub-mucosa in the oral cavity. Black = 
masticatory mucosa. Grey shading = lining mucosa. Stippled = specialised mucosa. Figure adapted 
from Roed-Petersen and Renstrup, 1969 (Roed-Petersen & Renstrup, 1969). 
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local environmental cues (Oshima, et al., 2001; Ito, et al., 2005; Silva-Vargas, et al., 
2005; Clayton, et al., 2007; Levy, et al., 2007). 
 Early epidermal studies identified a proliferative heterogeneity in cell cycle 
time. This gave rise to the hypothesis that stem cells the basal layer divide 
asymmetrically to form both a replacement stem cell and a transit amplifying cell, an 
intermediate cell which retains self-renewal potential for a small number of divisions 
before becoming a post-mitotic cell. Post-mitotic cells are no longer able to divide and 
undergo terminal differentiation as they progress through the suprabasal cell layers. 
As such, a single stem cell surrounded by transit amplifying cells was predicted to 
reside at the base of a column (or epidermal proliferative unit (EPU)) made up of their 
differentiated progeny (Potten, 1988).  
Lineage tracing studies have been performed to track the fate of tail epidermal 
stem cells in the basal layer of a murine model. Findings confirmed that terminally 
differentiated cells of the suprabasal layers were the progeny of undifferentiated cells 
beneath them. However, linage tracing did not support the EPU model. Studies 
revealed that the average number of basal cells per clone increased over time. The 
clones remained cohesive and formed distributions consistent with a single progenitor 
cell capable of undergoing unlimited divisions (Clayton, et al., 2007).  
A second model proposes that homeostasis in the epithelium is maintained by 
a balance in cell division in a subset of basal cells. When a cell divides, the daughter 
cells can retain the ability to undergo self-renewal or be fated to undergo terminal 
differentiation. A cell division can be symmetric, whereby both daughter cells share 
the same destiny or asymmetric, whereby one follows each fate (Clayton, et al., 2007; 
Jones, et al., 2007; Watt & Jensen, 2009; Ghadially, 2012).  
When primary cultures of epidermal cells are derived three types of colonies 
are formed, namely holoclones, meroclones and paraclones. Holoclones have a long 
replicative lifespan and are considered representative of stem cells. Paraclones have a 
short replicative potential and are thought to behave as transit amplifying cells. 
Meroclones act as an intermediate. Culture of holocone populations give rise to 
paraclones and meroclones (Barrandon, 1987). In a recent study, the De Luca group 
described the use of autologous transgenic keratinocytes to regenerate an entire 
functioning epidermis for a 7 year old junctional epidermolysis bullosa patient. The 
group demonstrated that the original post graft cultures where made up of many 
holoclones, meroclones and paraclones with thousands of genetic integrations. After 8 
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months, the number of integrations had dropped to a few hundred and those found in 
paraclones and meroclone were the same as those found in the holoclone population. 
It was therefore predicted that the meroclons and paraclones were lost over time and 
the skin graft was maintained by a limited number of holoclones or long-lived stem 
cells (Hirsch, et al., 2017).  
In keratinized epithelium of the oral cavity, the basal layer is made up of 
cuboidal cells which are attached to the underlying basement membrane. These cells 
begin to acquire mechanical strength through the formation of a cytoskeletal network 
of keratin filaments. On initiation of terminal differentiation, cells lose adherence to 
the basement membrane and migrate upwards to form the spinous layer, which 
comprises several layers of prickle cells. Cells then advance to form the granular layer 
of cells filled with keratohyaline granules. At this stage, the keratin filaments form 
bundles and cells lose organelles, become flattened and secrete phospholipids stored 
in lamella bodies. Finally, terminally differentiated cells at the epithelial surface make 
up the cornified layer. By this stage, cells are flat, free of nuclei and full of keratin 
(Figure 1.3a). As cells migrate apically from the basal layer of non-keratinized 
epithelium, they also differentiate and flatten. However, they do not accumulate 
keratin or lose their nuclei. As such, the granular and cornified layers are replaced with 
intermediate and superficial layers (Figure 1.3b) (Janes & Watt, 2006; Nanci, 2013; 
Calenic, et al., 2015). 
 
1.1.5 Clinical Presentation 
 
 Patients with SCCHN present with a variety of symptoms depending on the 
location of the primary tumour. The most common signs of oral cancer are a sore in 
the mouth that doesn’t heal and / or a discomfort in the mouth that doesn’t go away 
(Macmillan, 2017).  
 











 The cancer stage, tumour location and patient health are considered in tailoring 
a treatment plan. Conventionally, in early stage cancers, surgery and radiotherapy are 
the usual treatments. At later stages, a combination of surgery, post-surgery 
radiotherapy and chemotherapy is often used (Macmillan, 2017).  
 The anatomical sites of SCCHN are important for speech, swallowing, taste 
and smell. As such, the effect of both the cancer and treatment often has a considerable 
impingement on quality of life. Frequently, a significant quantity of tissue is required 
to be removed during surgery. As such, organ preservation has been a major 
consideration over the past three decades and reconstructive work is often performed 
(Poole, et al., 2001).  
Despite improvements in treatment, survival rates have remained largely 
unchanged. Neoadjuvant chemotherapy is sometimes used in combination with 
radiotherapy in order to shrink tumours prior to surgery. However, this therapy has 
only been seen to improve outcome in a select subset of patients with locally advanced 
and unresectable SCCHN (Vishak, et al., 2015).  
Figure 1 3: The organisation of the human stratified oral epithelium. (a) The keratinized epithelium is 
maintained by progenitor cells in the basal layer. On initiation of differentiation, cells flatten, acquire 
keratin and lose their nuceli as they progress through the spinous, granular and cornified layers. 
Terminally differentiated cells are eventually sloughed off from the epithelial surface. (b) As cells 
migrate apically through the non-keratinized epithelium, they also differentiate and flatten. However, 
they do not acquire keratin or lose their nuclei. Therefore the granular and cornified layers are replaced 
with the intermediate and superficial layers.  Figure adapted from Calenic et al. (Calenic, et al., 2015). 
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Existing chemotherapeutic agents are toxic and non-selective. By better 
understanding the molecular mechanisms underpinning SCCHN, properties specific 
to the tumours can be exploited to target drugs to cancer cells whilst having a minimal 
effect on other cells of the body.  Dysregulation of the epidermal growth factor 
receptor (EGFR) pathway is detectable in most SCCHN patients, with a high 
expression of EGFR being associated with poor survival. Arguably, the most 
significant advancement in SCCHN treatment in the past decade has been the approval 
of cetuximab, an EGFR inhibitor. Although effects are modest, research has shown 
that the use of cetuximab with cisplatin-based chemotherapy or radiotherapy has 




SCCHN prognosis varies according to the stage at diagnosis, which is 
determined by histopathology of the primary tumour post-surgery and the extent of 
lymph node and distant metastasis (Rousseau & Badoual, 2012).  Patients diagnosed 
at early clinical stages (I and II) have similar survival rates of 70-90%; however 
prognosis of patients with advanced stage disease is strongly associated with tumour 
location and histopathology (Denis, et al., 2004). Notably, two-thirds of patients 
present with advanced stage disease. (Duray, et al., 2011; Leemans, et al., 2011; 
Rothenberg & Ellisen, 2012). 
Unlike most solid tumours, where metastatic spread is the main cause of death, 
the dominant clinical problem in SCCHN is local recurrence or locally progressive 
disease. Despite surgical removal presenting tumour-free margins, 10-30% of patients 
develop a locally recurrent tumour. This persistence post-treatment is a major clinical 
challenge and responsible for a substantial proportion of SCCHN mortalities (Tabor, 
et al., 2004; Duray, et al., 2011; Rousseau & Badoual, 2012). This high level of 
recurrence is partially explained by the field cancerisation model, which is discussed 
further in section 1.1.8. 
 In the U.K., as of 2016, the overall five year survival for cancers of the oral 
cavity was approximately 55%. Hypopharyngeal cancers had the lowest five year 
survival of all SCCHN subtypes at approximately 28%. Conversely, cancers of the 
salivary gland had the highest five year survival at approximately 67% (Cancer 
Research UK, 2016).   
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1.1.8 Field Cancerisation 
 
As aforementioned, post treatment, SCCHN patients have a high level of 
recurrence at the primary tumour site as well as a high incidence of independent 
tumour formation elsewhere in the head and neck region. In 1953, Slaughter et al. 
studied the presence of histologically abnormal tissue surrounding oral SCCs. The 
group subsequently proposed the ‘field cancerisation’ model, in which primary 
tumours develop from a field of dysplastic pre-cancerous tissue (Slaughter, et al., 
1953). In 1996, Califano’s group confirmed the molecular basis of this theory, 
associating loss of heterozygosity at specific loci with dysplasia (Califano, et al., 
1996).  
This progression model is comprised of the following stages: (1) a cell capable 
of self-renewal acquires a genetic alteration, (2) this cell and its similarly mutated 
daughters make up a clonal unit termed a patch, (3) cumulative genetic alterations 
advances this patch into a field made up of various sub-clones, (4) this field expands 
and displaces areas of normal epithelium, (5) a carcinoma develops through clonal 
selection of cells within the field (Braakhuis, et al., 2003).  
The clonal units are often detectable through mutations in Tumour Protein-53 
(TP53), widely recognised as one of the first oncogenic changes in the squamous 
epithelium (Nees, et al., 1993; Rothenberg & Ellisen, 2012). Molecular analysis of 
SCCHN has identified a number of chromosomal aberrations that precede histological 
changes in the field (Welkoborsky, et al., 2000; Tabor, et al., 2001). Using these 
markers, Tabor et al. confirmed that at least 35% of oral and oropharyngeal tumours 
are surrounded by this genetically-altered epithelium (Tabor, et al., 2001).  
 Clinically, the field cancerisation model provides an explanation for the 
frequent recurrence of tumours at the same anatomical location from which a tumour 
has been surgically excised. These fields are often found at the margins of surgical 
excisions and hence remain in the patient post-surgery (Leemans, et al., 2011). Studies 
have shown that these fields play a major role in local tumour recurrence and are a 
source of second primary tumours (Tabor, et al., 2004; Roesch-Ely, et al., 2007; 
Schaaij-Visser, et al., 2009).  
By investigating squamous epithelia adjacent to and at a variety of sites 
significantly separated from the primary tumour, different mutations in TP53 have also 
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been recorded in distant epithelia in the same patient. This data provides a potential 
molecular basis for the development of multiple tumours (Nees, et al., 1993).  
The detection of biomarkers for areas of field cancerisation has tremendous 
potential in early detection and clinical outcome (Jaiswal, et al., 2013).  
 
1.1.9 Heterogeneity  
 
SCCHN is strikingly heterogeneous and differs significantly in aggressiveness 
and response to treatment (Ramshankar & Krishnamurthy, 2013). In part, this is due 
to differences at the site of the primary tumour. However, RNA and DNA expression 
profiling has highlighted molecular heterogeneity and complex karyotype changes 
independent of tumour-location (Hermsen, et al., 2001; Jin, et al., 2006). Subclasses 
of SCCHN have been classified by their genetic profiles and shown to harbour distinct 
clinical behaviours and ultimately different prognoses (Chung, et al., 2004; De Cecco, 
et al., 2015). Comparative genome hybridisation has also identified sub-groups based 
on levels of chromosome aberration and confirmed a negative correlation between 
groups with higher aberrations and survival (Smeets, et al., 2009).  
Biologically, limited understanding of this heterogeneity makes it particularly 
challenging to identify causative cancer genes. Clinically, it is hindering accurate 
prognostics, treatment planning, and translation of new therapies. 
In 2011, Agrawal and Stransky simultaneously published next generation 
sequencing data for 32 and 74 SCCHN tumours respectively. These studies 
highlighted the power of whole exome sequencing as a tool for exploring cancer 
genomics and began to elucidate the genetic heterogeneity of SCCHN (Agrawal, et al., 
2011; Stransky, et al., 2011).  
 
1.1.10 Analysis of SCCHN epidemiology using The Cancer Genome Atlas 
(TCGA) 
 
The results shown in this section are based upon data generated by the TCGA 
Research Network: http://cancergenome.nih.gov/. TCGA is a publically accessible 
database of cancer sequencing data from international research groups. The cBioPortal 
for Cancer Genomics tool was used to mine the most recent large-scale SCCHN 
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genomic data set from TCGA to explore the mutational landscape (Cerami, et al., 
2012; Gao, et al., 2013).  
Tumour biopsies were sequenced for a total of 504 patients. Consistent with 
epidemiology data, a high proportion (73%) of patients were male and the most 
common age of diagnosis was 50-70 years. The overall mutation frequency per 
primary tumour varied from less than 30 to more than 300. Mutation count followed a 
normal distribution around the median of 90-120. The frequency of mutations is not 
specified over the count of 300; however, approximately 8% of samples harboured 
more than 300 mutations (Figure 1.4). For reference, the average frequency of 
mutations in solid tumours ranges from 33-66. Leukaemia’s have the lowest frequency 
of mutations at 9.6 per tumour whereas the highest are found in lung cancers and 
melanomas, which have an average of approximately 200. The higher than average 
mutation frequency may be associated with the relatively high exposure of the head 
and neck region to environmental and carcinogenic influences. This is especially true 













































1.2 The NOTCH Signalling Pathway 
 
1.2.1 Functionality  
 
 The NOTCH pathway is a highly conserved signalling system that was first 
described in Drosophila (Poulson, 1939). It is a key player in cell-to-cell 
communication and functions via the processes of lateral inhibition and boundary 
induction (Cabrera, 1990). NOTCH signalling plays a vital role in development and is 
involved in a wide array of key cellular processes such as the government of cell fate, 
the maintenance of stem cells, cell survival, proliferation and apoptosis (Go, et al., 
1998; Miele & Osborne, 1999; Ehebauer, et al., 2006; Bray, 2006; Kopan & IIagan, 
2009). In order to regulate these processes, NOTCH signalling interacts with a range 
Figure 1 4: Investigation into sequencing data for SCCHN patients stored by TCGA. a) Patient gender. 
b) Patient age at diagnosis. c) Frequency of mutations per tumour. Figure adapted from cBioPortal 
(Cerami, et al., 2012; Gao, et al., 2013). 
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of different pathways and mediates both cell autonomous and non-autonomous 
changes (Watt, et al., 2008). The core NOTCH signalling pathway signals through 
‘CBF-1, Suppressor of Hairless, Lag-2’ (CSL; named after its mammalian, Drosophila 
and Caenorhabditis Elegans orthologues) (Kopan & IIagan, 2009). However, 
signalling can occur through CSL dependent and independent mechanisms (Brennan 
& Gardner, 2002; Arias, et al., 2002; Bray, 2006). 
 
1.2.2 NOTCH Receptors 
 
 NOTCH proteins are heterodimeric single-pass Type 1 transmembrane 
receptors that reside at the cell surface. They are made up of the NOTCH extracellular 
domain (NECD) and the NOTCH transmembrane and intracellular domain (NTMIC). 
These two subunits are held together by non-covalent interactions which cause auto-
inhibition of the protein. In humans there are four known NOTCH isotypes (NOTCH 
1-4) which share this same basic structure (Kopan & IIagan, 2009). 
 The NECD is located at the N-terminus and is primarily involved in ligand 
binding. Depending on isotype, it comprises 29-36 tandem epidermal growth factor 
(EGF)-like repeats with embedded ligand binding sites (Wharton, et al., 1985). They 
are each approximately 40 amino acids in length and undergo extensive post-
transcriptional N- and O- glycosylation that is thought to regulate ligand specificity.  
 The EGF-like repeats are flanked by a Negative Regulator Region (NRR), 
which is made up of three Lin12-NOTCH repeats (LNR) and a heterodimerization 
domain. The NRR prevents ligand-independent activation of NOTCH (Gordon, et al., 
2007).  
 The NOTCH intracellular domain (NICD) is comprised of four distinct 
domains. (1) The RBPJ associated module (RAM) domain is responsible for initiating 
transcriptional activation by binding to transcription factor CSL in the nucleus 
(Johnson & Barrick, 2012). (2) Seven ankyrin repeats make up the ANK domain and 
mediate protein interactions involved in the activation of chromatin remodelling 
proteins (Kadam & Emerson, 2003). (3) NOTCH 1 and 2 contain a transcriptional 
activator domain (TAD) that is absent in NOTCH 3 and 4. (4) Finally, a proline, 
glutamic acid, serine, threonine-rich (PEST) domain resides at the C-terminus. The 
PEST domain contains degradation signals that regulate the stability and 
ubiquitination of the NICD (Öberg, et al., 2001). The NICD also harbours two nuclear 
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localisation signals (NLS), situated before and after the ANK domain (Fryer, et al., 
2004; Kopan & IIagan, 2009; Yavropoulou & Yovos, 2014). The common structural 


















1.2.3 The Canonical NOTCH Signalling Pathway 
 
 Despite the wide-scale influence of NOTCH signalling, the pathway is 
relatively simple. Following proteolytic cleavage, the NICD translocates directly to 
the nucleus to act as a transcriptional regulator; there is no amplification of signal via 
secondary messenger cascades. The number of NOTCH ligands and receptors at the 
cell membrane is regulated by endocytosis and membrane trafficking (Bray, 2006; 
Kopan & IIagan, 2009; Kandachar & Roegiers, 2012). 
On translation, the receptor is glycosylated by enzymes O-fut and Rumi. Most 
NOTCH receptors then undergo a site-1 cleavage event by furin-like convertases 
within a loop protruding from the heterodimerization domain. This cleavage event 
converts the NOTCH polypeptide to the NOTCH extracellular domain – NOTCH 
transmembrane and intracellular domain heterodimer (NECD-NTMIC). In cells 





Figure 1 5: Basic structure of NOTCH receptors. The NOTCH extracellular domain (NECD) is made 
up of epidermal growth factor (EGF)-like repeats and a negative regulator region (NRR). The NRR 
comprises Lin12-NOTCH repeats (LNR) and a heterodimerization domain (HD). The transmembrane 
domain (TMD) spans the cell membrane. The NICD comprises four distinct domains: (1) the RBPj 
associated module (RAM), (2) ankyrin (ANK), (3) a transcriptional activator domain (TAD) that is 
absent in NOTCH 3 and 4, and (4) a c-terminal proline, glutamic acid, serine, threonine-rich (PEST) 
domain. The NICD also harbours two nuclear localisation sequences (NLS). Figure adapted from 
Yavropoulou and Yovos (Yavropoulou & Yovos, 2014). 
  
35 | P a g e  
 
enzymatic Fringe activity, resulting in altered ability of NOTCH receptor activation 
by specific ligands (Kopan & IIagan, 2009; Kakuda & Haltiwanger, 2017). 
NOTCH ligands belong to the Delta / Serrate / LAG-2 (DSL) protein family 
and are also single-pass transmembrane proteins. In mammals, there are two classes 
of recognised ligands known as Delta-like (DLL) and Jagged (JAG), which differ by 
the absence of a cysteine rich domain in the DLL ligands. Signalling occurs via 
juxtacrine signalling, with receptors and ligands interacting over short distances 
between neighbouring cells (Gray, et al., 1999).  
As aforementioned, ligands bind to the EGF-like repeats of the NECD. It is 
now understood that the repeats are able to mediate ligand specificity. Repeats 11-12 
are responsible for productive interactions with ligands expressed on neighbouring 
cells (trans interactions), whereas repeats 24-29 are responsible for the inhibitory 
interaction of NOTCH receptors with ligands co-expressed on the same cell (cis 
interactions). Many of the EGF-like repeats are also able to bind calcium, which 
contributes to the structure and affinity of NOTCH to its ligands (Raya, et al., 2004; 
Cordle, et al., 2008; Kopan & IIagan, 2009) 
Ligand binding to the EGF-like domain induces the proteolytic cleavage of the 
NECD by an ADAM-family metalloproteinase at site-2, twelve amino acids from the 
TMD within the NRR (Brou, et al., 2000). It is hypothesised that mechanical force 
generated by the initiation of ligand endocytosis leads to conformational changes that 
exposes the S2 site from the NRR. On release, the ligand-receptor complex is 
endocytosed into the ligand-expressing cell (Ploscariu, et al., 2014).  
The remaining membrane-tethered intermediate NOTCH extracellular 
truncation (NEXT) is a substrate for progressive site-3 cleavage within the TMD by 
an enzyme called γ-secretase (De Strooper, et al., 1999). The resultant cleaved protein, 
the NICD, is then able to translocate into the nucleus where it can modify gene 
expression through interaction with the transcription factor CSL via the RAM domain. 
In the absence of NICD, CSL associates with ubiquitous co-repressor proteins and 
represses gene-transcription; on binding NICD, allosteric changes induce the 
displacement of transcriptional repressors (Johnson & Barrick, 2012). The ANK 
domain of the NICD then also associates with CSL in order to recruit the co-activator 
Mastermind / Lag-3. This tri-complex is then able to recruit the MED8 mediator 
complex and activate transcription at target promoters. The most recognised 
downstream targets of the NOTCH pathway are the HES and HEY gene families 
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(Kitagawa, et al., 2001). Upon activation of NOTCH targets, the PEST domain of the 
NICD is targeted for ubiquitin-mediated degradation via phosphorylation (Jarriault, 
1995; Öberg, et al., 2001; Kopan & IIagan, 2009). An overview of the NOTCH 






























Figure 1 6: NOTCH Signalling Pathway. Transcribed NOTCH is glycosylated by O-fut and Romi and 
cleaved by a furin-like covertase to give rise to the  NECD-NTMIC heterodimer. Signalling occurs 
through association with a NOTCH ligand. On binding, the NECD is cleaved by an ADAM-family 
metalloproteinase and endocytosed.  The remaining NEXT can then be cleaved by γ-secretase. The 
resultant NICD is able to translocate into the nucleus where it can modify gene expression through 
interactions with the transcription factor CSL. In the absence of NICD, CSL associates with ubiquitous 
co-repressor proteins; on binding NICD, allosteric changes induce their displacement. NICD-CSL then 
associates with Mastermind; this tricomplex is able to recruit co-activators and activate transcription 
at target promoters, often the HES and HEY gene families. The complex is then targeted for 
proteasomal degradation. Figure reproduced from Kopan and IIagan (Kopan & IIagan, 2009).  
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1.2.4 NOTCH Signalling in Squamous Epithelium  
 
In the skin, NOTCH expression has been associated with growth arrest and 
entry into differentiation. The expression of NOTCH 1-3 in the epidermis has been 
well documented to coincide with cells that are committed to, or undergoing, terminal 
differentiation and is hence upregulated in the suprabasal layers. Active NOTCH 
signalling has also been confirmed in these cells by staining for NICD. (Lowell, et al., 
2000; Thélu, et al., 2002; Blanpain, et al., 2006; Vooijs, et al., 2007). Keratinocyte 
specific ablation of NOTCH1 gives rise to hyperplasia and deregulated expression of 
differentiation markers (Rangarajan, et al., 2001). Interestingly, although cells 
undergoing terminal differentiation must first exit the cell cycle, the processes of 
growth arrest and terminal differentiation are under separate control.  
Activation of NOTCH1 has been shown to induce growth arrest via p21 
induction. Induction is achieved through both direct CSL-dependent transcription and 
HES1 dependent up-regulation of transcription factor Nuclear Factor of Activated T-
cells (NFAT) (Rangarajan, et al., 2001; Mammucari, et al., 2005).  
NOTCH-induced differentiation is complex and incompletely understood. 
Loss and gain of function studies have associated canonical NOTCH signalling with 
commitment to terminal differentiation in epidermal cells. CSL has been shown to be 
required for both the induction of spinous layer genes and the repression of genes in 
the basal layer. HES1, which is expressed in the spinous layer, has been shown to be 
required for the induction of spinous layer genes. However, basal gene repression is 
mediated via HES1 independent mechanisms (Blanpain, et al., 2006).   
In normal epithelium, NOTCH and EGFR are negative regulators of each other 
and work together to regulate differentiation. EGFR expression is associated with 
increased proliferative potential, whereas NOTCH signalling promotes differentiation 
(Fuchs, 2008). In addition, ΔNp63 expression is highest in the basal cells where it 
encourages self-renewal and down-regulates NOTCH expression. Contrariwise, it 
becomes down-regulated during the process of terminal differentiation, coincident 
with NOTCH up-regulation (Dotto, 2009; Rothenberg & Ellisen, 2012).  
Moreover, NOTCH plays a role in cell adhesion and therefore cell location. 
The location of a cell in the epithelium is important as it dictates the microenvironment 
signals it receives. The NOTCH receptors, effectors and ligands themselves are 
expressed in a dynamic pattern throughout the epidermis (Figure 1.7). This patterning 
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also plays a major role in cell fate, i.e. directing self-renewal or differentiation (Watt, 
et al., 2008). 
JAG1 is primarily expressed in the suprabasal layers and in some cells of the 
basal layers. Deletion of JAG1 has been shown to cause a thickening of the epidermis 
(Estrach, et al., 2006). JAG2 and DLL1 are solely expressed in the basal cells and 
DLL1 expression has been associated with stem cell clusters (Watt, et al., 2008). 
DLL1-deficient epidermis presents with increased proliferation and disturbed 
differentiation marker expression (Estrach, et al., 2008; Watt, et al., 2008). Further, 
DLL1 inhibits NOTCH expression, protecting stem cells from NOTCH-mediated 
differentiation. Studies using transgenic reporter lines confirm an absence of NOTCH 
activity in the stem cell compartments. DLL1 has also been shown to actively promote 
differentiation in neighbouring cells (Lowell, et al., 2000). 
Consistent with findings of the skin, Casey et al. associated the activation of 
NOTCH1 with oral epithelial differentiation during development. Via the use of a 
JAG2 deficient mouse, the group showed that JAG2 is required for NOTCH1 
activation during differentiation (Casey, et al., 2006). There are fewer studies 
investigating the role of NOTCH in adult oral epithelium. However, staining for 
NOTCH1 reveals scanty and weak expression localised to the basal and parabasal 
layers (Sakamoto, et al., 2012; Yoshida, et al., 2013; Barakat & Siar, 2015). 
Whilst studies in skin can help to guide the understanding of molecular 
mechanisms in the oral mucosa, it is important to note that there are intrinsic 
differences between the tissues at both the structural and genetic levels. As a result, 
there are also functional differences between the two epithelia. For example, wounds 
in the oral mucosa heal faster and with less inflammation than equivalent wounds in 
skin. There are a number of potential evolutionary reasons for the differences between 
the two sites. Environmentally, the tissues have different base temperatures, microflora 
and exposure to air / salivary flow. Moreover, the microenvironment of the cells is 
affected by different anatomical structures such as the presence of hair follicles and 
sweat glands in skin but not in oral mucosa and the absence of salivary glands in skin 
(Slominski, 2014).  
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1.3 Genetic Alterations in the NOTCH Signalling Pathway in 
SCCHN 
 
1.3.1 Overview of the Role of NOTCH Signalling in SCCHN; Tumorigenic or 
Tumour Suppressive?  
 
NOTCH signalling is one of the most commonly deregulated signalling 
pathways in cancer and has been shown to exert both oncogenic and tumour-
suppressive effects. Activating translocations in NOTCH1 are present in a large 
percentage of T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic 
leukaemia, and diffuse large B-cell lymphoma tumours. As such, NOTCH is 
considered an oncogene in these cancers  (Weng, et al., 2004; Lee, et al., 2009; Puente, 
et al., 2011). Conversely, inactivating mutations in lung, myelomonocytic leukaemia 
and cutaneous cancers have indicated a tumour suppressor role for NOTCH (Wang, et 
al., 2011; Klinakis, et al., 2011; Sun, et al., 2014).  
Figure 1.4c details the frequency of NOTCH1 mutations in SCCHN but does 
not provide information on the nature of these mutations or how they affect the 
expression of NOTCH1 and NOTCH signalling pathway members. A number of 
Figure 1 7: Expression of NOTCH ligands and receptors in the epidermis. CL: cornified layer; GL: 
granular layer; SL: spinous layer. This figure is reproduced from Watt et al. (Watt, et al., 2008). 
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genetic studies have been performed to investigate the role of NOTCH signalling in 
SCCHN.  
Initially, NOTCH signalling was believed to play an oncogenic role in the 
development of SCCHN, largely as a result of the increased gene expression of 
pathway members. Approximately 30% of tumours are recorded to display an up-
regulation of downstream targets HES1/HEY1 as a result of mutations and copy 
number alterations in several components of the signalling pathway (Hijioka, et al., 
2010; Yoshida, et al., 2013; Gokulan & Halagowder, 2014; Sun, et al., 2014).  
In the past decade, evidence to suggest a tumour suppressor role for NOTCH1 
in SCCHN has come to light (Dotto, 2008; Agrawal, et al., 2011; Stransky, et al., 
2011). Mandasari et al. confirmed that the conditional knockout of NOTCH1 in the 
epidermis gave rise to increased susceptibility to oesophageal tumorigenesis in a 
mouse model. The protocol used a combined construct that induced the expression of 
single guide RNA targeting NOTCH1 and Cas9 via the KRT14 promotor (Mandasari, 
et al., 2016). 
Interestingly, in the skin, reduced NOTCH1 expression has been identified in 
pre-cancerous lesions and NOTCH1 mutations have been recorded in dysplastic 
regions prior to the development of cutaneous SCC, suggesting potential gate-keeper 
properties (South, et al., 2014). 
Subsequent comprehensive genome analysis of cell lines cultured from oral 
SCCs further supported a tumour suppressor role for NOTCH1 (Pickering, et al., 
2013). Members of the canonical NOTCH signalling pathway were found to be 
mutated in 66% of oral SCC patients. Copy number gains were recorded in ligands, 
JAG 1 and 2, and negative regulator NUMB. Consistent with mouse studies performed 
by Proweller et al., a loss of co-activator mastermind-like protein 1 (MAML1) was 
also recorded (Proweller, et al., 2006). As well as being able to activate the NOTCH 
pathway, JAG 1 and 2 are also able to inhibit signalling through cis-inhibition. As all 
other alterations pointed to a tumour suppressor function of NOTCH1, Pickering et al. 
suggested the amplifications were also likely to inhibit the signalling pathway 
(Pickering, et al., 2013).  
A further comprehensive genome analysis was carried out on a further 44 
SCCHN samples by Sun et al. in 2014. Consistent with previous studies, inactivating 
NOTCH1 mutations were recorded in 11% of tumours. Expression of downstream 
signalling targets HES1 and HEY1 was also documented as significantly reduced in 
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these samples (Sun, et al., 2014). Like Pickering et al., Sun et al. also revealed an 
upregulation of a number of NOTCH pathway components, including JAG 1 and 2. 
Interestingly, an upregulation of HES1/HEY1 was recorded in 32% of tumours, all of 
which were wild type for NOTCH1. The group put forth the notion of a mutually 
exclusive dual role of NOTCH signalling in SCCHN (Sun, et al., 2014). 
Inconsistent with previous studies, in 2016, Upadhyay et al. performed whole 
transcriptome sequencing on 68 early stage tongue SCC primary tumour samples and 
found only 4% harboured inactivating NOTCH1 mutations. Furthermore, the group 
observed a somatic amplification and upregulation in NOTCH1 expression in 
approximately 31% and 37% of tumours respectively. Cell lines with an upregulation 
of NOTCH1 were shown to express more stem cell markers and form spheroids. 
Spheroid forming ability was shown to be inhibited by the both the inhibition of 
NOTCH1 via a gamma secretase inhibitor and the shRNA mediated knockdown of 
NOTCH1 (Upadhyay, et al., 2016).  
Frequent mutations have also been recorded in ΔNp63 and F-Box and WD 
Repeat Domain Containing 7 (FBXW7), both of which are negative regulators of 
NOTCH. (Agrawal, et al., 2011; Stransky, et al., 2011). As previously described, 
ΔNp63 expression is highest in the basal cells where it encourages the renewal of 
keratinocytes and down-regulates NOTCH1 expression. Contrariwise, it becomes 
down-regulated during the process of terminal differentiation, coincident with Notch1 
up-regulation (Dotto, 2009; Rothenberg & Ellisen, 2012). FBXW7 is known to target 
NOTCH1 for degradation. Interestingly, a significant proportion of FBXW7 mutations 
identified in the whole exome sequencing studies were located in a region known to 
block this targeting mechanism (Baldus, et al., 2009; Agrawal, et al., 2011). Decreased 
expression of FBXW7 has been associated with poor prognosis in patients with 
oesophageal SCC (Naganawa, et al., 2010). Collectively, this data highlights the 
complexity of NOTCH1 signalling in SCCHN. It is possible that the NOTCH 
signalling pathway is able to confer both tumour suppressive and tumorigenic actions 
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1.3.2 Analysis of the TCGA Suggests Mutations in NOTCH1 may act as Drivers 
of SCCHN  
 
It is now understood that genetic variation exists not only between patients, but 
between cells of the same tumour. Tumours are made up of distinct subpopulations of 
cells known as ‘clones’. A recent paper has coined a ‘big bang’ model of tumour 
growth by which a cancer develops as a single uniform expansion of a large number 
of intermixed clones (Sottoriva, et al., 2015).  
Sequencing studies of human cancers have found the genomic landscape to be 
made up of two distinct classes of mutations, namely passengers and drivers.  
Passenger mutations make up the main body of mutations in a tumour but confer no 
selective growth advantage. Conversely, a typical tumour will carry 2-8 driver 
mutations in genes able to alter core cellular processes to promote tumorigenesis 
(Vogelstein, et al., 2013).  
Although simple to define, it can be difficult to identify which somatic 
mutations are drivers. Standard statistical methods often consider a high proportion of 
mutations in a particular gene indicative of driver function in that cancer. The predicted 
mutational effect is also considered (Vogelstein, et al., 2013). As aforementioned, 
NOTCH1 was identified as the second most frequently mutated gene in SCCHN after 
TP53, providing evidence for the role of NOTCH1 as a driver gene in SCCHN 
(Agrawal, et al., 2011; Stransky, et al., 2011). The alterations were further classified 
as follows: (1) 8.5% amplifications, (2) 10.5% deep deletions, (3) 35% truncating 
mutations, (4) 1% in-frame mutations, and (5) 45% missense mutations (Figure 1.8a).  
However, it is important to note that there is a difference between a driver gene 
and a driver mutation. A driver gene will harbour driver mutations able to promote 
tumour progression; however, they can also contain non-functional passenger 
mutations (Vogelstein, et al., 2013).  
Without extensive functional studies, it is difficult to assess the functional 
significance of a mutation in the initiation and progression of a given cancer. Similar 
to the assessment of driver genes, standard statistical methods consider the frequent 
recurrence of a mutation an indication of functional significance. More recently, the 
recurrence of mutations in ‘3D hotspots’, i.e. spatially close residues in protein 
structures that harbour clusters of mutations, have been considered an indication of 
potential driver function. In SCCHN, a 3D hotspot has been identified in NOTCH1 
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between amino acids 455-468. TCGA data shows 8% of all NOTCH1 mutations occur 
within this 3D hotspot, despite it making up less than 1% of the exonic NOTCH1 
coding sequence (Gao, et al., 2017). Several of these mutations were also found to 























The EGF-like repeats surrounding the 3D hotspot present with a higher 
mutation frequency than the remaining receptor, potentially indicating a wider region 
of functional importance. Specifically, 66% of NOTCH1 mutations occur between 
amino acids 295-481, which makes up just 13% of the total exonic coding sequence. 
Further, 89% of mutations occur in the EGF-like ligand binding domain. This finding 
aligns with the observations of Agrawal et al., who also noted a high frequency of 
NOTCH1 mutations in the EGF-like ligand binding domain in sequenced primary 





Figure 1 8: Investigation into sequencing data for 504 SCCHN patients stored by TCGA for NOTCH1 
mutations. a) Visual representation of the proportions of genetic alterations in NOTCH1. b) Location of 
NOTCH1 mutations. EGF-like Repeats = Epidermal Growth Factor-like Repeats. TMD = 
transmembrane domain. ANK = ankyrin domain. PEST = proline, glutamic acid, serine, threonine-rich 
domain. Figure adapted from cBioPortal (Cerami, et al., 2012; Gao, et al., 2013). 
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NOTCH1 mutations were found to be truncations and 60% were found to be missense. 
Most commonly, missense mutations that occur within the NOTCH1 extracellular 
domain are also found to be inactivating as they prevent effective ligand binding 
(Islaslab.org, 2014). 
Further investigation into the TCGA data set showed that the median survival 
for patients with a NOTCH1 mutation was 37 months, 19 months less than those with 
unaltered NOTCH1 who had a median survival of 56 months (Figure 1.9). As the 
majority of mutations are predicted to be either null or inactivating, this data suggests 
























Figure 1 9: Kaplan Meier estimate curves of the overall survival of a cohort of 504 SCCHN patients 
recorded in the TCGA. In this figure, the query gene was NOTCH1. Figure reproduced from cBioPortal 
(Cerami, et al., 2012; Gao, et al., 2013) . 
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1.4 The Functional Consequence of NOTCH Signalling in SCCHN; 
Focus on NOTCH1 
 
As well as genetic studies, a number of functional studies have investigated the 
biological significance of NOTCH signalling in SCCHN. Current understanding of the 
role of NOTCH signalling on field cancerisation, tumour growth, differentiation, cell 
death, invasion, cancer stem cells, angiogenesis and inflammation in SCCHN is 
reviewed in this section.  
 
1.4.1 Field Cancerisation   
 
In 2012, Hu et al. associated the loss of mesenchymal CSL, an important 
NOTCH effector, with field cancerisation in the skin (Hu, et al., 2012). In 2014, 
Alcolea et al. used a mouse model with a conditional dominant negative mutation in 
MAML1 (DNM) to inhibit NICD-induced transcription in murine oesophageal 
epidermis. A drug-inducible form of Cre recombinase was used to inhibit NOTCH in 
small number of scattered single oesophageal basal cells. The DNM cells were tagged 
with GFP for visualisation. The group showed that the inhibition of NOTCH1 in these 
cells prevented cell divisions that produced two differentiated daughter cells. As such, 
the mutant clones were no longer lost by differentiation and underwent clonal 
expansion. In addition, similar to the NOTCH negative / DLL positive stem clusters 
in skin epithelium, these NOTCH-inhibited clones were shown to promote NOTCH 
signalling and subsequent differentiation in adjacent wild type cells. Said cells were 
consequentially lost from the population (Lowell, et al., 2000). Within one year, the 
DNM cell population had replaced the entire epithelium and formed a new homeostasis 
i.e. the balance of proliferation and differentiation was restored.  
Stabilising p53 mutations in the DNM epithelium were found to generate large 
areas of double-mutant epithelium. In addition, the DNM epithelium was found to give 
rise an increased number and size of tumours in response to carcinogen treatment. As 
such, the authors hypothesised that field cancerisation occurs as a result of an 
imbalance in progenitor cell differentiation as a result of genetic mutation (Alcolea, et 
al., 2014).  
Interestingly, in 2015, Martincorena et al. published deep-sequencing data 
showing that known cancer drivers were found in 18-32% of normal skin cells which 
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still maintained the normal function of the epidermis. NOTCH1 was the most 
frequently mutated genes with relatively high bi-allelic loss in normal skin. 
(Martincorena, et al., 2015). However, no studies were performed to assess whether 
this population was at heightened risk for SCC.  
Collectively, these two studies provide evidence to suggest that endogenous 
NOTCH expression is not essential for epidermal integrity but may contribute to the 
formation of field cancerisation. Further research is required to investigate the 
combination of mutation events sufficient for tumour formation.  
 
1.4.2 Tumour Growth  
 
Inhibition of the NOTCH signalling pathway by treating cells with a γ-
secretase inhibitor (preventing the final cleavage event), has been shown to reduce cell 
proliferation in human tongue and oral carcinoma cell lines (Yao, et al., 2007; Yoshida, 
et al., 2013; Sun, et al., 2014). The knockdown of NOTCH1 and HEY1 was also found 
to correlate with the inhibition of cell proliferation (Yoshida, et al., 2013; Sun, et al., 
2014).  
 Conversely, Duan et al. showed that the overexpression of NICD in tongue 
carcinoma cell lines resulted in reduced cell growth and cell cycle arrest at G0-G1 
(Duan, et al., 2006). Similarly, Pickering at al. demonstrated that the rescue of oral 
carcinoma cells lines harbouring NOTCH1 mutations with NICD led to reduced cell 
proliferation and cell cycle arrest in the G1 phase (Pickering, et al., 2013). A 
downregulation of free β-catenin and Wnt / β-catenin mediated signalling has been 
recorded in human tongue carcinoma cells overexpressing NICD, the active portion of 
the NOTCH protein, and has been suggested to act as a mechanism in NICD-mediated 
cell cycle arrest (Duan, et al., 2006).  
 Crosstalk between the NOTCH and Wnt / β-catenin signalling pathways is well 
documented. Several NOTCH pathway genes are upregulated in response to β-catenin 
activation in the skin (Ambler & Watt, 2007). Further, JAG1 is a direct target of the 
canonical Wnt signalling pathway (Estrach, et al., 2006) and β-catenin has been shown 
to drive NOTCH signalling via the activation of JAG1 in colorectal cancer (Rodilla, 
et al., 2009).  
However, there is also evidence for antagonism between the two pathways. 
Work by Nicolas et al. demonstrated that NOTCH1 inactivation in mouse skin inhibits 
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β-catenin signalling in cells that would normally undergo differentiation. The group 
then demonstrated that increased β-catenin signalling could be reversed via the 
introduction of NICD. This led to a reduction in the pool of free β-catenin able to 
initiate signalling. Collectively, these findings suggest NOTCH is able to inhibit β-
catenin mediated signalling (Nicolas, et al., 2003).  
NOTCH also plays a non-canonical role in the negative regulation of Wnt / β-
catenin signalling in progenitor cells. Of note, NOTCH does alter transcriptional levels 
of β-catenin, but instead regulates the active protein. Studies have demonstrated that 
membrane-bound NOTCH is able to form a complex with β-catenin and facilitate 
destruction-complex-independent endolysosomal degradation of both NOTCH and β-
catenin (Hayward, et al., 2005; Kwon, et al., 2011). The complexity of the crosstalk 
between the NOTCH and Wnt signalling pathways may contribute to cell 
heterogeneity in SCCHN tumours.  
The conflicting observations as to the effect of NOTCH signalling on tumour 
growth in SCCHN provides evidence to suggest that the functional consequence of 
NOTCH1 expression may be dependent on molecular landscape. Research performed 
by Kagawa et al. confirmed the role of NICD in the induction of cell cycle arrest in 
oesophageal cell lines and showed the senescent phenotype to be associated with both 
CSL signalling and the p16 pathway. Cellular senescence was corroborated by a flat 
and enlarged cell morphology, β-galactosidase activity Retinoblastoma protein (Rb) 
dephosphorylation and induction of G0/G1 cell cycle arrest. However, the group went 
on to show that the loss of p16 not only prevented NICD-induced senescence, but also 
permitted NICD to increase xenograft tumour growth and proliferation and reduce 
squamous cell differentiation. As such, the authors suggest that cellular senescence 
check points determine the role of NOTCH1, either as an oncogene or as a tumour 
suppressor (Kagawa, et al., 2015).  
 
1.4.3 Differentiation  
 
As previously described, NOTCH signalling is known to promote 
differentiation in normal skin epithelium (Lowell, et al., 2000; Rangarajan, et al., 2001; 
Nickoloff, et al., 2002). Fewer studies have been performed in the oral epithelium; 
however, consistent with findings in the skin, Casey et al. associated the activation of 
NOTCH1 with the differentiation of oral epithelium during development. In addition, 
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the inhibition of NOTCH signalling (via the direct deletion of NOTCH1 or 
overexpression of dominant negative inhibitor of MAML1) has been shown to inhibit 
terminal differentiation and result in the formation of immature epithelium and tumour 
development in mouse skin (Nicolas, et al., 2003; Proweller, et al., 2006; Sakamoto, 
et al., 2012). Likewise, a decreased expression of NOTCH1 is observed in poorly and 
moderately differentiated oral SCC tumours (Ravindran & Devaraj, 2012).   
However, Kagawa et al. were able to demonstrate that, in certain contexts, 
NICD was able to reduce squamous cell differentiation in cell lines derived from 
oesophageal SCC. Specifically, the group associated this switch with the loss of p16 
expression (Kagawa, et al., 2015).  
As well as cell autonomous effects, studies in the skin have shown that NOTCH 
is able to inhibit differentiation in neighbouring cells (Bray, 2006). Conversely, DLL 
is expressed in stem cell clusters and promotes differentiation in neighbouring cells 
(Lowell, et al., 2000).  
 
1.4.4 Cell Death  
 
 The expression of NOTCH1 has been positively associated with apoptosis in 
laryngeal and oesophageal SCC cell lines (Lu, et al., 2008; Jiao & Li, 2012). 
Conversely, the knockdown of NOTCH1 in laryngeal SCC has also been shown to 
induce apoptosis (Dai, et al., 2015).  
Treatment of SCCHN lines with curcumin has been shown to inhibit growth 
and induce apoptosis, as reviewed by Gao et al. (Gao, et al., 2012). In 2011, Liao et al. 
provided evidence to suggest that this mechanism works via the down-regulation of 
NOTCH1 in an oral SCC line (Liao, et al., 2011). In 2012, Subramaniam et al. 
confirmed that curcumin induced cell death by targeting the NOTCH1 activating γ-




 Metastasis is the spread of cancer to secondary sites in the body. Cancer cells 
metastasise by invading the blood and lymphatic systems to travel to distant secondary 
sites. Epithelial to mesenchymal transition (EMT) is a developmental process in which 
  
49 | P a g e  
 
epithelial cells lose cell-cell adhesions and polarity and acquire migratory 
mesenchymal phenotypes. This process is often re-activated in cancer and is associated 
with cell invasion. Mesenchymal to epithelial transition (MET) is the reverse process 
and allows metastatic cancer cells to seed at distant sites (Birchmeier, et al., 1996).  
In tongue and laryngeal SCC, NOTCH1 protein expression has been positively 
correlated with both lymph node metastasis and the depth of tumour invasion (Joo, et 
al., 2009; Zhang, et al., 2011; Dai, et al., 2015). Moreover, strong NICD expression 
has been recorded in cells located at the invasive tumour front of oral SCCs (Yoshida, 
et al., 2013). These findings have been further explored experimentally, and several 
studies have confirmed a reduction of invasive and metastatic phenotypes in response 
to NOTCH1 downregulation in SCCHN (Yu, et al., 2012; Yoshida, et al., 2013; Dai, 
et al., 2015; Li, et al., 2015; Jing, et al., 2016).  Further, recent research has shown that 
miR-140-5p is able to supress tumour migration by inhibiting the expression of 
ADAM10 and thus decreasing NOTCH signalling in hypo-pharyngeal SCC (Jing, et 
al., 2016). 
Studies by Yoshida et al. suggest that the expression of NOTCH1 contributes 
to the maintenance of Tumour Necrosis Factor- (TNF-)-mediated invasion in oral 
SCC, which functions via the transcriptional regulation of SNAI2 and TWIST (Casas, 
et al., 2011). During EMT, TWIST is known to induce SNAI2, which supresses the 
epithelial phenotype; TWIST and SNAI2 then work together to promote EMT and 
metastasis. Notably, Ambler et al. also showed an increased TNF- and SNAI2 
expression in response to NICD expression in the epidermis (Ambler & Watt, 2010). 
In addition, the increased epidermal NOTCH expression was shown to give rise to an 
accumulation of cells in the dermis. As SNAI2 has been associated with EMT, the 
group postulated whether these dermal cells could be epidermis-derived (Leong, et al., 
2007). A Green Fluorescent Protein (GFP) reporter was used to investigate this theory 
but SNAI2-mediated EMT was not found to occur (Ambler & Watt, 2010). 
Targeting NOTCH-mediated metastasis as a potential therapy for SCCHN has 
been explored. Treatment of oral SCCs with the γ-secretase inhibitor, GSI, has been 
shown to successfully inhibit this TNF--mediated invasiveness (Yoshida, et al., 
2013).  
 Finally, in order to undergo metastasis, cells must first detach from the primary 
tumour and degrade the basement membrane and surrounding extracellular matrix 
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(ECM). Matrix metalloproteinases (MMPs) are a family of enzymes involved in the 
degradation of ECM. They are commonly up-regulated in cancers and aid in tumour 
invasion. There is evidence to suggest that NOTCH1 is able to mediate metastasis via 
the regulation of MMP2 and MMP9 in lingual SCC (Yu, et al., 2012). Collectively, 
this data suggests a key role for NOTCH1 in metastasis and tumour invasion in 
SCCHN.  
   
1.4.6 Cancer Stem Cells 
 
The Cancer Stem Cell (CSC) hypothesis states that not all cells of the tumour 
population are equally able to initiate tumour growth, metastasis and recurrence. 
Instead, it is theorised that there is a small population of CSCs which is able to undergo 
self-renewal and differentiate into the entire heterogeneous tumour (Mackenzie, 2008; 
Routray & Mohanty, 2014). CSCs have been shown to be able to undergo EMT and 
MET. The plasticity to switch between an epithelial and post-EMT population has 
been associated with enhanced therapeutic resistance (Biddle, et al., 2016).  
In other cancers, NOTCH expression has also been associated with EMT and 
chemo-resistance (Capaccione & Pine, 2013). In lung adenocarcinoma cell lines, 
NOTCH pathway activity has been associated with cells with CSC-like properties. 
Treatment of these cells with γ-secretase inhibitors has been shown to inhibit tumour 
formation in serial re-implantation studies, suggesting that NOTCH inhibition may be 
appropriate for targeting lung adenocarcinoma CSCs (Hassan, et al., 2013). Further, 
the inhibition of NOTCH signalling in murine glioblastoma xenografts resulted in 
significantly reduced tumour growth and stem cell marker expression (Chu, et al., 
2013). 
Increased NOTCH1 expression has also been associated with CSCs in SCCHN 
(Upadhyay, et al., 2015; Wilson, et al., 2016). In 2016, Zhao et al. confirmed elevated 
NOTCH1 / HES1 expression in SCCHN lymph node metastases and post-
chemotherapy tissue; both of which are associated with CSCs. The group went on to 
show that the expression of NOTCH1 and HES1 positively correlated with CSC 
markers CD44, SOX2 and ALDH1. The introduction of DAPT, a NOTCH1 inhibitor, 
was shown to reduce the proportion of cells expressing CSC markers and tumour self-
renewal both in vitro and in a mouse xenograft model (Zhao, et al., 2016).  
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Further, the prolonged exposure of oral SCC lines to the pro-inflammatory 
cytokine TNF- has been shown to enhance the CSC phenotype. In this study stemness 
was associated with increased tumour sphere forming ability, tumorgenicity, chemo-
resistance and increased expression of CSC associated genes. Consistent with findings 
from Zhao et al, enhanced NOTCH signalling was confirmed in cells exposed to TNF-
. Further, the inhibition of either NOTCH1 or HES1 was shown to reverse the CSC 
phenotype. As such, the group concluded that exposure to TNF- is able to enhance 
the CSC phenotype of oral SCC via NOTCH / HES1 signalling (Lee, et al., 2012). 
Likewise, the overexpression of NOTCH1 has been associated with the maintenance 
of a stem-like phenotype in tongue SCC lines. Similarly, this group utilised tumour-
sphere formation assays and the expression of CSC markers as a measure of stemness 
(Upadhyay, et al., 2016).   
 
1.4.7 Angiogenesis  
 
 Angiogenesis is the formation of new blood vessels. The process involves the 
migration, growth and differentiation of endothelial cells to form the vessel walls. This 
neovascularisation is essential to the progression of cancers as the sustained 
proliferation and growth of solid tumours requires an oxygen supply and the removal 
of waste products. Moreover, it facilitates metastatic spread (Nishida, et al., 2006). The 
presence of EMT markers has been associated with pro-angiogenic protein expression. 
Both EMT and angiogenesis are key promoters of carcinogenesis and there is evidence 
to suggest that the same factors that promote EMT may also drive endothelial cells 
towards an angiogenic phenotype (Holderfield & Hughes, 2008; Ribatti, 2017). 
 The expression of NOTCH1 has been positively associated with micro-vessel 
density in oral SCC (Joo, et al., 2009).  In addition, NOTCH1 expression has been 
correlated with the expression of vasculature endothelial growth factor (VEGF), a 
direct stimulant of angiogenesis. However, the same study did not find any correlation 
between NOTCH1 and EGFR (a NOTCH antagonist in the epidermis), a distal but 
well recognised promoter of angiogenesis in SCCHN.  The authors therefore suggest 
that NOTCH1 is able to induce angiogenesis independently of EGFR signalling in 
SCCHN (Troy, et al., 2013).  
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Conversely, Sun et al. reported a reverse correlation between NOTCH1 and 
VEGF expression in oesophageal SCC (Su, et al., 2009). Further, treatment of SCCHN 
with cetuximab, an EGFR inhibitor, has been shown to downregulate NOTCH1 and 
reduce angiogenesis, indicating a potential link between EGFR and NOTCH1 in the 




 Inflammation is a consequence of the host response to the detection of cancer 
cells. It is well recognised that a chronic inflammatory compartment is critical to solid 
tumour progression (Grivennikov, et al., 2010). Deregulation of NOTCH in the 
epidermis has been associated with a JAG1-mediated Cluster of Differentiation 4 
(CD4) -positive T cell infiltrate as a result of barrier dysfunction. It has been shown 
that NOTCH activation induces TNF- which in turn activates JAG1 expression via 
NF-κB. AS JAG1 also activates NF-κB, it is predicted that a positive auto-regulatory 
loop is formed (Ambler & Watt, 2010).  
Further, several studies have associated NOTCH signalling with inflammatory 
mediators in cancer (Fazio & Ricciardiello, 2016). Specifically, in tongue SCC, pro-
inflammatory cytokine IL-β1 has been shown to increase the expression of CXC 
Chemokine Receptor 4 (CXCR) via NOTCH1. CXCR4 is a known regulator of cancer 





 A number of high throughput genomic sequencing studies have identified loss-
of-function NOTCH1 mutations in approximately 11% of SCCHN tumours, 
suggesting a tumour suppressor role for NOTCH1 (Agrawal, et al., 2011; Stransky, et 
al., 2011; Sun, et al., 2014). However, approximately one third of SCCHN tumours 
have also been shown to exhibit activated NOTCH signalling, as indicated by the 
upregulation of downstream targets HES1/HEY1. Importantly, inactivating NOTCH1 
mutations and the overexpression of HES1/HEY1 have been found to be mutually 
exclusive (Sun, et al., 2014).  
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 Section 1.4 provides an overview of the current understanding of the functional 
significance of NOTCH1 in SCCHN. SCCHN is highly heterogeneous. Whether 
NOTCH1 acts as a tumour suppressor or oncogene is likely to depend on the 
mutational landscape of the individual tumour as well as interactions with the 
microenvironment. For example, for NOTCH1 to act as a tumour suppressor, other 
factors must override the NOTCH-mediated promotion of metastasis. 
 A better understanding of the complexities of the functional consequence of 
NOTCH signalling in SCCHN is essential before the pathway could be targeted 
therapeutically. In vitro and in vivo functional studies are required to elucidate the 
mechanisms by which different genetic alterations in NOTCH1 result in changes in 
cell behaviour in SCCHN. Moreover, the interplay of NOTCH1 with other SCCHN 
mutations must be considered as well as the effect of the tumour microenvironment.  
 
 
1.6 Aims of this Thesis 
 
 This chapter has discussed the clinical significance of SCCHN worldwide and 
highlighted the need for further research to improve the 5 year survival, which 
currently stands at approximately 50%. By better understanding the molecular 
mechanisms underpinning SCCHN, properties specific to the tumours can be exploited 
therapeutically. 
 This research will build upon work performed by Hayes et al. (Hayes, et al., 
2016). Whole exome sequencing studies have identified NOTCH1 mutations in 11-
15% of original tumours suggesting a potential tumour suppressor role in SCCHN. 
Subsequent functional studies suggest a complex and context dependent role of 
NOTCH signalling in SCCHN. It is the aim of this thesis to further understanding of 
NOTCH signalling in SCCHN by investigating the effect of NOTCH1 inactivating 
mutations on cell behaviour. It is hoped that better understanding of the functional 
consequence of changes in NOTCH1 expression will ultimately aid in the development 
of more targeted treatment plans.  
 It is the aim of this thesis to investigate the effect of NOTCH1 expression on 
the following cellular functions in SCCHN: (1) tumour growth, (2) differentiation, (3) 
migration and invasion and (4) angiogenesis.  
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Chapter 2 
Materials and Methods 
 
 




2.1 Cell Line Derivation 
 
2.1.1 Cell culture medium and supplements 
 
Culture medium for J2-3T3 feeder cells 
 
 Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich) 
supplemented with 10% bovine serum (Life Technologies), 100 U/ml penicillin (Life 
Technologies) and 100 µg/ml streptomycin (Life Technologies). Medium was stored 
at 4oC for up to two weeks.  
 
Culture medium for oral SCCs  
 
 Based on the Rheinwald and Green method (Rheinwald & Green, 1975): FAD 
medium, made from one part Ham’s F12 medium and three parts DMEM 
supplemented with 1.8x10-4 M adenine (Life Technologies), was further supplemented 
with 10% fetal bovine serum (FBS) (Life Technologies), 100 U/ml penicillin (Life 
Technologies), 100 µg/ml streptomycin (Life Technologies), 5 µg/ml insulin (Sigma-
Aldrich), 450 µg/ml glutamine (Life Technologies), 1.8 µm calcium chloride (Sigma-
Aldrich) and a cocktail (HCE) of 0.5 µg/ml hydrocortisone (ThermoFisher Scientific), 
10-10 M cholera toxin (Enzo Life Science) and 10 ng/ml EGF. Medium was stored at 
4oC for up to two weeks. 
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Culture medium for oral SCCs during experimental assays 
 
 Keratinocyte-SFM (KSFM; Life Technologies) was supplemented with 25 mg 
bovine pituitary extract and 2.5 µg human recombinant EGF, as supplied by the 
manufacturer. Medium was stored at 4oC. Cells were moved into serum free medium 
for experimental assays as serum composition is variable between batches. As such, 
results from serum-free conditions have increased reproducibility and are more 
comparable. KSFM has been optimised to meet the nutritional needs for the growth 
and maintenance of epithelial cells without the need for a feeder layer (Thermo Fisher 
Scientific, 2003). It is worth noting that changing cells to KSFM medium from FAD 
medium can have an effect on cell morphology. However, all comparative 
observations in this study are between cells cultured in identical conditions.   
 
Culture medium for HEK293 cells 
 
 DMEM (Sigma-Aldrich) supplemented with 10% FBS (Life Technologies), 
100 U/ml penicillin (Life Technologies), 100 µg/ml streptomycin (Life Technologies) 
and 900 µg/ml glutamine (Life Technologies). Medium was stored at 4oC for up to 
two weeks.  
 
2.1.2 Isolation of human oral SCCs 
 
This work was carried out in compliance with the UK Human Tissue Act 
(2004) and with appropriate ethical approval from the National Research Ethics 
Service (08/H0306/30) by Mr Simon Broad (Centre for Stem Cells and Regenerative 
Medicine, King’s College London). Samples were donated to research, with informed 
consent, from patients diagnosed with oral SCC in Addenbrooke’s Hospital, 
Cambridge. Reports derived by the consultant pathologist were used to define the 
depth of invasion and grade of differentiation of tumour samples, as detailed in Table 
2.1. Cell lines were derived as previously described (Rheinwald & Beckett, 1981). 
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Table 2 1: Patient and Primary Tumour Background for Derived Cell Lines 












3 Male 61 Ex Minimal 13 Well 20 N0 T4a 
4 Female 49 Yes Moderate 4.1 Poor 20 N1 T2 
6 Female 63 No Minimal  12 Poor 46 Nx T4a 
8 Male 68 Ex Heavy 2 Well 18 N0 T1 
13 Female 54 No Minimal 12 Well 35 Nx T4a 
15 Female 51 No None 9 Well 22 N1 T2 
16 Male 28 Ex-Cannabis Minimal 4 Moderate 7 N0 T1 
17 Female 48 Yes Moderate 6 Well 8 Nx T1 
18 Female 79 Yes Moderate 12.1 Moderate 14.6 N0 T1 
21 Male 76 Ex None 14 Poor 26 N0 T2 
24 Female 55 Ex Minimal 16.2 Moderate 40 N2c T3 
25 Male 59 Yes Heavy 1.5 Well 24 N0 T2 
26 Male 74 Ex Minimal 14.2 Moderate 22 N1 T4a 
27 Male 30 No None 10.5 Moderate 35 N2b T2 
28 Female 37 Ex Minimal 7 Well 18.5 N0 T1 
31 Female 65 Ex Moderate 6.5 Moderate 16 Nx T4a 
32 Female 79 Ex Minimal 9 Moderate 20 N0 T1 
33 Male 78 Ex Minimal 8.5 Well 13 N0 T1 
37 Male 29 No Minimal 0.7 Moderate 1.7 N0 T1 
41 Female 55 Ex Minimal 8.5 Poor 25 N1 T2 
42 Female 56 Ex None 2.6 Well 29 N0 T2 
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2.1.3 Culture of J2-3T3 cells as feeder layers 
 
 The culture of oral SCC lines is supported by co-cultivation with inactivated 
J2-3T3 cells, a.k.a. feeder cells (Rheinwald & Green, 1975). On thawing, J2-3T3 were 
quickly re-suspended in supplemented DMEM medium, seeded onto the surface of a 
T75 flask and maintained in a humidified incubator at 37oC and 5% CO2. The medium 
was changed three times per week and the cells split and re-seeded at a density of 
1x105 when they reached confluence. Cells were lifted using a solution of Trypsin-
Ethylenediaminetetraacetic acid (Trypsin-EDTA; 0.25%) (Sigma Aldrich) further 
diluted in Versene (Life Technologies) at a ratio of 1:4 for approximately 2 minutes at 
37oC. 
 To prepare J2-3T3 cells as a feeder layer for oral SCC co-culture, they were 
grown to a density of approximately 1.8x106 – 2.0x106 and mitotically inhibited by 
incubation with 4 µg/ml Mitomycin-C (Sigma Aldrich) for 2hrs at 37oC. Following 
treatment, the cell layers were washed three times with PBS and oral SCCs were 
introduced at a density of 1x105 per T75 in complete FAD medium.  
 
2.1.4 Culture of human oral SCC lines 
 
 On thawing, oral SCC lines were quickly re-suspended in complete FAD 
medium, seeded in co-culture with a mitotically inactivated J2-3T3 feeder layer and 
maintained in a humidified incubator at 37oC and 5% CO2. The medium was changed 
three times per week and the cells were split and re-seeded at a density of 1x105 per 
T75 flask when they reached confluence. When splitting cells, the feeder layer was 
first removed by incubating with Versene (Life Technologies) for 5 minutes at 37oC. 
The oral SCC lines were then lifted using a solution of Trypsin-EDTA (0.25%) (Sigma 
Aldrich) further diluted in Versene (Life technologies) at a ratio of 1:4 for 
approximately 10 minutes at 37oC.  
 
2.1.5 Culture of HEK 293 cells 
 
 On thawing, HEK 293 cells were quickly re-suspended in supplemented 
DMEM medium, seeded onto the surface of a T175 flask and maintained in a 
humidified incubator at 37oC and 5% CO2. The medium was changed three times per 
  
58 | P a g e  
 
week and the cells split and re-seeded at a density of 2x106 when they reached 
confluence. Cells were lifted via pipetting in Versene (Life Technologies).   
 
2.1.6 Freezing Cell Stocks 
 
 Cells were frozen at a concentration of 5x105 – 1x106 in a solution of 10% 
Dimethyl Sulfoxide (DMSO) in FBS. A Nalgene container was used to slowly cool 




2.2 Plate Coating 
 
2.2.1 Collagen coating 
 
 Plates were coated with Collagen Type 1, Rat Tail, (Corning®) at a dilution of 
10 µg/cm2 of growth surface in sterile PBS (Sigma Aldrich) at room temperature. After 
2hrs, the solution was removed and plates washed 3x in PBS.  
 
2.2.2 Fibronectin coating  
 
 Plates were coated with Human Fibronectin (Corning®) at a dilution of 1, 5 or 
25 µg/ml in sterile PBS (Sigma Aldrich) at room temperature. After 2hrs, the solution 
was removed and plates washed 3x in PBS.  
 
 
2.3 Genomic Analysis 
 
2.3.1 Analysis of the TCGA 
 
 TCGA has collected sequencing data from over 500 head and neck cancer 
patients (http://cancergenome.nih.gov/). This publically accessible database was 
mined using cBioPortal for information on the frequency, type and location of 
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NOTCH1 mutations in SCCHN as well as survival statistics (Gao, et al., 2013; Cerami, 
et al., 2012). 
 
2.3.2 Whole exome sequencing  
 
 Genomic DNA from passaged oral SCC lines and patient-matched blood was 
extracted by Dr Nathan Beniach using a Blood & Tissue Kit (Qiagen) with RNase 
treatment according to the manufacturer’s instructions. Samples were eluted in Buffer 
AE (Qiagen). Whole exome sequencing was performed by Beijing Genomics Institute 
(BGI, Hong Kong) and raw image files were processed as previously described 
(Hayes, et al., 2016). The sequencing data for each cell line was mined for mutation 
frequency as well as the presence, type and location of NOTCH1 mutations. 
 
2.3.3 Sanger sequencing 
 
 Genomic DNA from passaged oral SCC lines and patient-matched blood was 
extracted using a Blood & Tissue Kit (Qiagen). PrimeSTAR GXL DNA Polymerase 
(TaKaRa) was used to perform PCR amplification of Notch receptor genes 1-3 
according to the manufacturer’s instructions. The PCR products were run on a 1.5% 
Ultrapure Agarose gel (Life Technologies) and gel extraction was performed using a 
Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. This work 
was performed by Dr Kazunori Sunadome. Sanger sequencing was performed by 
Source Bioscience (UK) and analysed using Lasergene 11 (DNASTAR) and 
CodonCode Aligner software.  
 
 
2.4 Lentiviral Transduction 
 
2.4.1 Plasmid derivation 
 
In order to achieve constitutive expression of NICD, 3xFlagNICD (Ong, et al., 
2006) was cloned into the multiple cloning site, and under the SFFV promoter, of the 
LeGO-iC2 plasmid (Weber, et al., 2008) using gateway cloning. In order to make the 
LeGO-IC2 vector into a Gateway compatible destination vector, The Gateway Vector 
Conversion System (ThermoFisher Scientific) was used. An internal ribosome entry 
  
60 | P a g e  
 
site (IRES) was used to express the mCherry selectable marker. The 3xFlagNICD was 
a gift from Raphael Kopan (Adgene plasmid #20183), and the LeGO-iC2 plasmid was 
a gift from Boris Fehse (Adgene plasmid #27345). This work was performed by Dr 
Kazunori Sunadome and Dr Samuel Woodhouse. SnapGene software was used to 
visualise the resultant plasmid (Figure 2.1). 
In order to perform a knock-down of SPANXA1/2, a SMARTvector Human 
Doxycycline Inducible shRNA targeting the 3’UTR from Dharmacon was used 
(V3SH11252-226413760 GTTGAGAGATGTAGCTTC). The mCMV promoter 
system was utilised and Turbo GFP expression acted as a selectable marker.  
Second generation packaging plasmid, psPAX2, and VSV-G envelope 
expressing plasmid, pMD2.G, were used as packaging vectors. Both were gifts from 






Figure 2 1: NICD - LeGO-IC2 plasmid map. 
  
61 | P a g e  
 
2.4.2 Viral component cloning and maxi prep 
 
 E. coli competent cells were used as the host system to clone and expand DNA 
fragments of interest.  1 µl of DNA was gently mixed with 50 µl One Shot Top10 
Chemically Competent E. Coli (ThermoFisher Scientific) and incubated on ice for 30 
minutes. To allow the DNA to enter the host cell, the solution was then heat shocked 
for 45 seconds at 42oC before returning to ice for a further 2 minutes. Samples were 
then incubated at 37oC in 500 µl LB Broth (Sigma Aldrich), a growth medium used 
for the cultivation of E.coli, for 1hr.  
As the number of colonies formed can vary significantly, the reaction mixture 
was seeded at a 10% and 90% density on ampicillin-agar plates to ensure a good 
density was acquired. Ampicillin resistance was used as a selectable marker (10 
µg/ml). The plates were then inverted and incubated overnight at 37oC. 
 A small number of colonies were selected using an inoculation loop and 
incubated at 37oC in 5 ml LB Broth and 50 µl ampicillin. After 8hrs, 100 µl was 
transferred into a solution of 1L LB Broth and 1 ml ampicillin for overnight incubation. 
Maxi prep was performed using an EndoFree Plasmid Maxi Kit (Qiagen) according to 
the manufacturer’s instructions.  
 
2.4.3 Lentiviral packaging  
 
 HEK293 cells, seeded at a concentration of 1x107 per T175 flask in 
supplemented DMEM medium, were used as the host system. At 24hrs, 15 µg of 
lentiviral vector, 11.25 µg psPax2 and 2.75 µg pMD2.G were introduced. JetPRIME® 
(Polyplus Transfection) was used as a transfection reagent according to the 
manufacturer’s guidelines for lentiviral production. 
At 48hrs, cell medium was changed. At 72 and 96hrs, medium was collected 
and filtered through a Corning® 0.45 µm Bottle Top Vacuum Filter System (Sigma 
Aldrich). Lenti-X Concentrator (Clontech) was added at a dilution of 1:4 to the 
resultant filtrate and the solution was incubated at 4oC. After 24hrs, the lentivirus 
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2.4.4 Lentiviral transduction 
 
 The SJG6 oral SCC cell line was seeded at a density of 1x106 per well of a 
collagen coated 6 well plate. Derived lentivirus and 5 µg/ml polybrene (Sigma 
Aldrich) was diluted in serum and antibiotic free FAD medium and incubated with 
cells at 37oC. At 72hrs, the medium was replaced with complete FAD. At 96hrs, cells 
were collected and sorted for the expression of markers of interest. To select for 
constitutively expressing NICD cells, Fluorescence-Activated Cell Sorting (FACS) for 
mCherry expression was performed using a BD Aria II by the BRC Core Facility, 
King’s College London. In order to select for cells which had incorporated the 
SPANXA1/2 shRNA, puromycin selection was performed at a concentration of 1 
µg/ml. Both sets of cell lines were expanded in culture and stocks were frozen in liquid 
nitrogen for future use.  
 
2.4.5 Induction of SPANXA1/2 shRNA 
 
 In order to induce the SPANXA1/2 shRNA, doxycycline was introduced to the 
cell medium at a concentration of 1.5 µg/ml. The co-expression of turbo-GFP acted as 
a marker for successful transcription of the shRNA. At 48hrs post-induction, cells were 
seeded for in vitro assays and RNA and protein samples were collected.  
 
 
2.5 Molecular Biology 
 
2.5.1 RNA isolation  
 
 Total RNA was collected from cell cultures. Cells were first lifted using a 
solution of Trypsin-EDTA (0.25%) (Sigma Aldrich) further diluted in Versene (Life 
technologies) at a ratio of 1:4 for approximately 10 minutes at 37oC, then centrifuged 
at 1,200rpm for 3 minutes. The supernatant was removed and the cell pellet was re-
suspended in 350 µl RLT Lysis Buffer with 1% β-Mercaptoethanol.  
 Total RNA was also collected from xenograft tumour samples which had been 
embedded in OCT and frozen at -80oC. A cryostat was used to cut 50 µm sections, 
which were collected in 350 µl RLT Lysis Buffer with 1% β-Mercaptoethanol. A 
gentleMACS dissociator (Miltenyi Biotec) was used to homogenise samples. 
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For both sample types, the RNeasy Mini Kit (Qiagen) was used according to 
the manufacturer’s instructions. RNA quantity was calculated using a NanoDrop 
spectrophotometer by measuring sample absorbance at 260nm. The ratio of 
absorbance at 230/260nm and 260/280nm was used to ensure samples were acceptably 
pure (based on a score of approximately 2.0-2.2 and 2.0 respectively). Total RNA was 
stored at -80oC.  
 
2.5.2 Reverse transcription  
 
The SuperScript III Reverse Transcriptase kit (Life Technologies) was used, 
according to the manufacturer’s instructions, to synthesise cDNA from 500 ng total 
RNA. Derived cDNA was diluted 1:10 in RNase free water and stored at -80oC. 
 
2.5.3 Quantitative Real Time Polymerase Chain Reaction (RT-qPCR) 
 
 RT-qPCR reactions were set up using TaqMan ® probes (Invitrogen) as 
detailed in Table 2.2. Samples were run in triplicates on a 384 well plate and analysed 
using a CFX 384 Touch RT-qPCR machine (Bio-Rad). The RT-qPCR reaction mix 
was prepared as described in Table 2.3. The reactions took place under conditions 
described in Table 2.4. Gene expression was normalised to housekeeping probes, 
GAPDH and 18S, and expression levels were calculated using the ∆∆CT method. 
Statistical analysis was performed using GraphPad Prism 7. Based on a normal 
distribution of sample means, a student’s t-test was used to test the null hypothesis that 
the mean values of two groups are equal. A t-test value less than 0.05 was considered 
a statistically significant difference. 
 
2.5.4 Human NOTCH1 Signalling Pathway RT2 Profiler Array  
 
 The Human NOTCH Signalling Pathway RT2 Profiler Array (Qiagen) was 
used according to manufacturer’s guidelines.  Each well of a 96 well plate contained a 
single probe for a panel of 35 NOTCH related genes, 5 housekeeping genes and 
patented controls to monitor PCR quality and efficiency. The array allows for the 
simultaneous RT-qPCR expression analysis of the 35 NOTCH-related genes in two 
cDNA samples. Similar to other RT-qPCR reactions, a solution of Taqman ® Fast 
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Universal PCR Master Mix, cDNA and nuclease free water was added to the probes 
in the equivalent proportions to those detailed in Table 2.3. The reactions took place 
under conditions described in Table 2.4. Gene expression was normalised to 
housekeeping probes, GAPDH and 18S, and expression levels were calculated using 
the ∆∆CT method. Statistical analysis was performed using GraphPad Prism 7. Based 
on a normal distribution of sample means, a student’s t-test was used to test the null 
hypothesis that the mean values of two groups are equal. A t-test value less than 0.05 
was considered a statistically significant difference. 
 
 
Table 2 2: TaqMan ® probes 
Probe ID Supplier 
NOTCH1 Hs01062014_m1 Invitrogen 
Custom mCherry 
Forward Primer Sequence: 
GACCACCTACAAGGCCAAGAAG 





SPANXA1+A2 Hs03007483_gH Invitrogen 
SPANXB1 Hs02387419_gH Invitrogen 
SPANXC+D Hs04191733_gH Invitrogen 
TMEM27 Hs00252907_m1 Invitrogen 
HEY1 Hs01114113_m1 Invitrogen 
CTH Hs00542282_m1 Invitrogen 
ITGBL1 Hs01557019_m1 Invitrogen 
ITGB6 Hs00168458_m1 Invitrogen 
GAPDH Hs02786624_g1 Invitrogen 







65 | P a g e  
 
Table 2 3: Taqman® RT-qPCR reaction mix 
Component Volume for one reaction (µl) 
Taqman ® Fast Universal PCR Master Mix (2x) 5 
TaqMan ® Probe 0.5 
Nuclease Free Water 3.5 
cDNA 1 
Total Volume 10 
 
 
Table 2 4: TaqMan ® FAST RT-qPCR method 
Cycles Step Time (seconds) Temperature (oC) 
1 Activate 20 95 
40 
Denature 1 95 




2.5.5 Preparation of protein lysates   
 
 Protein lysates were collected from cells cultured on collagen-coated six well 
plates. Plates were kept on ice, the cell medium was removed and wells were washed 
twice with ice cold PBS. 100 µl RIPA buffer was added to each well and cells were 
collected into a pre-cooled Eppendorf using a cell scraper. RIPA buffer composition 
is described in Table 2.5; stocks were aliquoted and frozen at -20oC for future use. 
 Samples were left to lyse on ice, with frequent agitation, for 30 minutes before 
centrifuging at 15,000 rpm for 20 minutes at 4oC. The supernatant, which contained 
the protein lysate, was then transferred to a fresh pre-cooled Eppendorf. Protein 
concentration was calculated using a Pierce BCA Protein Assay Kit (ThermoFisher 
Scientific) according to the manufacturer’s instructions and samples were stored at -
80oC for future use. 
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Table 2 5: RIPA buffer composition 
10x RIPA Buffer (New England 
BioLabs) 
 1x Complete RIPA Buffer 
Component Quantity  Component Quantity 
Tris HCl (pH 7.5) 20 mM  10x RIPA  1 ml 
NaCl 150 mM  ddH2O 9 ml 
Na2EDTA 
EGTA 
1 mM  
PhosSTOP Inhibitor Cocktail 
tablet (Roche) 
1 tablet 
NP-40 1 %  
Complete Mini EDTA-free 
Protease Inhibitor Cocktail tablet 
(Roche) 
1 tablet 
Sodium deoxycholate 1 %    
Sodium 
pyrophosphate 
2.5 mM    
β-glycerophosphate 1 mM    
Na3VO4 1 mM    
Leupeptin 1 µg/ml    
 
 
2.5.6 Western blot 
 
 10 µg protein lysate was diluted with RIPA buffer to a volume of 7.5 µl and 
added to 2.5 µl 4x Laemmli sample buffer containing 10% β-mercaptoethanol (Bio-
Rad). Samples were reduced and denatured by heating to 95oC for 5 minutes.  
 The 10 µl lysates were loaded into pre-cast 4-15% Mini-PROTEAN® TGX™ 
Gels (Bio-Rad) alongside Precision Plus Protein™ Dual Colour Standard (Bio-Rad) 
and run at 300V in Tris/Glycine/SDS Running Buffer (Bio-Rad). The run was stopped 
when the lysates reached the indicator line at the bottom of the gel. 
 Protein was transferred from gels to membranes using a Trans-Blot® Turbo™ 
Mini PVDF Transfer Pack. As cleaved NOTCH1 was the protein of interest 
(approximately 100 kDa), the high molecular weight setting on the Trans-Blot Turbo 
System (Bio-Rad) was used. 
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 Resultant membranes were washed in TBST (a mixture of Tris Buffered Saline 
and Tween 20), the components of which are described in Table 2.6.  
 
 
Table 2 6: TBST components 
10x TBS  1x TBST  
Component Quantity  Component Quantity 
NaCl 150 mM  10x TBS 100 ml 
KCl 2 mM  ddH2O 900 ml 
Tris 25 mM  Tween20 1 ml 
ddH2O    
Adjust pH to 7.4 with HCl   
 
  
Membranes were blocked for one hour at room temperature in 5% skimmed 
milk powder diluted in TBST. As the predicted molecular weights of cleaved 
NOTCH1 and the loading control (Cyclophilin B) was approximately 100kDa and 
20kDa respectively, membranes were cut at the 37kDa ladder mark and staining was 
performed simultaneously. Primary antibodies were used at 1:1,000 in the blocking 
buffer. Staining was performed overnight at 4oC and membranes were washed for 3 x 
10 minutes in TBST prior to introduction of the species-specific secondary antibody. 
Secondary antibodies were used at 1:10,000 in 5% Bovine Serum Albumin (BSA; 
Sigma Aldrich) diluted in TBST. After staining for 2hrs at room temperature, a further 
3 x 10 minutes washes in TBST were performed. Table 2.7 details the antibodies used.  
 Clarity™ ECL Western Blotting Substrate (Bio-Rad) was used according to 
the manufacturer’s guidelines to image the membranes. Imaging was performed using 
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Table 2 7: Western blot antibodies 
Antibody (Primary) ID Supplier 
Cleaved NOTCH1 (Rabbit) Val1744 Cell Signalling 
Technologies 
Cyclophilin B (Mouse) MAB5410 R&D Systems 
 
 
Antibody (Secondary) ID Supplier 
Peroxidase AffiniPure Donkey Anti-




Peroxidase AffiniPure Donkey Anti-






2.5.7 Immunocytochemistry  
 
  Cells were seeded at a density of 2x103 / well in a collagen-coated flat bottomed 
96 well plate in supplemented KSFM medium. Prior to staining, cells were fixed for 
10 minutes in 4% paraformaldehyde (PFA; diluted in 1x PBS) and permeabilised for 
a further 10 minutes in 0.05% Triton-X (Sigma Aldrich; diluted in deionised water). 
Non-specific antibody binding was inhibited by blocking for 1hr at room temperature. 
The blocking buffer composition is detailed in Table 2.8. 
 Primary antibodies were diluted in blocking buffer and samples incubated 
overnight at 4oC. The primary antibodies and the concentrations used are detailed in 
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Table 2 8: Blocking buffer composition 
Component  Quantity 
1x TBS (Table 6; diluted in deionised water) 0.01 M 
Donkey Serum (Sigma Aldrich) 10 % 
BSA (Sigma Aldrich) 0.3 % 
Triton (Sigma Aldrich) 0.05 % 
Tween20 (Sigma Aldrich) 0.05 % 
Gelatin from Fish Skin (Sigma Aldrich) 0.25 % 
 
 
Table 2 9: Primary antibodies for immunocytochemistry and immunohistochemistry 
Antibody Species Reference Supplier Dilution 
NOTCH1 Rabbit ab27526 Abcam 1:200 
SPANXA1 / A2 Rabbit ab115632 Abcam 1:200 
Transglutaminase Mouse (Ruhrberg, et 
al., 1996) 
In house 1:500 
RFP Rabbit 600-401-379 Rockland Inc. 1:100 
CD31 Rat 553370 BD Pharming 1:200 
 
 
 Following 3 x 10 minute washes in TBS, samples were stained with appropriate 
species-specific Alexa Fluor conjugated secondary antibodies (1:1,000), DAPI (Life 
Tech; 1 µg/ml) and Cell Mask Deep Red Plasma Membrane Stain (ThermoFisher 
Scientific; 1:500) in blocking buffer for 1hr at room temperature. Samples were then 
washed 3 x 10 minutes in TBS before imaging with the Perkin Elmer Operetta High 
Content Imaging System. Analysis pipelines were derived using Harmony Software, 











































Figure 2 2: a) Pipeline for analysis of cells using Harmony Software on the Perkin Elmer High Content 
Imaging System: Images were acquired and DAPI staining was used to find nuclei. Nuclei morphology 
was calculated and those measuring over 500 µm2 were considered unlikely to be single nuclei and 
excluded from further analysis. Based on selected nuclei, Cell Mask Deep Red Plasma Membrane Stain 
was used to find cell boarders. Cell morphology was calculated and selections considered unlikely to 
be single cells were excluded (detailed further in bi). Respective staining intensities were then 
calculated for each cell and the mean value for cells per well was exported. b) Downstream pipelines. 
bi) In order to accurately investigate differences in cell area, thresholds were applied to ensure only 
single cells were included in downstream analysis: cells measuring under 400 µm2 were considered 
debris and cells measuring over 3000 µm2 were considered unlikely to be single cells. bii and biii) Cells 
could be considered either Transglutaminase 1 or EdU positive or negative. As such, a staining 
intensity threshold was applied in order to count the number of positive cells as a percentage of the 
total cell population. A threshold of 4 x 103 and 1.8 x 103 (a.u.) was applied for transglutaminase and 
EdU respectively. 
  
71 | P a g e  
 
2.5.8 Microarray  
 
 Total RNA was extracted from passaged oral SCC line SJG6 (Table 2.1) 
transformed with a lentiviral vector either expressing NICD or an empty control 
(Figure 2.2). Three biological replicas were used for each line. 
The microarray was performed by King’s Genomics Centre (King’s College 
London, London) using the Affymetrix GCS3000 system. Briefly, DNA probes able 
to capture the whole human transcriptome were deposited via photolithography onto 
silicon chips (Affymetrix GeneChip® Human Exon 1.0 ST array). The total RNA 
samples underwent reverse transcription to cDNA followed by in vitro transcription to 
cRNA. Note that only polyadenylated RNA undergoes reverse transcription; therefore, 
the microarray identifies mRNA expression but not that of microRNA or other non-
polyadenylated sequences. Samples were then biotin-labelled, fragmented and 
hybridised to complementary sequences on the chips. Wash steps removed any 
unbound fragments prior to staining and optical detection.  
 Statistical analysis of the raw microarray data was performed using Genespring 
14.5. The raw optical image of the hybridised chip was processed alongside an 
annotation file that describes the layout of the chip (HuGene 2_0). Differential 
significance between the two experimental groups was assessed using a 2-way analysis 
of variance (ANOVA) and quality control was assessed via Principal Component 
Analysis. Data was then filtered by expression; transcripts that did not express above 
the 20th percentile in any of the six samples were removed from further analysis to 
reduce background. Differences in fold change between the two experimental groups 
were assessed and a cut-off of 1.2 fold difference in expression was applied. A Go-
Term and Gene Set Enrichment Analysis (GSEA) was run prior to exporting the 
resultant gene list and fold change values to Ingenuity Pathway Analysis (IPA) 
Software. 
 Top canonical pathways and molecular and cellular functions with an 
Activation Z-Score greater than 2 or less than -2 (considered significant by software 
guidelines) were identified by the IPA core analysis platform for further analysis. Gene 
members that were predicted by the IPA database or published literature to be directly 
or indirectly linked to NOTCH signalling were identified and possible pathways were 
explored. The Molecule Activity Predictor (MAP) tool was used to simulate 
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2.6 In Vitro Assays 
 
2.6.1 Colony formation assay 
 
 Cells were seeded at a density of 500 cells per well onto a J2-3T3 feeder layer 
in a 6 well plate. Supplemented FAD medium was replaced every 2-3 days. On day 
14, the remaining feeder cells were removed by pipetting in PBS and SCC colonies 
were stained for 2hrs with 1% Rhodanile Blue. Plates were imaged using a Molecular 
Imager Gel Doc XR+ (BioRAD), and analysed using the Colony Area plug-in for FIJI. 
Statistical analysis was performed using GraphPad Prism 7. Based on a normal 
distribution of sample means, a student’s t-test was used to test the null hypothesis that 
the mean values of two groups are equal. A t-test value less than 0.05 was considered 
a statistically significant difference. 
 
2.6.2 EdU and cell morphology assay 
 
 Cells were seeded onto fibronectin-coated 96 well plates at a density of 2x103 
cells / well in KSFM. Cells were removed from the J2 feeder layer to ensure no feeder 
contamination during analysis. KSFM was used to promote single cell attachment for 
high content analysis. At 22hrs, pre-warmed EdU (Life Technologies) was added to 
the cell medium at a concentration of 10 µM. At 24hrs, cells were fixed for 10 minutes 
in 4% PFA (Sigma Aldrich). Following 3 x washes in PBS, the Click-iT Alexa Fluor 
488 Imaging Kit (Life Technologies) was used according to the manufacturer’s 
instructions to measure proliferation over the 2hr period. Nuclei were stained with 
DAPI (ThermoFisher Scientific) at a concentration of 1 µg/ml and cytoplasm was 
stained with Cell Mask Deep Red Plasma Stain at a concentration of 1:500 for 1hr at 
room temperature. The percentage of EdU positive cells, cell area and cell roundness 
was calculated using Harmony Software on the Operetta High Content Imaging 
System (PerkinElmer). The derived pipelines are detailed in Figure 2.2. Statistical 
analysis was performed using GraphPad Prism 7. Based on a normal distribution of 
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sample means, a student’s t-test was used to test the null hypothesis that the mean 
values of two groups are equal. A t-test value less than 0.05 was considered a 
statistically significant difference. 
 
2.6.3 Differentiation assay 
 
Cells were seeded onto fibronectin-coated 96 well plates at a density of 2x103 
cells / well in KSFM medium. At 24hrs post-seeding, cells were fixed and stained for 
Transglutaminase 1 via the immunocytochemistry method previously detailed. The 
percentage of differentiated cells was calculated using Harmony Software on the 
Operetta High Content Imaging System (PerkinElmer). The derived pipeline is 
detailed in Figure 2.2. Statistical analysis was performed using GraphPad Prism 7. 
Based on a normal distribution of sample means, a student’s t-test was used to test the 
null hypothesis that the mean values of two groups are equal. A t-test value less than 
0.05 was considered a statistically significant difference. 
 
2.6.4 Cell migration assay 
 
  Cells were seeded onto collagen-coated 96 well image-lock plates (Essen 
BioScience) at a density of 5x104 cells / well in KSFM medium and mitotically 
inhibited by incubation with 4 µg/ml Mitomycin-C (Sigma Aldrich) for 2hrs at 37oC. 
A wound was created using the Essen 96-Well Wound Maker (Essen BioScience) 
according to the manufacturer’s instructions. The plates were secured in the IncuCyte 
Zoom (Essen BioScience) and imaged once per hour at 10x magnification. The 
IncuCyte Zoom software was used to calculate the confluence of cells in the wound 
area over a period of 20hrs. The analysis process is detailed in Figure 2.3. Statistical 
analysis was performed using GraphPad Prism 7. Based on a normal distribution of 
sample means, a student’s t-test was used to test the null hypothesis that the mean 
values of two groups are equal. A t-test value less than 0.05 at each time point was 



























2.7.1 Establishing the xenograft  
 
 All animal experiments were subject to local ethical approval and performed 
under the terms of the UK Government Home Office Licence. The technical staff of 
the animal facility in King’s College London maintained the mice according to 
University guidelines. Mice were housed in a pathogen-free environment and exposed 
to a 12hr light / dark cycle. Caging, food, water and bedding were autoclaved prior to 
use. This experiment was performed in collaboration with Dr Inês Sequeira. 
The role of NICD in vivo was explored using a tongue xenograft assay that 
recapitulates aspects of SCCHN (Goldie, et al., 2012; Benaich, et al., 2014). The 
methodology was derived from previously published literature, which has been well 
reviewed by Sano and Myers (Sano & Myers, 2009). Female NSG (Jax Strain) mice, 
4-6 weeks old, were sourced from Charles River and acclimatised for two weeks.  Mice 
were anesthetised via intraperitoneal injection of ketamine and xylazine, as previously 
Figure 2 3: Analysis of cell migration assays using the IncuCyte Zoom Software. A number of phase 
focus images from different wells and time points were used as a representative cohort; cells were 
characterised and a cell mask applied (orange). The software calculates the original wound area and 
creates a new wound outline for each time lapse image (green). Each hour, the percentage of original 
wound area overlaid with the cell mask was measured and data exported for analysis. 
0hrs 20hrs 
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described by Sequeira et al. (Sequeira, et al., 2014). For a 2 ml solution, 0.5 ml 
Imalgene 1000 (Ketamine, 100 mg/ml, Merial) was mixed with 0.25 ml Rompun 
Injection Solution 2% (xylazine hydrochloride, Bayer) and 1.25 ml PBS. A dose of 0.1 
ml / 25 g body weight was administered using a 0.3 ml U-100 insulin syringe with 
needle (VWR). The anaesthetised mice were maintained on a heated block for the 
duration of the procedure.  
The SJG6 oral SCC cell lines (Table 2.1), transduced with either NICD or a 
blank vector control, were re-suspended in pre-warmed PBS. Forceps were used to 
secure the mouse tongues and a 30-gauge hypodermic needle with a 0.3 ml insulin 
syringe was used to perform a submucosal injection of either 105 or 104 cells, in a 
volume of 30 µl, into the lateral tongue. An analgesic of 1.5 µl Carprieve, diluted in 
30 µl sterile water, was administered by subcutaneous injection using a 0.3 ml U-100 
insulin syringe with needle.  
Mice were observed until they had recovered from anaesthesia and were 
housed with paper bedding, paper lining and gel food. Mice were weighed twice per 
week and culled on ethical grounds if they lost more than 20% of their body weight.  
 
2.7.2 Harvesting the tumours 
 
 Mice were sacrificed on day 30 or 60 via cervical dislocation. The tongues 
were removed and washed in PBS. 2hrs prior to harvesting, mice were injected 
intraperitoneally with EdU (ThermoFisher Scientific) at a concentration of 50 µg / 
gram of body weight using a 0.3 ml U-100 insulin syringe with needle.  
 
2.7.3 Macroscopic imaging  
 
 The dorsal and ventral surfaces of the tongue were imaged using the Nikon 
SMZ18 Stereo Zoom Microscope and DS-R12 camera. FIJI software was used to 










Following macroscopic imaging, the tongues were embedded in OCT (VWR) 
in 22 mm2 square Peel-A-Way embedding moulds (Sigma Aldrich) and frozen at -




 Frozen OCT samples were sectioned using a CryoStar NX70 (ThermoFisher 
Scientific). For H&E and immunohistochemistry staining, 8 and 10 µm samples 
respectively were mounted onto slides and stored at -80oC for future use. For PCR, 50 
µm sections, collected from several tumour depths, were collected into lysis buffer and 
processed as previously described (section 2.5.1-2.5.3).  
 
2.7.6 H&E staining 
 
 H&E staining was performed according to standard protocols. OCT sections of 
8 µm were fixed in 4% PFA (diluted in 1x PBS) for 10 minutes at room temperature. 
Slides were then washed in 1x PBS followed by Millipore water prior to staining with 
Hematoxylin solution for 1 minute. Slides were again washed 3 x in distilled water 
and 1x in Millipore water before counter-staining for 1 minute in Eosin. Slides were 
dehydrated through 10 second incubations in 75%, 90% and 2 x 100% ethanol, and 
cleared via 2 x 5 minute incubations in xylene. Finally, samples were mounted in DPX 





 OCT sections of 10 µm were thawed for 5 minutes at room temperature. A 
Dako Pen (Sigma Aldrich) was used to form a hydrophobic seal around the sections 
for staining. The sections were washed twice in PBS, fixed for 2 minutes in 2% PFA 
and washed a further 2x prior to permeabilising with 0.5% Trition X-100 for 10 
minutes. The blocking buffer detailed in Table 2.8 was used to block samples for 1hr 
at room temperature.  
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 Primary antibodies were diluted in blocking buffer and samples were incubated 
overnight at 4oC. The primary antibodies used are detailed in Table 2.9. Following 3 
x 10 minute washes in TBS, samples were stained with appropriate species-specific 
Alexa Fluor conjugated secondary antibodies, diluted 1:200, and DAPI (Life Tech), 
diluted 1 µg / ml, in blocking buffer for 1hr at room temperature. Samples were again 
washed 3 x 10 minutes in TBS before mounting with Prolong Gold Anti-fade Reagent 
(Invitrogen) according to the manufacturer’s guidelines. Imaging was performed using 
an A1 Nikon Upright Confocal Microscope (located at the Nikon Imaging Centre, 
King’s College London) and NIS Elements Software.  
FIJI software was used to measure the area of positive Transglutaminase 1 
staining (488 channel) as a percentage of total tumour area. Statistical analysis was 
performed using GraphPad Prism 7. Based on a normal distribution of sample means, 
a student’s t-test was used to test the null hypothesis that the mean values of two groups 
are equal. A t-test value less than 0.05 was considered a statistically significant 
difference. 
 
2.7.8 EdU  
 
 Mice were injected intraperitoneally with EdU at a concentration of 10 mg / kg 
body weight 2hrs prior to harvesting. The Click IT EdU kit was used to fluorescently 
label 10 µm OCT sections according to manufacturer’s instructions. Cell nuclei were 
stained with DAPI, diluted 1 µg/ml, and FIJI was used to calculate proliferating cells 
as a percentage of total tumour cells. The tumour area was selected, an image threshold 
was applied for both DAPI and EdU (Alexa Flour 488) and cell number was calculated 
using the measurement tool. Statistical analysis was performed using GraphPad Prism 
7. Based on a normal distribution of sample means, a student’s t-test was used to test 
the null hypothesis that the mean values of two groups are equal. A t-test value less 












Validation and Rescue of a Truncating NOTCH1 Mutation 
in Oral SCC Line SJG6 
 
 
This chapter provides the building blocks for this research project. SCCHN patient 
derived cell lines have been characterised and the truncating NOTCH1 mutation 
identified in SJG6 was validated. The rescue of SJG6 via lentiviral transduction of 




3.1 Analysis of NOTCH1 Mutations in SCCHN Patient Derived Cell 
Lines  
 
 Cell lines have been derived from 21 anonymised SCCHN patient biopsies and 
named SJG after the initials of the scientist principally responsible for their derivation, 
Stephen J Goldie. The biopsies were obtained from surplus material taken for 
investigative histological examination. Females made up 57% of the sample group and 
the median age was 55. All samples were HPV negative.   
Of the 21 SJG lines, patient matched blood was available for 17 and 16 passed 
DNA quality control measures for whole exome sequencing. Whole exome sequencing 
confirmed the lines were representative of the mutational spectrum of primary oral 
SCC lines in The Cancer Genome Atlas (Hayes, et al., 2016). Patient and primary 
tumour data is detailed in Table 2.1.  
The number of nonsynonymous somatic mutations in the lines varied from 32 
to 639 (Figure 3.1). Of the 16 sequenced lines, 3 (18.75%) were found to harbour 
mutations in NOTCH1, namely SJG6, SJG17 and SJG41. Further, 2 of 4 mutations 
(50%) were found to be truncating, both of which were identified in the SJG6 line 
(Table 3.1). Sanger sequencing performed by Dr Kazunori Sunadome confirmed the 
presence of the two heterozygous truncating mutations. There was no correlation 
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between NOTCH1 mutation status and the mutation count per line. The two 
nonsynonymous SNV mutations and one of the truncating mutations were located in 
the EGF-like ligand binding domain of the NOTCH1 receptor. The second truncating 




























Mutation Effect Mutation Type 
SJG6 C936A C312X G  T Stopgain SNV Heterozygous 
SJG6 G5529A W1843X C  T Stopgain SNV Heterozygous 










Figure 3 1: Frequency of somatic mutations identified by whole genome sequencing in SJG lines.   
  













3.2 Validation of Inactivating NOTCH1 Mutations in SJG6 
 
 As the aim of this study is to investigate the effect of changes in NOTCH1 
expression on changes in cell behaviour in SCCHN, the truncating mutations in SJG6 
made it the most promising line for further investigation. I sought to further 
characterise and validate these potentially inactivating mutations.  
 
3.2.1 Relative Expression of NOTCH1 in SJG6: mRNA Level  
 
 In order to investigate the relative expression of NOTCH1 in the SJG6 line, a 
comparative RT-qPCR was performed alongside two SJG lines that did not harbour 
any NOTCH pathway mutations: SJG13 (Figure 3.3a) and SJG32 (Figure 3.3.b). 
NOTCH1 expression was found to be significantly reduced in SJG6 compared to said 
lines: approximately 12% and 18% of SJG13 and SJG32 respectively. There was no 










Figure 3 2: Location of NOTCH1 mutations in patient derived SJG lines. EGF-like Repeats = epidermal 
growth factor-like repeats. TMD = transmembrane domain. ANK = ankyrin domain. PEST = proline, 
glutamic acid, serine, threonine-rich domain. Figure created using cBioPortal (Cerami, et al., 2012; 
Gao, et al., 2013). 
  















3.2.2 Relative Expression of NOTCH1 in SJG6: Protein Level  
 
 In order to investigate the expression of NOTCH1 at the protein level, western 
blots were performed (Figure 3.4). SJG6 lysate was run with SJG32 for comparison. 
A cleaved NOTCH1 antibody that recognises an epitope downstream of both 
truncating mutations was used. To validate the cleaved NOTCH1 antibody, a siRNA-
mediated knockdown of NOTCH1 in SJG32 was undertaken. DharmaFECT NOTCH1 
siRNA and control transfection reagents were used according to manufacturer’s 
guidelines. Following a 72hr incubation, protein lysates were derived from respective 
cell cultures. A clear reduction in the level of cleaved NOTCH1 expression can be seen 
in the SJG32 knockdown compared to the original line, GAPDH control and scrambled 
control line, hence confirming the specificity of the antibody. There was no cleaved 









Figure 3 3: RT-qPCR analysis of NOTCH1 expression in SJG6 compared to two SJG lines that do not 
harbour any NOTCH pathway mutations; SJG13 (a) and SJG32 (b). Expression was normalised to s18 
and GAPDH housekeeping genes. n=3. * = student’s t-test value <0.05. ** = student’s t-test value 
<0.01. RT 
  


















3.3 NOTCH Signalling Pathway in SJG6 
 
3.3.1 Mutational Landscape of the NOTCH Signalling Pathway in SJG Lines  
 
 Although NOTCH1 is the focus of this study, the four NOTCH receptors are 
highly conserved, meaning there is potential for compensation. Whole exome 
sequencing did not identify any somatic mutations in the NOTCH 2-4 receptors in 
SJG6, SJG13 or SJG32. However, deeper-depth Sanger sequencing at the NOTCH 
target region identified a small number of further mutations. Of these mutations, only 
one in SJG6 was found to be both in a coding region and non-synonymous: namely, a 
homozygous SNV in the PEST domain of NOTCH3 (A2223). Sanger sequencing was 
performed by Dr Kazunori Sunadome.  
 Whole exome sequencing data was also mined for other key components of the 
NOTCH signalling pathway for SJG6, SJG13 and SJG32. SJG13 and SJG32 were not 
found to harbour any nonsynonymous mutations in other pathway members. On the 
contrary, SJG6 was found to have mutations in a number of other pathway members, 
as detailed in Table 3.2. The mutational status of the following genes or gene families 
were sought: (1) ADAM, (2) JAG, (3) DLL, (4) CTNNB1, (5) FBXW7, (6) HAT1, (7) 
Figure 3 4: Western blot showing the protein expression of cleaved NOTCH1 in SJG6, SJG32, SJG32 
+ NOTCH1 siRNA, SJG32 + GAPDH siRNA control and SJG32 + scrambled siRNA control. 
Cleaved 
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HDAC, (8) FNG, (9) MAML, (10) NCOR2, (11) NOTCH, (12) PSEN, (13) CSL, (14) 
HES, (15) HEY and (16) SNW1.  
 
 










ADAM15 G884A R295Q G  A 
Nonsynonymous 
SNV 
ADAM29 G1650C Q550H G  C 
Nonsynonymous 
SNV 
JAG1 C1124T S375L G  A 
Nonsynonymous 
SNV 
DLL4 C1707A N569K C  A 
Nonsynonymous 
SNV 
HDAC1 G1186A E396K G  A 
Nonsynonymous 
SNV 
HDAC7 C106G Q36E G  C 
Nonsynonymous 
SNV 





3.3.2. Relative Expression of NOTCH Signalling Pathway Members in SJG6  
 
 In order to investigate the wider effect of the truncating NOTCH1 mutations in 
SJG6, a RT2 Profiler PCR Array (Qiagen) for the human NOTCH signalling pathway 
was performed for SJG6 and SJG32. The array is in a 96 well format. Each well 
contains a single probe for a panel of 35 NOTCH related genes, 5 housekeeping genes 
and patented controls to monitor PCR quality and efficiency. The array allows for the 
simultaneous RT-qPCR expression analysis of the 35 NOTCH-related genes in two 
cDNA samples. Findings indicated a down-regulation of a high proportion of NOTCH 
pathway associated genes in SJG6 compared to SJG32 (Figure 3.5a). 
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Ingenuity Pathway Analyser was used to visualise expression differences in 
key members of the canonical NOTCH signalling pathway (Figure 3.5b). As well as 
reduced NOTCH1 expression, SJG6 was found to have a lower expression of ligands 
JAG1, JAG2 and DLL1; co-activators MAML1-3 and CSL; and post-transcriptional 
regulators LFNG and MFNG. Conversely, cleavage enzymes ADAM17 (TACE) and 
γ-secretase (represented in the array heatmap by subunits APH1A and APH1B) were 
found to be upregulated in SJG6 compared to SJG32.  
Of the 35 genes analysed using the PCR array, none were significantly 
upregulated in SJG6 relative to SJG32, but 6 were found to be significantly 
downregulated: (1) JAG1 (21%), (2) HDAC8 (61%), (3) MAML2 (27%), (4) MAML3 
(16%), (5) MFNG (5%), and (6) NOTCH2 (13%) (Figure 3.5c). As discussed in 
section 3.3.1, JAG1 has been shown to harbour a non-synonymous SNV mutation in 
SJG6. No mutations were identified in the remaining five genes by whole exome 
sequencing in the SJG6 line.  
The NOTCH array did not assess any downstream targets of the NOTCH 
signalling pathway. Therefore, a further RT-qPCR was performed to calculate the 
relative expression of the well-documented down-stream targets HES1, HES5 and 
HEY1 in SJG6 relative to SJG32 (Figure 3.6). HES5 expression was found to be lower 
and HES1 and HEY1 expression was found to be significantly lower in SJG6 




















































Figure 3 5: RT2 Profiler PCR Array for the human NOTCH signalling pathway. SJG6 was normalised 
to SJG32. a) Heat map of 3 biological replicates for each of the 35 genes. Green = downregulation. Red 
= upregulation.  Jag = Jagged. DLL = Delta-like Canonical NOTCH Ligand. FBXW = F-Box/WD. HAT 
= Histone Acetyltransferase. HDAC: Histone Deacetylase. DLK = Delta-like Non-Canonical NOTCH 
Ligand. LFNG = Lunatic Fringe. MAML = Mastermind-like. MFNG = Manic Fringe. NCOR = Nuclear 
Receptor Co-Repressor. NCSTN: Nicastrin. PSEN: Presenilin. PSENEN: Presenilin Enhancer. RBPJ = 
Recombining Binding Protein Supressor of Hairless. RFNG = Radical Fringe. b) Canonical NOTCH 
signalling pathway overlay with expression data. The pathway was created using Ingenuity Pathway 
Analyser (Qiagen). c) Relative expression of the 6 genes which were found to have statistically significant 
expression differences.  n=3. *= student’s t-test value <0.05. **= student’s t-test value <0.01. 
  















3.4 Validation of NOTCH1 Rescue in SJG6 
 
 A lentiviral system was used to rescue NOTCH1 signalling in SJG6 by 
introducing NICD, the active domain of the NOTCH1 receptor. A control line was 
derived by transfecting SJG6 with the empty vector (here-on referred to as SJG6 
Blank). In both cases, expression of mCherry was used as a marker of successful 
transfection and mCherry positive cells were selected by FACS. Figure 3.7a shows 
both stably expressing cell lines growing on J2 feeder layers.  
 In order to confirm the expression of NICD at the protein level, a western blot 
was performed (Figure 3.7b). A strong band can be seen immediately post-sorting and 
a fainter band can be seen in the stably expressing cell line (here-on referred to as SJG6 
+ NICD. No band is detected for SJG6 Blank. This western blot was performed by Dr 
Kazunori Sunadome.  
 RT-qPCR was performed to quantify the mRNA expression levels of NICD. 
NICD expression in SJG6 + NICD was found to be approximately 3x higher than in 
the empty vector control (Figure 3.7c).   
 It is proposed that the stably expressing cell line has lower NICD protein 
expression than the cell line immediately post sorting as the cells with the highest 
levels of NICD differentiate and are lost from the population. Therefore, the resulting 
stably expressing cell line is made up of cells expressing lower levels of NICD, which 
is more representative of wild type expression. In order to investigate this, a colony 
Figure 3 6: RT-qPCR analysis of HES1, HES5 and HEY1 expression in SJG6 and SJG32. Expression 
was normalised to s18 and GAPDH housekeeping genes. n=4. ** Student’s t-test calculated at <0.01. 
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formation assay was performed on cells which had been FACS sorted for high and low 
mCherry expression. Consistent with the differentiation hypothesis, cells expressing 
higher levels of mCherry formed fewer colonies than those with low expression levels 
(Figure 3.7d).    
Finally, immunocytochemistry staining for activated NOTCH1 was performed 
on the SJG6 Blank and SJG6 + NICD line. Activated NOTCH1 staining intensity was 





3.5.1 The SJG Lines are Representative of SCCHN 
 
Previously published work has characterised the SJG lines and whole exome 
sequencing confirmed the mutational spectrum of the lines to be representative of 
primary oral SCCs in TCGA (Hayes, et al., 2016). Consistent with the larger TCGA 
database, whole exome sequencing identified NOTCH1 mutations in 18.75% of SJG 
lines. Moreover, 50% of these mutations were truncating and 75% were found to occur 
in the EGF-like ligand binding domain. In SCCHN patient samples, a 3D hotspot for 
mutations has been identified in NOTCH1. One of the truncating mutations recorded 
in SJG6 was located 143 amino acids towards the N-terminus of this 3D hotspot and 
within the wider region of increased mutation clustering (Cerami, et al., 2012; Gao, et 
al., 2013; Gao, et al., 2017).  
It is worth noting that 57% of the SJG lines were derived from females, 
compared to 27% of the TCGA lines. The epidemiology of SCCHN currently records 
these tumours to occur more frequently in males, by a ratio of 2:1 to 4:1. However, the 
number of cases in females is steadily increasing (although a proportion of this 
increase is due to an increase in HPV positive cancers) and there is no published 
evidence to suggest mutational differences in the genetic landscape of SCCHN 
between the sexes. The median age at which the biopsies were collected is consistent 









































Figure 3 7: Validation of successful transfection of SJG6 with NICD. a) Phase focus image showing 
mCherry expression in the non-transfected SJG6 line, SJG6 cells transfected with a blank vector control 
and SJG6 transfected with an NICD-expressing lentiviral plasmid. b) Western blot showing the protein 
expression of NICD in the SJG6 + NICD cell line immediately post FACS for mCherry expression, the 
SJG6 Blank vector control line and the stable  SJG6 +NICD line. c) RT-qPCR showing the relative 
expression of NOTCH1 (Taqman probe targeted to the NICD domain) in SJG6 Blank and SJG6 + 
NICD. Expression was normalised to housekeeping genes s18 and GAPDH. n=3. ** = student’s t-test 
value <0.01. (d) Colony formation assay comparing SJG6 + NICD cells FACS sorted for high and low 
mCherry expression. (e) Activated NOTCH1 immunocytochemistry staining (red) for SJG6 Blank and 
SJG6 + NICD. Nuclei were stained with DAPI (blue).  
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3.5.2 Characterisation of NOTCH1 Mutations in SJG6  
 
 The aim of this study is to assess the role of NOTCH1 in SCCHN, as such, the 
truncating mutations in SJG6 makes it the most appropriate line for in depth analysis.  
SJG6 was found to harbour the highest number of genetic alterations of all the 
SJG lines. High mutation counts are often associated with cancers caused by mutagen 
exposures. However, the patient was categorised as a non-smoker and was not found 
to consume alcohol excessively (Table 2.1).  
The SJG6 primary tumour was graded at stage 4a, suggesting rapid growth and 
spread. In addition, the tumour was found to be the largest by diameter, have deep 
invasion and be poorly differentiated. As such, it is possible that the tumour had 
acquired higher levels of genetic alterations as it was biopsied at a later stage and had 
undergone excessive cell cycling. Alternatively, the reverse may be true. Higher 
chromosomal abnormality has been positively associated with more aggressive 
tumours and reduced survival. As such, the advanced tumour stage may be as a direct 
result of the high mutation rate rather than the other way round (Smeets, et al., 2009). 
The mRNA levels of NOTCH1 in SJG6 were confirmed to be approximately 
15% of that measured for SJG lines that do not harbour any NOTCH pathway 
mutations. Notably, the Taqman probe targeted downstream of both truncating 
mutations but the Ct value of NOTCH1 mRNA in SJG6 still exceeded the water 
control threshold. No NOTCH1 was detected at the protein level via western blot. 
However, the western blot image is at an exposure time immediately prior to pixel 
saturation for the SJG32 NOTCH1 protein band. It is therefore possible that a longer 
exposure time would have identified a low level of NOTCH1 expression in the SJG6 
lysates.  
There are two potential NOTCH1 statuses in the SJG6 line. (1) The two 
heterozygous truncating mutations occur on the same allele and do not confer 
compound heterozygosity. (2) The two heterozygous truncating mutations occur on 
different alleles giving rise to compound heterozygosity. As the NOTCH1 mRNA 
expression is substantially lower than 50%, it is likely that the mutations occur on two 
separate alleles. There is high conservation between the four NOTCH receptors, it is 
therefore possible that the low levels detected by RT-qPCR could be a result of 
unspecific amplification. As the cells were grown from resected tumours on a feeder 
layer to reduce selective pressures, another possibility is that the two heterozygous 
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mutations occur on the separate alleles but there is a heterogeneous cell population in 
which some cells harbour the truncating mutations and some do not. This would be 
consistent with the big bang theory of clonal evolution in cancer and the most 
representative of a tumour cell population (Sottoriva, et al., 2015). This theory is 
further supported by NOTCH1 staining performed on the SJG6 Blank cell population 
in Figure 3.7e which appears to show positive staining in a proportion of the cell 
population. Single cell sequencing analysis will be required to confirm the mutation 
status.  
Of note, the majority of published NOTCH1 mutations are heterozygous and 
NOTCH proteins commonly demonstrate haploinsufficiency in tissue patterning. As 
such, the loss of function of a single copy of NOTCH1 or mosaic inactivation in a cell 
population is predicted to be sufficient to impede signalling and contribute to 
tumorigenesis (Wang, et al., 2011). Therefore, the rescued SJG6 cell line provides an 
adequate tool for studying the role of NOTCH1 in SCCHN.  
 
3.5.3 Characterisation of the NOTCH1 signalling pathway in SJG6 
 
Further investigation into the genomic landscape of SJG6 identifies mutations 
in several other members of the NOTCH signalling pathway. Ligands, DLL4 and 
JAG1 were both found to harbour non-synonymous SNVs and JAG1 was found to be 
significantly reduced at the mRNA level in SJG6 compared to a line that does not 
harbour any NOTCH pathway mutations. As discussed in section 1.2.4, there are few 
studies investigating the role of JAG1 as a ligand of NOTCH1 in the oral epithelium. 
However, low ligand expression is predicted to decrease overall NOTCH signalling 
due to reduced pathway activation. Further, studies in a murine model have shown 
JAG2 to be essential for NOTCH activated differentiation in the oral epithelium during 
platelet development (Casey, et al., 2006). As a result, this down-regulation of JAG1 
must be considered when analysing the role of NOTCH1 in SJG6. Cell rescue via the 
introduction of the NICD domain will bypass ligand-mediated activation of the 
NOTCH signalling pathway in order to investigate the effect of downstream pathway 
activation in the SJG6 cell line. The consequence of mutations in NOTCH pathway 
members will be discussed further in Chapter 8.  
During the induction of NOTCH mediated transcription, CSL switches from a 
transcriptional repressor to activator. The HDAC family of proteins interact with CSL 
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as part of a co-repressor complex and it has been shown that the inhibition of HDAC1 
can lead to increased activation of downstream targets. Conversely, the mastermind 
like protein family (MAML) make-up part of the co-activator complex and their down-
regulation has been shown to inhibit downstream NOTCH signalling (Moellering, et 
al., 2009).  
SJG6 was found to harbour mutations in histone deacetylases (HDAC) 1 and 
7. mRNA expression of HDAC1 was not calculated as part of the NOTCH array, 
however, HDAC7 was confirmed to be reduced and HDAC8 was found to be 
significantly reduced. SJG6 was not found to harbour mutations in any of the MAML 
genes, however, MAML 2 and 3 were found to be significantly down regulated 
compared to SJG32, a line that does not harbour any NOTCH pathway mutations. In 
order to assess the status of downstream targets of the NOTCH pathway, a RT-qPCR 
was performed to compare the mRNA levels of HES1, HES5 and HEY1 compared to 
the SJG32 control line. All targets were found to be expressed at reduced levels when 
compared to the control line, providing further evidence for reduced NOTCH 
signalling in SJG6.  
SJG6 was also found to harbour mutations in ADAM 15 and 29. ADAM 17 
was assessed as part of the NOTCH array but not found to be significantly altered. The 
ADAM family of proteins are responsible for the first NOTCH cleavage event. As 
such, mutations in these genes may contribute to the deregulation of NOTCH 
signalling by preventing the successful dissociation of the NOTCH heterodimer.  
Finally, the NOTCH receptors are a highly conserved protein family. 
Therefore, the possibility of compensation must be considered. In the SJG6 line, 
NOTCH2 was found to harbour no somatic mutations but Sanger sequencing identified 
a single non-synonymous SNV in NOTCH3. As calculated by RT-qPCR, mRNA 
expression of NOTCH 2 and 3 was found to be significantly and non-significantly 
reduced when compared to a line that does not harbour any NOTCH1 mutations. As 
such, this data provides evidence against NOTCH family compensation in SJG6.  
 
3.5.4 NOTCH1 expression was successfully rescued in SJG6 
 
 In order to investigate the consequence of truncating NOTCH1 mutations in 
SCCHN, SJG6 was rescued via the lentiviral re-introduction of NICD; the active 
portion of the NOTCH1 gene.   
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 Immediately after FACS for the selectable marker, mCherry, the protein levels 
of NICD were substantially higher than that of the stably expressing cell lines. NICD 
is known to promote terminal differentiation in epithelial cells. As such, it is predicted 
that cells expressing the highest levels of NICD undergo terminal differentiation 
during the first passages and those that remain may be a closer representation of wild 
type levels. Colony formation assays assess the ability of single cells to undergo 
numerous rounds of self-renewal in order to form a colony (Franken, et al., 2006).  As 
such, a colony formation assay comparing SJG6 + NICD cells with high mCherry 
expression (and therefore high NICD expression) to those with low mCherry 
expression was performed. Consistent with the differentiation hypothesis, the cells 
with higher NICD expression formed much fewer colonies.  
The expression of NICD mRNA in SJG6 was found to be 12% and 18% of 
SJG13 and SJG32 respectively (Figure 3.3). Therefore the three-fold increase in NICD 
expression in the SJG6 + NICD cell line is still less than SCC lines that do not harbour 
any NOTCH pathway mutations. However, the Taqman probe used to identify NICD 
expression recognises both NICD and membrane bound NOTCH1 in the SJG13 and 
SJG32 cell lines. Therefore, a direct comparison cannot be made.  
As detailed in section 1.4.1, Alcolea et al. investigated the conditional knock-
out of NOTCH1 in a small percentage of oesophageal progenitor cells in a mouse 
model. The group demonstrated that within one year, the NOTCH1 knock-out cells 
had replaced the normal epithelium and entered a new state of homeostasis (Alcolea, 
et al., 2014). It is possible that the SJG6 cell line has acquired a steady state between 
proliferation and differentiation in the absence of NOTCH1. Therefore, lower NICD 
expression would be sufficient to induce differentiation. 
RT-qPCR of the stably expressing cell line confirmed a 3 fold higher mRNA 
expression of NICD in the rescued vs the blank control line and immunocytochemistry 
showed a higher intensity and more extensive staining for activated NOTCH1. 
Staining was present in the cytoplasm as well as the nuclear compartment. As the 
NICD domain has a NLS, stronger staining is expected in the nucleus. Therefore, the 
specificity of this antibody requires further testing. However, NICD is known to 
interact with a number of proteins in both the cytoplasm and the nucleus. Therefore 
competitive protein binding could influence the staining location. For example, under 
certain conditions, NICD is known to interact with sonic hedgehog in the cytoplasm 
(Fortini & Artavanis-Tsakonas, 1994). 
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3.5.5 SJG6 as a tool for investigating the role of NOTCH1 in SCCHN 
 
 SJG6 was successfully rescued for NICD. A control line was also derived using 
a blank plasmid. However, it is important to consider the disadvantages as well as the 
advantages of SJG6 as a system for studying the role of NOTCH1 in SCCHN. 
 The use of SJG6 is advantageous as it is an oral SCC line which harbours 
NOTCH1 mutations representative of those commonly seen in wider SCCHN studies, 
i.e. two truncating mutations. Further, one of these truncating mutations occurs in the 
frequently-mutated EGF-like ligand binding domain.   
 A disadvantage of the SJG6 line for use is the high mutation rate in the line. In 
particular, mutations presence in other members of the NOTCH pathway which may 
complicate analysis. However, SCCHN is a highly heterogeneous cancer and it is 
important to further understanding of the interaction of mutations. As such, this study 
could be strengthened in future by repeating on other NOTCH-mutant SCCHN lines 
with a known mutational landscape. It would also be of interest to knock-down 
NOTCH1 expression in a cell line without mutations in NOTCH pathway members. 
 A further disadvantage of a lentiviral based system is the potential for 
activation of viral response genes. In particular, viral transfer has been shown to induce 
an immune response (Follenzi, et al., 2007). However, the use of a blank vector line 




In summary, whole exome sequencing of derived SJG lines found their 
mutational landscape  to be representative of SCCHN as a whole. SJG6 was found to 
harbour two truncating NOTCH1 mutations and was therefore considered a good tool 
for the study of the functional consequence of these mutations. The NOTCH signalling 
pathway was further characterised in the SJG6 line and downstream targets were 
confirmed to be reduced compared to a line that does not harbour any NOTCH 
pathway mutations.  
In order to investigate the consequence of inactivating NOTCH1 mutations in 
SCCHN, SJG6 was successfully rescued for NICD. A control line was also derived 
using a blank plasmid. This provides a useful tool to study the effect of NOTCH1 in 
an otherwise genetically identical system and forms the foundation of this study.  
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Chapter 4 
Investigating the Role of NOTCH1 in SCCHN in vitro 
 
 
This chapter begins to explore the role of NOTCH1 in SCCHN. A range of in vitro 
assays have been derived to provide a direct comparison of the original and rescued 




This chapter aims to provide an overview of the effect of NICD on cellular 
properties associated with cancer in SCCHN. The most basic definition of cancer is a 
collection of cells with uncontrolled proliferation. As such, the rate of proliferation 
over a short time period will be assessed using an EdU assay. A colony formation 
assay will investigate the ability of cells to undergo long-term self-renewal. Coupled 
to uncontrolled proliferation, another characteristic of most cancer cells is failure to 
undergo normal differentiation. Staining for Transglutaminase 1, a maker of epithelial 
differentiation, will be used to compare differentiation in the two SJG6 cell lines. Cell 
morphology can also provide information on cell behaviour. As such, staining with 
Deep Red Plasma Cell Mask and analysis of cell phenotype will be performed using 
the Operetta High Content Imaging System. Finally, locally progressive tumours are a 
dominant clinical problem in SCCHN. Therefore, the rate of cell migration in the two 
lines will be compared by investigating the closure of a scratch wound. 
 
 
4.1 Clonogenicity  
 
 A colony formation assay was used to assess the ability of single cells to 
undergo numerous rounds of self-renewal in order to form a colony (Figure 4.1a) 
(Franken, et al., 2006). SJG6 Blank and SJG6 + NICD were seeded onto inactivated 
J2 feeder layers at single cell density. Total colony area was calculated as a percentage 
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of the well area. After two weeks, SJG6 Blank presented with a significantly higher 
average colony area percentage (12%) than SJG6 + NICD (9%) (Figure 4.1bi).  
The FIJI colony intensity percentage tool uses image pixel intensity as a 
measure of relative cell density between two colonies of the same size. The colonies 
formed by SJG6 Blank were found to have a significantly higher colony intensity 




























Figure 4. 1: Colony formation assay to compare the clonogenicity of SJG6 Blank and SJG6 + NICD. 
(a) Representative colony images of the two cell lines. (b) Colony area percentage. (c) Colony intensity 
percentage. n=3. ** Student’s t-test value <0.01.   
  




 An EdU assay was performed to compare the proliferative potential of SJG6 
Blank and SJG6 + NICD (Figure 4.2a). The cells lines were seeded at a concentration 
of 2,000 cells per well in KSFM medium onto collagen-coated 96 well plates and fixed 
at 24hrs. At 22hrs, EdU was introduced. The EdU incorporates with the newly 
synthesised DNA of proliferating cells and can be detected by fluorescent labelling. 
Over the two hour period, a significantly higher percentage of proliferating cells were 


















  In order to compare the level of differentiation in SJG6 Blank and SJG6 + 
NICD, cells were stained with Transglutaminase 1; a marker of epithelial 
differentiation (Figure 4.3a). Both cell lines were seeded at a concentration of 2,000 
cells per well in KSFM medium onto collagen coated 96 well plates. At 24hrs, the cells 
were fixed and stained with Transglutaminase 1. Nuclei were stained with DAPI. The 
Operetta High Content Imaging system was used to identify the percentage of 
Transglutaminase 1 positive cells in both populations (Figure 2.2). A significantly 
Figure 4. 2: EdU assay comparing the proliferative potential of SJG6 Blank and SJG6 + NICD. (a) 
Representative image of nuclei (DAPI; blue) staining positive for EdU (Alexa 488; green). (b) 
Percentage of proliferating cells. n=8. ** Student’s t-test value <0.01. 
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higher proportion of differentiated cells were recorded in the SJG6 Blank (8.5%) than 
















4.4 Cell Morphology 
 
 Cytoplasmic Cell Mask staining was performed to investigate morphological 
differences between SJG6 + NICD and SJG6 Blank. The cell lines were seeded at a 
concentration of 2,000 cells per well in KSFM medium onto four concentrations of 
fibronectin (0 µg/ml, 1 µg/ml, 5 µg/ml and 25 µg/ml) in 96 well plates. Fibronectin 
was used in line with a previously established protocol (Leha, et al., 2016). At 24hrs, 
cells were fixed, stained with Cell Mask and DAPI and analysed using the Operetta 
High Content Imaging System. The analysis pipeline is detailed in Figured 2.2a.  
 Morphological differences were observed between the two cell lines (Figure 
4.4a). In both lines, cells were found to have a larger cell area when seeded onto higher 
fibronectin concentrations (Figure 4.4b). SJG6 Blank was found to be significantly 
larger than SJG6 + NICD on fibronectin concentrations greater than 1 µg/ml. At each 
fibronectin concentration, SJG6 + NICD was found to be more rounded than SJG6 
Blank (Figure 4.4c). This finding was statistically significant at fibronectin 
concentrations of 1 µg/ml and 5 µg/ml. 
Figure 4. 3: Transglutaminase 1 staining to compare the percentage of differentiated cells in the SJG6 
Blank and SJG6 + NICD cell lines. (a) Representative image of Transglutaminase 1 staining (yellow) 
in SJG6 Blank (top) and SJG6 + NICD (bottom). Nuclei were stained with DAPI (blue). (b) Percentage 
of differentiated cells. n=3. * Student’s t-test >0.05.  
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 In both cell populations, a small number of elongated cells were observed 
(Figure 4.4di). Cells were identified using Cell Mask Deep Red Plasma Stain by the 
High Content Operetta Imaging System as detailed in Figured 2.2a. The percentage of 
elongated cells in each line was then calculated by thresholding for cells with a 
roundness ratio of less than 0.6. SJG6 Blank was found to have a higher percentage of 
elongated cells than SJG6 + NICD at all fibronectin concentrations and a significantly 
higher percentage at fibronectin concentrations greater than 5 µg/ml. In both cell lines, 
the percentage of elongated cells increased with increasing fibronectin concentrations 
(Figure 4.4dii). Duan et al. previously associated an elongated cell morphology in 
tongue carcinoma cells with cellular senescence (Duan, et al., 2006). This will be 
discussed further in section 4.6. 
 
 
4.5 Cell Migration 
 
 A scratch wound assay was performed to compare the rate of cell migration 
between SJG6 Blank and SJG6 + NICD (Figure 4.5). Both cell lines were first treated 
with mitomycin-C to remove bias from potential differences in the rates of 
proliferation between the lines. Both cell lines were seeded at a concentration of 
50,000 cells per well in KSFM medium onto collagen coated 96 well plates. A scratch 
wound was then created using the Essen BioScience 96-Well Wound Maker and the 
confluence of cells in the wound area was calculated over a 20hr period. SJG6 Blank 

















































Figure 4. 4: Operetta analysis comparing the morphology of SJG6 Blank and SJG6 + NICD on four 
concentrations of fibronectin (0 µg/ml, 1 µg/ml, 5 µg/ml and 25 µg/ml). (a) Representative images of 
SJG6 + NICD (top) and SJG6 Blank (bottom) on 5 µg/ml fibronectin. Nuclei were stained with DAPI 
(blue) and cytoplasm was stained with cell mask (red). (b) Measure of cell area. (c) Measure of cell 
roundness ratio. (d) By thresholding and excluding cells with a roundness ratio of less than 0.6 (red), 
elongated cells in the population were identified (green). (Note: the red and green colours are an 
overlay mask from the analysis pipeline and not representative of staining. White dots are EdU positive 
nuclei which was stained for in the same assay) (i) and calculated as a percentage of total cell number 
(ii). n=3. * Student’s t-test value <0.05.   
  

















4.6.1 NICD expressing cells exhibit reduced clonogenicity 
 
 Colony formation assays test the ability of individual cells in a population to 
undergo numerous rounds of self-renewal. As discussed in the introduction, when 
primary cultures of epidermal cells are derived, three types of colonies are formed; 
namely holoclones, meroclones and paraclones. Holoclones form large colonies, have 
a long replicative lifespan and are considered representative of stem cells. Paraclones 
form small colonies, have a short replicative potential and are thought to behave as 
transit amplifying cells. Meroclones act as an intermediate and form both growing and 
abortive colonies. Culture of holocone populations give rise to paraclones and 
meroclones (Barrandon, 1987). 
This approach has been extended to cancer cell lines. Data from colony 
formation assays suggest that the expression of NICD gives rise to cells with reduced 
clonogenicity i.e. reduced colony area and density (Figure 4.1). Not all cells within a 
tumour are equally able to initiate growth, metastasis and recurrence. This behaviour 
has been associated with a small population of CSCs. As such, this data provides 
evidence to suggest that NICD may act as a tumour suppressor by reducing the 
proportion of CSCs in the population. This data is not consistent with studies that have 
associated increased NOTCH1 expression with CSCs in SCCHN (Upadhyay, et al., 
Figure 4. 5: Scratch wound assay to compare the rate at which SJG6 Blank and SJG6 + NICD migrate 
to recolonise the initial wound area. n=5. *Student’s t-test value <0.05 between 7 and 20hrs.  
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2015; Wilson, et al., 2016).  Further experiments would be required to confirm this 
finding. It would be of interest to serially passage the colonies to further assess the 
potential for self-renewal. Staining for CSC markers (CD44, SOX2 and ALDH1) 
would also be required (Harper, et al., 2007).  
 
4.6.2 NICD expressing cells exhibit reduced proliferation 
 
Findings suggest that the expression of NICD gives rise to cells with a reduced 
ability to proliferate (Figure 4.2). This data is consistent with previous studies that 
have associated NICD expression with cell cycle arrest in oral and tongue SCC lines 
(Duan, et al., 2006; Pickering, et al., 2013). As such, data suggests a tumour suppressor 
role for NOTCH1 in SCCHN.  
However, there have been several studies showing the opposite effect, 
associating the loss of NOTCH1 expression with reduced proliferation (Yao, et al., 
2007; Yoshida, et al., 2013; Sun, et al., 2014). The effect of NOTCH1 signalling is 
likely to be influenced by the mutational landscape of individual tumours. Duan et al. 
provided evidence to suggest that the downregulation of Wnt / β-catenin signalling 
may act as a mechanism for cell cycle arrest in cell lines showing an anti-proliferative 
effect in response to NOTCH1 expression in SCCHN (Duan, et al., 2006). This idea 
will be further explored in Chapter 5.  
Interestingly, in this study as well as those also showing reduced proliferation 
in response to NOTCH1 expression, NICD was constitutively introduced. Conversely, 
NOTCH1 had been targeted for knockdown in studies showing the opposite effect.  In 
a number of cancers, the effect of NOTCH signalling has been shown to be highly 
context dependent and contingent on signal strength and timing, which may go some 
way to explain inconstancies between studies (Radtke & Raj, 2003; Weng & Aster, 
2004).  
 
4.6.3 NICD expressing cells exhibit deregulated differentiation 
 
As discussed in Chapter 3, it is predicted that cells expressing the highest levels 
of NICD underwent terminal differentiation prior to the formation of a stable cell line. 
This data is consistent with the known role of NOTCH1 in the commitment to terminal 
differentiation in normal keratinocytes and studies that have previously associated 
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NOTCH1 expression with differentiation in SCC (Lowell, et al., 2000; Rangarajan, et 
al., 2001; Nickoloff, et al., 2002; Nicolas, et al., 2003; Sakamoto, et al., 2012; 
Ravindran & Devaraj, 2012).  
Surprisingly, a lower percentage of cells in the stably expressing SJG6 + NICD 
line were found to express differentiation marker, Transglutaminase 1, when compared 
to the empty vector control (Figure 4.3). As described in the previous section, the effect 
of NOTCH signalling has been shown to differ, even within the same tumour type, as 
a result of signal strength and timing. It is therefore possible that whilst high levels of 
NICD expression results in terminal differentiation, those cells with lower NICD 
expression could give rise to the opposite effect. Kagawa et al. showed that under 
certain conditions, NICD expression could switch from being a driver of cellular 
senescence to actively decreasing levels of differentiation. Kagawa et al. linked this 
senescence checkpoint to the loss of p16 expression (Kagawa, et al., 2015). This theory 
shall be explored further in Chapter 5.  
Alternatively, Alcolea et al. investigated the conditional knock-out of 
NOTCH1 in a small percentage of oesophageal progenitor cells in a mouse model. The 
group demonstrated that within one year, the NOTCH1 knock-out cells had replaced 
the normal epithelium and entered a new state of homeostasis (Alcolea, et al., 2014). 
It is therefore possible that both SJG cell lines have acquired independent steady states 
between proliferation and differentiation irrespective of their NOTCH1 status.  
It is also important to note that Transglutaminase 1 is an intermediate 
differentiation expression marker. In normal epithelium it is expressed in the granular 
and spinous layers. In future experiments it would therefore be of interest to stain for 
earlier (such as Keratin 1 and 10) and later (such as filaggrin) markers of differentiation 
in order to get a more thorough picture of the whole differentiation process in both cell 
lines.  
 
4.6.4 NICD expression alters cell morphology 
 
 Both cell lines showed an increased cell area when seeded onto higher 
fibronectin concentrations. It is predicted that the higher concentrations of fibronectin 
provide a preferable environment for cells to seed and spread (Adams & Watt, 1993).  
 The expression of NICD gave rise to a smaller, more rounded morphology with 
fewer elongated cells in the population. The presentation of a more rounded 
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morphology in lines constitutively expressing NICD is consistent with the 
observations of Pickering et al. Complementary to proliferation data, Pickering et al. 
also confirmed the induction of β-galactosidase in these rounded cells, suggesting they 
had become senescent (Pickering, et al., 2013).  
 Conversely, Duan et al. noted that the expression of NICD gave rise to a more 
elongated cell population. The group suggested that this may be reflective of 
senescence, cell cycle arrest or apoptosis, but no validating experiments were 
performed (Duan, et al., 2006).  
 Another potential explanation for changes seen in cell morphology is EMT. 
When epithelial cells undergo EMT, they lose their cobblestone-like epithelial 
phenotype and acquire an elongated invasive mesenchymal phenotype 
(Krisanaprakornkit & Iamaroon, 2012). Therefore, the increased percentage of 
elongated cells identified in the SJG6 Blank cell line may associate NICD expression 
with reduced EMT, supporting a tumour suppressor role for NOTCH1. This idea is 
consistent with the increase in elongated cells at higher fibronectin concentrations as 
ECM substrates have been confirmed to enhance EMT (Kumar, et al., 2014). Staining 
for epithelial (such as E-cadherin and desmoplankin) and mesenchymal (such as N-
cadherin and vimentin) cell markers would be required to confirm this hypothesis. 
 
4.6.5 NICD expression is associated with reduced cell migration 
 
Findings suggest that the expression of NICD results in reduced cell migration. 
This data is inconsistent with that of currently published literature (Joo, et al., 2009; 
Zhang, et al., 2011; Yu, et al., 2012; Yoshida, et al., 2013; Dai, et al., 2015; Li, et al., 
2015; Jing, et al., 2016).  
However, it is important to note that wound closure is not a direct measure of 
invasive potential. Other factors must be considered, such as the ability to invade 
through the ECM. Nonetheless, this data demonstrates that the expression of NICD is 
able to successfully alter cell motility. This is of particular interest in SCCHN as 
locally progressive tumours are a dominant clinical problem.  
This work provides an observation of cell motility in SJG6 + NICD and SJG6 
Blank. Potential mechanisms will be explored in Chapter 5 and the role of NICD in 
tumour invasion will be investigated further in Chapter 6.   
 
  




Broadly, in vitro findings suggest that the expression of NICD is able to reduce 
clonogenicity and proliferation, promote differentiation and inhibit cell migration, 
thereby providing potential mechanisms for a tumour suppressor function of NOTCH1 
in SCCHN. However, within the framework of previously published literature, these 
findings add to existing evidence to suggest that the effect of NOTCH1 is highly 
context dependent and highlights the need for further study to better understand this 
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Chapter 5 
Investigating the Role of NOTCH1 in SCCHN: Microarray 
 
 
This chapter begins to explore the effect of NOTCH1 expression within the wider 
genetic landscape of SCCHN. A microarray was used to investigate how the rescue of 
NOTCH1 in SJG6 altered gene expression in the whole transcriptome. Microarray was 
chosen for the study as it is a robust, economical and well established method of gene 
expression analysis. In addition, validated analysis pipelines are available and several 




5.1 Microarray Analysis Confirms that the Expression of NICD 
Alters the Genetic Landscape of SJG6 
 
 In order to investigate how the expression of NICD alters the genetic landscape 
in SCCHN, microarray analysis of SJG6 Blank and SJG6 + NICD was undertaken. 
The three biological replicates naturally clustered into the two respective groups, 
suggesting that the expression of NICD changes the wider genetic landscape of the 
cell line (Figure 5.1a). The top 10 up- and down- regulated genes are highlighted in 
Figure 5.1b. Notably, fold changes identified in the SPANX family (co-increased with 
NICD) were 3x greater than that of any other gene. SPANX expression will be 
considered further in Chapter 6. 
 Before further analysis was performed, the validity of the microarray was 
assessed. RT-qPCR was used to confirm the relative expression of 5 genes (TMEM27, 
HEY1, CTH, ITGBL1 and ITGB6) that microarray showed to be significantly 

























5.2 The Differentially Expressed Gene Set between SJG6 Blank and 
SJG6 + NICD can be linked to Functional Characteristics  
 
 The Gene Ontology (GO) project was established to form a common language 
for describing a gene product’s cellular component, molecular function and biological 
process. This consistency of vocabulary allows gene sets to be interpreted for shared 
functional characteristics. This analysis technique is a GO term enrichment analysis. 
Genes are assigned to ‘bins’ based on their functional characteristics. One gene can be 
assigned to numerous bins. By assessing the bins which have been allocated to the full 
gene set, statistical tests can assess whether a bin is enriched for the input genes. As 
such, underlying cellular components, molecular functions and biological processes 
can be identified.  (Ashburner, et al., 2000).  
The top 20 GO terms for the differentially expressed gene set between SJG6 
Blank and SJG6 + NICD are shown in Figure 5.2a. Seven of the top eight terms are 
linked to cell location and include the nucleosome, intracellular region and 
extracellular region. A high proportion of derived GO terms are also linked to DNA 
organisation: (1) nucleosome, (2) DNA packaging complex, (3) histone H4-K20 
Figure 5. 1: Microarray analysis comparing gene expression in SJG6 Blank and SJG6 + NICD. (a) 
Heatmap showing that the three biological replicas of SJG6 Blank and SJG6 + NICD cluster with clear 
areas of up- (red) and down- (blue) regulation. (b) Top ten genes up- and down- regulated. (c) RT-qPCR 
validation of 5 (TMEM27, HEY1, CTH, ITGBL1, ITGB6) genes found to differ between SJG6 Blank and 
SJG6 + NICD via microarray. n=3. x / x = microarray / RT-qPCR. n=3. * = Student t-test value <0.05. 
** = Student’s t-test value <0.01.  
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demethylation, (4) histone demethylase activity (H4-K20 specific), (5) protein-DNA 
complex assembly and (6) nucleosome assembly. Two terms describe protein targeting 
to the membrane and endoplasmic reticulum respectively, and two terms are associated 
with viruses. Metabolic processes, differentiation of megakaryocytes and cell cycle 
progression are also included in the list.  
Due to the high number of GO terms related to DNA organisation and histone 
modification, microarray data was mined for changes in the expression of histone 
related genes. Of the 3150 genes found to have greater than a 1.2 fold change 
difference, 68 were found to be histones or histone regulators (2.2%). Further, 62 of 
the 68 genes were found to be downregulated (91%). These genes are detailed in Table 
5.1. 
A gene set enrichment analysis (GSEA) is a computational method to 
determine whether sets of genes show significant differences between two biological 
states or phenotypes (Subramanian, et al., 2005). The top 18 hits for microarray data 
comparing SJG6 Blank and SJG6 + NICD are shown in Figure 5.2b. Of note, 7 of 
these hits are associated with cancers and 2 are directly linked to oesophageal cancers. 
Further, and in corroboration with in vitro data in Chapter 4, proliferation and 























Figure 5. 2: Analysis of the differentially expressed gene set between SJG6 Blank and SJG6 + NICD. (a) 
GO term analysis which interprets the gene set in relation to the Gene Ontology classification system. 
Genes are assigned to ‘bins’ based on their functional characteristics. One gene can be assigned 
numerous bins. By assessing the bins which have been allocated to the full gene set, statistical tests can 
assess whether a bin is enriched for the input genes. As such, underlying cellular components, molecular 
functions and biological processes can be identified. Findings are plotted by corrected p-value. (b) Gene 
Set Enrichment Analysis (GSEA) which determines whether the pre-defined set of genes shows a 
statistical difference between two biological states or phenotypes. Top findings are plotted by q-value. 
n=3. 
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Table 5 1: Expression fold change in histone related genes in SJG6 + NICD compared 
to SJG6 Blank 
 
Gene Expression 
Fold Change  




ALKBH1 -1.217889   ↓ 1 HIST1H4A -1.525091 ↓ 
ASF1A -1.212881      ↓ 1 HIST1H4B -1.525091 ↓ 
ASH1L -1.393696      ↓ 1 HIST1H4C -1.525091 ↓ 
CDK1 1.2140411     ↑ 1 HIST1H4D -2.294169 ↓ 
DUSP1 -1.266398      ↓ 1 HIST1H4E -1.525091 ↓ 
DUSP12 -1.217831      ↓ 1 HIST1H4F -1.525091 ↓ 
DUSP22 -1.257568 ↓ 1 HIST1H4H -1.525091 ↓ 
H1F0 -1.238573 ↓ 1 HIST1H4I -1.525091 ↓ 
H1FX -1.577241 ↓ 1 HIST1H4J -1.525091 ↓ 
H2AFY2 -1.569221 ↓ 1 HIST1H4K -1.525091 ↓ 
HIST1H1A -1.310469 ↓ 1 HIST1H4L -1.525091 ↓ 
HIST1H1B -1.503214 ↓ 1 HIST2H2AA3/4 -1.637142 ↓ 
HIST1H1C -1.559918 ↓ 1 HIST2H2AB -1.804308 ↓ 
HIST1H1D -1.522174 ↓ 1 HIST2H2BA -1.556849 ↓ 
HIST1H1E -1.607831 ↓ 1 HIST2H2BE -1.305367 ↓ 
HIST1H2AB -1.251657 ↓ 1 HIST2H3D -1.536129 ↓ 
HIST1H2AC -1.356173 ↓  HIST2H4A -1.525091 ↓ 
HIST1H2AD -1.315778 ↓ 1 HIST2H4B -1.525091 ↓ 
HIST1H2AG -1.290961 ↓ 1 HIST4H4 -1.525091 ↓ 
HIST1H2AH -1.290961 ↓ 1 PTP4A1 -1.269656 ↓ 
HIST1H2AI -1.290961 ↓  PTPN13 -1.354828 ↓ 
HIST1H2AK -1.290961 ↓  PTPN7 1.2007923 ↑ 
HIST1H2AL -1.290961 ↓  PTPRH -1.251692 ↓ 
HIST1H2AM -1.664963 ↓  PTPRJ 1.5388035 ↑ 
HIST1H2BG -1.23888 ↓  PTPRM -1.799454 ↓ 
HIST1H2BI -1.301587 ↓  PTPRR 1.3578755 ↑ 
HIST1H2BJ -1.23888 ↓  PTPRS -1.376989 ↓ 
HIST1H2BK -1.228102 ↓  PTPRZ1 -1.830176 ↓ 
HIST1H2BN -1.283633 ↓  RBBP5 -1.252708 ↓ 
HIST1H2BO -1.446285 ↓  RBBP7 1.3903811 ↑ 
HIST1H3E -1.463825 ↓  SETD7 -1.428182 ↓ 
HIST1H3F -1.34566 ↓  SIN3A -1.36823 ↓ 
HIST1H3G -1.384561 ↓  SMYD2 -1.230749 ↓ 
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5.3 The Expression of NICD Alters Cellular and Molecular 
Functions in SJG6 
 
Ingenuity pathway analyser (IPA) is an omics tool able to identify the most 
relevant signalling and metabolic pathways, networks and functions for a list of genes 
based on current literature (Krämer, et al., 2013).  
Figure 5.3a shows the 52 cellular and molecular functions with an activation Z 
score of more than 2 for the genes found to differ between SJG6 Blank and SJG6 + 
NICD. In collaboration with differences presented in cell behaviours in Chapter 4, the 
majority of these functions could be related to decreased cell migration (35%; green) 
and proliferation (10%; blue). Further, a significant proportion could be associated 
with reduced angiogenesis (17%; red), which will be explored further in Chapter 7, 
and increased cell death (13%, brown). In order to assess potential mechanisms for the 
difference in each of these cell behaviours, the network with the most gene members 
for each function was selected as a representative for further analysis. This included: 
(1) proliferation of cells, (2) migration of tumour cell lines, (3) cell death and (4) 
angiogenesis.  
In order to identify the potential key players in each network, the relationship 
between each gene member and NOTCH1 was assessed. In order to create the most 
direct potential mechanism for each phenotype, genes found to directly interact with 
NOTCH1 and have an expression change consistent with their known role in the 
respective cell behaviours were selected. The interactions between the selected genes 
were then also assessed (Figure 5.3b).  
 
 5.3.1 Proliferation 
 
 NOTCH1 has been shown to inhibit the expression of ITGB1, ITGB4 and 
SERPINE1, each of which have been positively correlated with cell proliferation. 
Notably, ITGB1 is also known to increase the expression of ITGB4 and SERPINE. 
Further, HEY1 has been shown to inhibit cell proliferation and is increased as a 
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5.3.2 Migration of tumour cell lines  
 
 Similarly to proliferation, NOTCH1 is known to inhibit the expression of 
ITGB1 and SERPINE1, each of which have been positively correlated to the migration 
of tumour cells lines. Equally, GATA3 has been shown to inhibit the migration of 
tumour cell lines and is increased in response to increased NOTCH1 expression 
(Figure 5.3bii).  
 
5.3.3 Cell Death  
 
 ITGB4 and SERPINE1 have been negatively correlated with cell death. In 
addition, NOTCH1 is able to promote the expression of HEY1, IL7R and NRG1, each 




 Once again, NOTCH1 has been shown to inhibit the expression of ITGB1 and 
SERPINE1, each of which have been positively correlated to angiogenesis. 
Conversely, AHR, FOXC1, CD44 and HEY1 have been shown to inhibit angiogenesis 
and are increased in response to increased NOTCH1 expression (Figure 5.3biv).  
 
5.3.5 SERPINE1 as a common regulator 
 
 Analysis of each cell behaviour identified SERPINE1 as a common key 
regulator. NOTCH1 is known to actively inhibit the expression of SERPINE1, which 
in turn has been associated with increased angiogenesis, cell migration, proliferation, 












































5.4 The Expression of NICD Alters Key Genes in SCCHN 
 
 Previously published literature has associated the effect of NOTCH1 
expression on cell behaviour with a number of key genes, as described in Chapter 1.  
Microarray analysis was used to assess relative expression fold change of the following 
genes in SJG6 + NICD compared to SJG6 Blank: (1) WNT, (2) CTNNB1, (3) CSL, 
(4) p16, (5) MMP2, (6) MMP9, (7) TNF-, (8) SNAI2, (9) TWIST, (10) miR-140-5P, 
(11) ADAM10, (12) VEGF, (13) EGFR and (14) NF-κB. An up- or down- regulation 
of more than 20% was recorded in WNT (up; 23%), MMP9 (down; -32%), SNAI2 
(down; -31%), and VEGF (down, -37%). Findings are detailed in Table 5.2. 
Figure 5. 3: (a) Cellular and molecular functions with an activation Z score of more than 2 for genes 
found to differ between SJG6 Blank and SJG6 + NICD using microarray analysis. Many functions 
could be associated with angiogenesis (red), cell death (brown), cell migration (green) and cell 
proliferation (blue). (b) The most direct potential mechanism for the effect of NOTCH1 in the 
proliferation of cells (i), migration of cell lines (ii), cell death (iii) and angiogenesis (iv). (c) SERPINE1 
is a common key regulator of each cell behaviour. n=3. 
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Table 5 2: Key genes with a relative expression fold change of more than 1.2 in SJG6 
+ NICD compared to SJG6 Blank 
 
Gene Cellular Function % Expression Change  




MMP9 Invasion -32% 
SNAI2 Invasion -31% 
VEGF (family member A) Angiogenesis -37% 
 
 
5.5 The Expression of NICD Alters Key Pathways in SCCHN 
 
 As well as individual genes, previously published literature has associated the 
effect of NOTCH1 expression with Wnt / β-catenin and p16 signalling pathways. IPA 
analysis of microarray data was used to assess how NICD-mediated changes in gene 
expression altered said pathways as well as the wider NOTCH signalling pathway.  
 
5.5.1 NOTCH signalling pathway 
 
 As expected, there was an overall increase in NOTCH signalling in the SJG6 
+ NICD line, with 6 out of 11 (55%) pathway members showing altered expression. 
The constitutive lentiviral expression of NICD was reflected by a recorded increase in 
NOTCH and downstream targets, HES1/5/7 and HERP. Coactivator, CSL, and 
ligands, DLL / JAG, were also upregulated. There was a downregulation in γ-secretase. 
This would usually result in inhibition of NOTCH signalling by reducing the cleavage 
of full length NOTCH, however, it is unable to decrease ectopic levels of NICD 













































5.5.2 Wnt / β-catenin signalling pathway 
 
 In the Wnt / β-catenin signalling pathway, 18 out of 65 (28%) gene members 
were found to be altered as a result of NICD expression in SJG6. Despite an 
upregulation in WNT, the majority of pathway members were found to be 
downregulated (Figure 5.5).  
In order to further elucidate the consequence of expression changes within the 
pathway, the IPA Molecule Activity Predictor (MAP) tool was used and findings 
overlaid. The MAP tool uses known expression states to predict the activity of 
neighbouring molecules. Although microarray analysis assesses the whole 
transcriptome, the stringent filter removes expression changes in genes that were not 
Figure 5. 4: NICD-mediated gene expression changes in SJG6 + NICD compared to the SJG6 Blank 
in the NOTCH signalling pathway. The pathway was created using IPA (Qiagen). 
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consistent across the three biological replicas or less than 1.2 fold. Further, the 
microarray analysis only provides a snapshot of expression data. Whilst repeating the 
experiment minimises this limitation, the cells were still treated identically prior to 
analysis, i.e. lifted, centrifuged and FACS sorted. As such, valuable information can 
still be gained from MAP. The MAP analysis predicted an overall decrease in Wnt / 
β-catenin signalling targets and a resultant reduction in proliferation as a result of 
























5.5.3 p16 signalling pathway 
 
 The expression of p16 was not found to significantly differ between SJG6 + 
NICD and SJG6 Blank. Further, only 6 out of the 45 (13%) pathway members were 
found to be altered (Figure 5.6).   
Figure 5. 5: NICD-mediated gene expression changes in SJG6 + NICD compared to SJG6 Blank in 
the Wnt / β-catenin signalling pathway. The pathway was created using IPA (Qiagen). 
  





5.6.1 The expression of NICD alters the genetic landscape of SJG6  
 
 Microarray analysis shows a distinct difference in the genetic expression 
profile of SJG6 as a result of NICD expression. Further, GSEA analysis showed the 
difference in the biological state aligned with the genetics of several cancers, including 
oesophageal SCC. This data provides further evidence for the importance of NOTCH1 
in SCCHN.  
 Of the top ten genes found to be up- or down- regulated in response to NICD 
expression, only STEAP4 has been previously recognised as a target of NOTCH1 
(Wang, et al., 2017). Of the down-regulated genes, the expression of PLAG1, CTH 
and Vimentin (VIM) has been positively correlated with SCCHN (Marques Filho, et 
al., 2006; Giefing, et al., 2008; Bayo, et al., 2015). Further, increased expression of 
RMRP, SULT1 and LTBP1 has been recorded in other cancers (Xu, et al., 2012; Cao, 
Figure 5. 6: NICD-mediated gene expression changes in SJG6 + NICD compared to SJG6 Blank in the 
p16 signalling pathway. The pathway was created using IPA (Qiagen). 
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et al., 2015; Meng, et al., 2016). Therefore, the downregulation of this gene set in 
response to NICD expression provides evidence to suggest a tumour suppressor role 
for NOTCH1 in SCCHN.  
 Synonymously, the expression of VGLL4, a recognised tumour suppressor of 
oesophageal SCC, was found to decrease in response to NICD in SJG6 (Jiang, et al., 
2015). In addition, TMEM27 and SFTA1P have been shown to act as tumour 
suppressors in other cancer and were also shown to be downregulated in response to 
NICD in SJG6 (Javorhazy, et al., 2016; Zhang, et al., 2017).  
Conversely, CXCL11 and SPANX have been shown to be upregulated in 
SCCHN and are co-increased with NICD in SJG6 (Xia, et al., 2011; Zamunér, et al., 
2015). STEAP4 and ITGB1 are also recognised oncogenes in other cancers and are 
found to be upregulated in response to NICD (Wu, et al., 2015; Kurozumi, et al., 2016).  
Collectively, findings show that NICD is able to alter the expression of a 
number of key oncogenes and tumour suppressors in SJG6. Of the top 20 genes, the 
expression change in 9 would suggest a tumour suppressor role for NOTCH1 in 
SCCHN, whereas the expression change of 4 would indicate an oncogene function. 
Further research would be required to see how these genes work together in SCCHN 
to alter phenotype. One possibility is that the expression changes in individual genes 
compete with each other and the ‘winning’ genes govern the resultant changes in cell 
behaviour. Inversely, a single change in cell behaviour, such as EMT, could be 
responsible for expression changes in all genes. As aforementioned, NOTCH1 has 
been shown to have opposing role in SCCHN. This data highlights how the wider 
mutational landscape may influence this (Yap, et al., 2005).   
Notably, fold changes identified in the SPANX family (co-increased with 
NICD) were 3x greater than that of any other gene. This will be explored further in 
Chapter 6.   
 
5.6.2 NICD alters the expression of histones and their regulators 
 
 More than a quarter of GO terms for NICD-mediated expression differences in 
SJG6 were related to DNA organisation and 10% were specifically histone-related. As 
such, microarray data was mined for changes in the expression of histone related 
genes. Of the 3150 genes found to have greater than a 1.2 fold change difference, 68 
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were found to be histones or histone regulators (2.2%). Further, 62 of the 68 genes 
were found to be downregulated (91%).  
 Histones are the chief proteins involved in shaping chromatin structure and, 
consequently, gene expression. Recently, a role for histone variants in cancer 
progression has been suggested (Vardabasso, et al., 2014). More specifically, histone 
modifications have been associated with CSC plasticity in SCCHN and several histone 
regulator genes have been found to be frequently altered in oesophageal SCC (Le, et 
al., 2014; Song, et al., 2014). Interestingly, one of these genes, ASHL1, was found to 
be downregulated in the rescued SJG6 + NICD line (Song, et al., 2014).  
Histone gene expression is cell cycle regulated. Histone protein synthesis is 
restricted to the S-phase of the cell cycle, coupled to DNA replication. During DNA 
replication, histones are essential for packaging DNA into chromosomes (Pogo, et al., 
1966; Meshi, et al., 2000). As such, a decrease in histone related genes is consistent 
with in vitro and microarray data that have provided evidence to suggest that NICD 
expression gives rise to reduced cell proliferation.  
To my knowledge, there are no studies linking NOTCH1 expression with that 
of histones or histone regulators. Further experiments would be required to confirm 
the association and underpin potential mechanisms. It is possible that NICD expression 
could lead to a downregulation in histone-related genes which subsequently gives rise 
to a decrease in cell proliferation. Alternatively, the decrease in histone related genes 
could be as a result of decreased cell proliferation.  
 
5.6.3 Microarray analysis supports in vitro data and highlights SERPINE1 as a 
potential master regulator of NOTCH1 in SCCHN 
 
In collaboration with in vitro data detailed in Chapter 4, proliferation and 
invasiveness were some of the top hits for GSEA analysis. The differentially expressed 
gene set between SJG6 + NICD and SJG6 Blank was assessed using IPA for molecular 
and cellular functions with an activation score of more than 2. Of the 52 functions, 18 
suggested NICD expression could be associated with a decrease in cell migration and 
5 predicted a decrease in proliferation. This data supports the in vitro findings. Further, 
9 functions were related to decreased angiogenesis and 7 to increased cell survival, 
both of which shall be further considered in Chapter 7. It is important to note that IPA 
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is only able to provide information on known pathways. Therefore the 52 significant 
functions is unlikely to be exhaustive of all NICD-mediated changes.  
 Microarray data was mined for genes which could link NOTCH1 to the 
respective phenotypes. Interestingly, a downregulation of SERPINE1 was found to be 
common to all pathways, providing evidence to suggest a potential key role in 
instigating the effect of NOTCH1 in SCCHN. NICD expression has previously been 
linked to the inhibition of SERPINE1 in thyroid cancer (Yu, et al., 2016). Little is 
known about the role of SERPINE1 in SCCHN but, consistent with in vitro and 
microarray data, high expression has been correlated with increased cell migration 
(Pavón, et al., 2015). Moreover, the expression of SERPINE1 in the tumour 
microenvironment has been shown to promote amoeboid cell behaviour associated 
with cell migration in the metastatic process. Studies by Cartier-Michaud et al. showed 
a heterogeneous distribution of SERPINE1 at the tumour periphery and confirmed it 
is required for cells of a colorectal cancer cell line to undergo mesenchymal-amoeboid 
transition (Cartier-Michaud, et al., 2012).   
 
5.6.4 Exploring the role of NOTCH1 in SCCHN in association with changes in 
key genes and pathways  
 
Cell Cycle Arrest 
 
 Both in vitro and microarray data have provided evidence to suggest that the 
expression of NICD gives rise to cells with a reduced proliferative potential. A 
downregulation of free β-catenin and Wnt / β-catenin mediated signalling has been 
recorded in cells overexpressing NICD and has been suggested to act as a mechanism 
in NICD mediated cell cycle arrest (Nicolas, et al., 2003; Duan, et al., 2006). Although 
microarray data shows Wnt to be upregulated in response to NICD, overall Wnt / β 
catenin signalling is predicted to be decreased. Of note, in normal mouse epidermis, 
the deletion of β-catenin was not found to alter proliferation or differentiation of 
keratinocytes (Posthaus, et al., 2002). 
In addition, in the skin, NOTCH1 expression induces growth arrest via p21 
induction. In corroboration, microarray data confirmed a 1.21 expression fold increase 
in CDK1 (aka p21) in in response to NICD rescue (Table 5.1) 
 Finally, Kagawa et al. showed cell cycle arrest to be associated with both 
canonical CSL and p16 signalling. Microarray data confirmed the upregulation of CSL 
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and downstream target in SJG6 in response to NICD expression. However, expression 
of p16 was not found to change and fewer than 15% of pathway members were altered 




 Of the 52 cellular and molecular functions identified within the differentially 
expressed gene set between SJG6 Blank and SJG6 + NICD, 19 were associated with a 
decrease in cell migration (13) and invasion (6) as a result of NICD expression.  
 Both in vitro and microarray data suggest that the expression of NICD reduces 
cell migration in SCCHN. This is inconsistent with research performed by Jing et al., 
who demonstrated a reduction in cell migration as a result of ADAM10 mediated 
downregulation of NOTCH1 in hypopharyngeal carcinoma (Jing, et al., 2016). 
Further, NOTCH1 expression has been shown to localise to the invasive tumour front 
in oral SCC and the expression of NOTCH1 has been positively associated with the 
depth of tumour invasion in tongue SCC (Joo, et al., 2009; Yoshida, et al., 2013).  
Microarray data also suggests that expression of NICD reduces cell invasion 
in SCCHN. This is inconsistent with research by Yu et al. that provided evidence to 
suggest that NOTCH1 is able to mediate metastasis via the regulation of MMP2 and 
MMP9 in SCCHN (Yu, et al., 2012). Further, studies by Yoshia et al. suggest that the 
expression of NOTCH1 contributes to the maintenance of Tumour Necrosis Factor- 
(TNF-)-mediated invasion via the transcriptional regulation of SNAI2 and TWIST. 
During EMT, TWIST is known to induce SNAI2 which supresses the epithelial 
phenotype; TWIST and SNAI2 then work together to promote EMT and metastasis 
(Yoshida, et al., 2013). On the contrary, microarray data identified a decrease in 
MMP9 and SNAI2 in response to NICD. These findings add to the growing body of 
evidence showing that the effect of NOTCH signalling is highly context dependent 
and contingent on signal strength and timing (Radtke & Raj, 2003; Weng & Aster, 











 Microarray data provides evidence to suggest that the expression of NICD 
reduces angiogenesis and downregulates the expression of VEGF. Likewise, Sun et al. 
reported a reverse correlation between NOTCH1 and VEGF expression in oesophageal 
SCC (Su, et al., 2009). Conversely, Troy et al. showed a positive correlation between 
NOTCH1 and VEGF expression. NOTCH1 has also been associated with increased 
micro-vessel density in oral SCC (Joo, et al., 2009; Troy, et al., 2013). Once again, 
this data provides further evidence for a context dependent role of NOTCH1 in 




 In conclusion, microarray data has confirmed the expression of NICD in SJG6 
is able to alter the genetic landscape, supporting the importance of NOTCH1 
expression in SCCHN. Many of the top up- and down- regulated genes were found to 
be recognised oncogenes and tumour suppressors as well as histones and histone 
regulators. The genome wide effect of histone alterations opens up avenues for further 
understanding the role of NOTCH1 in SCCHN. 
  Overall, microarray data has provided evidence to suggest NICD expression 
gives rise to decreased proliferation, decreased cell migration, reduced angiogenesis 
and increased cell death. As such, and consistent with in vtiro data, findings suggest a 
tumour suppressor role for NOTCH1 in SCCHN. Inhibition of SERPINE1 was also 
highlighted as a potential mediator of NICD-induced changes in cell behaviour. Taken 
with current literature, findings further highlight the complexity of NOTCH signalling 
in SCCHN. 
 Notably, fold changes identified in the SPANX family were 3x greater than 
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Chapter 6 
Investigating the Relationship between NOTCH1 and 
SPANX in SCCHN 
 
 
This chapter begins to explore the relationship between NOTCH1 and SPANX in 
SCCHN. Microarray analysis identified a large increase in SPANX family gene 
expression in the SJG6 cell line rescued for NICD (SJG6 + NICD) compared to the 
empty vector control (SJG6 Blank). In order to investigate the functional consequence 
of SPANX expression, a shRNA system was used to knockdown SPANX in SJG6 + 
NICD. In vitro assays developed in Chapter 3 were then performed to compare cell 
behaviour in SGJ6 + NICD and the SJG6 + NICD – SPANX Knockdown (hereby 
referred to as ‘SPANX Knockdown’).  
 
 
6.1 Introduction to SPANX 
 
 A number of genes that are normally expressed in the testis are found to be 
induced in tumour cells and are collectively referred to as Cancer Testis Antigens 
(CTAs) (Old, 1982). The human SPerm Associated with the Nucleus on the X 
chromosome (SPANX) genes make up a family of 5 recognised members (SPANX-
A1, -A2, -B, -C and –D), all of which are CTAs. The gene family encodes small 
unfolded proteins able to make complexes with other proteins (Westbrook, et al., 
2000). In transformed mammalian cells, the SPANX family proteins have been 
affiliated with the nuclear envelope (Westbrook, et al., 2004).  
 The SPANX genes map to a region of the X chromosome (Xq27) shown to be 
associated with cancers. The most well studied association is with familial prostate 
cancer (Peters, et al., 2001; Stephan, et al., 2002; Kouprina, et al., 2005; Yaspan, et al., 
2008). However, The Atlas of Genetics and Cytogenetics in Oncology and 
Haematology details chromosomal abnormalities in Xq27 in the following tumour 
types: pharynx, skin, breast, bone, brain, brain stem, pancreas, ovary, liver, large 
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intestine, haematopoietic and lymphoid tissue, endometrial and kidney (Huret, et al., 
2012 ).  
 Staining for SPANX family members in both cancerous and normal prostate 
tissue has confirmed a significant upregulation of SPANX in the cancerous tissue. 
SPANX expression was found to be both cytoplasmic and nuclear in the cancerous 
tissue, compared to normal tissue which presented with localised nuclear expression 
(Salemi, et al., 2010). 
 In a similar study by the same group, SPANX staining was found to be 
recorded in 80% of melanomas. Approximately 44-54% of cells within each tumour 
stained positive for SPANX and staining was found to be largely nuclear. In 
comparison, no SPANX expression was recorded in normal skin tissue (Salemi, et al., 
2009). SPANX B and C have both been recorded in melanomas, however, SPANXA 
has been showed to be the most frequently expressed variant (Zendman, et al., 2003; 
Salemi, et al., 2008). Increased SPANX staining has also been associated with more 
aggressive melanomas, in particular distant, non-lymphatic metastases (Westbrook, et 
al., 2004). 
 The expression of SPANX has been positively correlated with invasion and 
metastasis in several tumour types, including skin, liver, breast, colorectal and lung 
(Westbrook, et al., 2004; Chen, et al., 2010; Yilmaz-Ozcan, et al., 2014; Maine, et al., 
2016; Hsiao, et al., 2016). In breast cancer studies, SPANX A/C/D has been shown to 
localise to the nuclear membrane where it associates with laminin A/C and is essential 
for the formation of actin-rich cell projections which are able to reorganise the 
extracellular matrix. SPANXA/C/D has been shown to be required for metastasis of 
primary breast tumours into the lung (Maine, et al., 2016). 
 SPANX expression has also been associated with EMT/MET. Yilmaz-Ozcan 
et al. correlated increased SPANX B expression with the spontaneous differentiation 
of a colorectal cell line and demonstrated that differentiation of these cells led to MET. 
MET was confirmed by the increased expression of mesenchymal markers (CDX2, 
claudin-4 and E-cadherin) and the downregulation of epithelial markers (vimentin, 
fibronectin and transgelin). The group showed that the reversal of differentiation gave 
rise to a downregulation of SPANX and the induction of EMT markers (Yilmaz-
Ozcan, et al., 2014). Further, Hsiao et al. showed that the expression of SPANXA was 
able to supress epithelial to mesenchymal transition (EMT) in lung adenocarcinoma 
by inhibiting c-JUN / SNAI2 signalling (Hsiao, et al., 2016).  
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 In 2009, a study performed by Almanzar et al. confirmed an increased 
expression of SPANX B in 146 tumours from skin, lung, ovary, colon and breast. 
Interestingly, PCR, western blot and immunostaining confirmed an immunogenic 
response by CD4+ and CD8+ T-cells. The largely tumour specific expression of 
SPANX and immunogenic properties indicate promise for targeting SPANX 
expression in immunotherapies (Almanzar, et al., 2009). 
 Finally, increased SPANX expression has been associated with CSCs in triple 
negative breast cancer. Knockdown of SPANX was shown to give rise to a decrease 
in the percentage of CSC markers in the cell population (Shahin, et al., 2017).    
Overall, the SPANX gene family has been found to be overexpressed in a 
number of cancers and has been associated with enhanced metastasis and maintenance 
of CSCs. The expression of SPANX genes in tumour cells has also been positively 
correlated with poor prognosis (Yang, et al., 2015).  
Very little is known about the role of SPANX in SCCHN, but SPANXC/D has 
been shown to be expressed in 71.9% of tumours (Zamunér, et al., 2015). This chapter 
aims to further elucidate the functional consequence of SPANX expression in SCCHN 
and the relationship between SPANX and NOTCH1. 
 
 
6.2 The Expression of SPANXA1/2 Increases in Response to NICD 
 
 Microarray analysis identified a 6-fold increase in SPANX family gene 
expression in SJG6 + NICD compared to SJG6 Blank. RT-qPCR was used to validate 
this expression change and investigate the individual gene family members (Figure 
6.1).  RT-qPCR confirmed a large fold expression increase of SPANXA1/2 (5.73 x) in 
the rescued SJG6 line. However, SPANXB1 and SPANXC/D were not found to be 































6.3 SPANXA1/2 was Successfully Knocked Down in SJG6 + NICD 
 
 In order to investigate the functional consequence of this increase in 
SPANXA1/2 expression, a doxycycline inducible puromycin-resistant shRNA system 
was used to knockdown SPANXA1/2 in SJG6 + NICD (Dharmacon). SJG6 + NICD 
was incubated with the SPANXA1/2-targeted shRNA for 72hrs. Cells were then split 
and allowed to recover for 48hrs before selecting the successfully transduced cells in 
1 µg/ml puromycin. The resultant ‘SPANX Knockdown’ population was expanded in 
culture and stocks frozen. Due to time constraints, all experiments from the 
SPANXA1/2 Knockdown were only run twice. Although statistical tests can be run on 
n=2, the power is significantly reduced. As such, no statistics were performed. Instead, 
measurements from both experiments have been displayed to show the level of 
consistency. 
 In order to validate the knockdown, SPANXA1/2 expression was assessed at 
the protein level by immunohistochemistry staining (Figure 6.2a). The SJG6 + NICD, 
SPANX Knockdown and SJG6 Blank cell lines were plated on collagen coated 96 well 
plates at a density of 2 x 103 / well. The knockdown of SPANXA1/2 was induced by 
introducing 1.5 µg/ml doxycycline to the culture media. The same concentration of 
doxycycline was introduced to the SJG6 + NICD and SJG6 Blank cell lines as a 
Figure 6 1: RT-qPCR expression analysis of SPANXA1/2, SPANXB1 and SPANXC/D in SJG6 Blank 
and SJG6 + NICD. Gene expression was normalised to the s18 and GAPDH housekeeping genes. *** 
Student’s t-test value <0.005. n=3. 
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control. At 48hrs, cells were fixed in 4% PFA and stained for SPANXA1/2 (red). 
Nuclei were stained with DAPI (blue). A clear reduction in the expression of 
SPANXA1/2 was observed in the SPANX Knockdown compared to SJG6 + NICD. 
SPANX expression in the knockdown returned to similar levels to that seen in SJG6 
Blank.  
 The mRNA expression of SPANXA1/2 was assessed via RT-qPCR (Figure 
6.2b). In both experiments, the mRNA expression of SPANXA1/2 in the SPANX 
Knockdown was found to decrease to 39.1% and 41.1% of SJG6 + NICD.  
 The mRNA expression of NOTCH1 and several genes that were found to be 
altered by NICD expression via microarray were also assessed. NOTCH1 expression 
showed a similar decrease in both SPANX Knockdown experiments to 86.5% and 
84.6% of SJG6 + NICD levels. Conversely, expression changes in TMEM27, HEY1, 
CTH, ITGBL1 and ITGB6 were more variable between the two experiments.  
 As a control, SJG6 + NICD was also transduced with a doxycycline inducible 
non-targeting control shRNA. SPANXA1/2 expression was not found to decrease in 
this line, further confirming the validity of the SPANX Knockdown (Figure 6.2c).  
 
 
6.4 Expression of SPANXA1/2 Potentially Increases Cell 
Proliferation 
 
 An EdU assay was performed to compare the proliferative potential of SJG6 + 
NICD and the SPANXA1/2 Knockdown (Figure 6.3). The cell lines were seeded onto 
collagen-coated 96 well plates at a density of 2 x 103 and doxycycline was introduced 
at a concentration of 1.5 µg/ml to induce the SPANX Knockdown. At 46hrs, EdU was 
introduced. At 48hrs, cells were fixed in 4% PFA. Over the two hour period, a higher 
percentage of proliferating cells were recorded in SJG6 + NICD (37.5% and 37.0%) 
than in the SPANX Knockdown (34.3% and 34.0%). Although the difference between 
the percentages of proliferating cells was small, it was highly consistent between the 
two experiments. Many factors can effect proliferation and further experiments would 
be required. However, this finding provides preliminary evidence for a potential 








































Figure 6 2: (a) Immunohistochemistry staining of SJG6 + NICD, SPANX Knockdown and SJG Blank. Red 
= SPANXA1/2. Blue = DAPI. (b) RT-qPCR analysis showing changes in the expression of SPANXA1/2, 
NOTCH1, TMEM27, HEY1, CTH, ITGBL1 and ITGB6 in SPANX Knockdown compared to SJG6 + NICD. 
The expression of SJG6 + NICD is normalised to 1 and shown by the grey line. (c) RT-qPCR analysis of 
SPANXA1/2 expression in SJG6 + NICD compared to SJG6 + NICD transduced with a non-targeting 
shRNA control. Gene expression was normalised to s18 and GAPDH housekeeping genes. n=2. 
  

















6.5 Expression of SPANXA1/2 does not Alter Commitment to 
Differentiation 
 
  In order to compare the level of differentiation in SJG6 + NICD and the 
SPANX Knockdown, cells were stained with antibodies to Transglutaminase 1, a 
marker of epithelial differentiation (Figure 6.4). Both cell lines were seeded onto 
collagen coated 96 well plates and doxycycline was introduced at a concentration of 
1.5 µg/ml to induce the SPANXA1/2 Knockdown. At 48hrs, the cells were fixed and 
stained with Transglutaminase 1. Nuclei were stained with DAPI. The Operetta High 
Content Imaging system was used to identify the percentage of Transglutaminase 1 
positive cells in both populations (pipeline detailed in Figure 2.2). No consistent 








Figure 6 3: EdU assay comparing the percentage of proliferating cells in SJG6 + NICD and the SPANX 
Knockdown. n=2. 
  















6.6 Expression of SPANXA1/2 Alters Cell Morphology 
 
 Cytoplasmic Cell Mask staining was performed to investigate morphological 
differences between SJG6 + NICD and the SPANX Knockdown. Both cell lines were 
seeded onto 5 µg/ml of fibronectin in 96 well plates and doxycycline was introduced 
at a concentration of 1.5 µg/ml to induce the SPANXA1/2 Knockdown. At 48hrs, cells 
were fixed, stained with Cell Mask and DAPI, and analysed using the Operetta High 
Content Imaging System (pipeline detailed in Figure 2.2). 
 Morphological differences were observed between the two cell lines (Figure 
6.5). In both experiments, SJG6 + NICD was substantially and consistently smaller 
and more round than the SPANX Knockdown. There was also fewer elongated cells 
(roundness <0.6) in the SJG6 + NICD population. Potential implications will be 
discussed further in the discussion of this chapter. 
 
 
6.7 Expression of SPANXA1/2 Potentially Increases Cell Migration 
 
 A scratch wound assay was performed to compare the rate of cell migration 
between SJG6 + NICD and the SPANX Knockdown (Figure 6.6). Both cell lines were 
first treated with mitomycin-C to remove proliferation bias. A scratch wound was then 
created and the confluence of cells in the wound area was calculated over a 25hr 
Figure 6 4: Transglutaminase 1 staining to compare the percentage of differentiated cells in the SJG6 
+ NICD and SPANX Knockdown lines. n=2. 
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period. In both experiments, SJG6 + NICD cells were found to migrate into the wound 

































Figure 6 5: Operetta analysis comparing the morphology of the SJG6 + NICD and the SPANX 
Knockdown lines. (a) Representative images of SPANX Knockdown (left) and SJG6 + NICD (right). 
Nuclei were stained with DAPI (blue) and cytoplasm was stained with Cell Mask (red). (b) Measure of 
cell area. (c) Measure of cell roundness ratio. (d) By thresholding for cells with a roundness ratio of 
less than 0.6, elongated cells in the population were identified and calculated as a percentage of total 
cell number. n=2. 
  

















6.8.1 Evidence suggests a correlation between NOTCH1 and SPANXA1/2 
Expression in SCCHN 
 
 RT-qPCR data confirmed a large increase in SPANXA1/2 expression in 
response to NICD. Conversely, family members SPANXB1 and SPANXC/D were not 
found to be expressed in the SJG6 cell line. Equally, the knockdown of SPANXA1/2 
in SJG6 + NICD resulted in a reduction of NOTCH1 expression, suggesting a feedback 
loop may exist between the two genes. Interestingly, an approximate 3x fold change 
increase in NICD resulted in a 6x fold change increase in SPANXA1/2 expression. 
Likewise, a decrease in SPANXA1/2 expression to approximately 40% of that of SJG6 
+ NICD led to a decrease in NOTCH1 expression to 85%. In both cases, the change in 
SPANXA1/2 expression is approximately double that of NICD, providing further 
evidence for a relationship between the two genes. Notably, this exaggerated 
expression change could be an interesting target to utilise SPANXA1/2 as a NOTCH1 
biomarker.  
 The expression of SPANXC/D has been previously recorded in 71.9% of head 
and neck cancers, but no evidence exists on the expression pattern of SPANXA1/2 
(Zamunér, et al., 2015). Moreover, evidence to suggest a relationship between 
SPANXA1/2 and NOTCH is novel.  
 
Figure 6 6: Scratch wound assay to compare the rate at which the SJG6 + NICD and the SPANX 
Knockdown cell lines migrate to recolonise the initial wound area. n=2. 
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6.8.2 SPANXA1/2 does not mediate NICD-induced differentiation or cell cycle 
arrest 
 
 No association between SPANXA1/2 and terminal differentiation was 
recorded. However, EdU data showed a potential decrease in proliferation in the 
SPANX Knockdown compared to the SJG6 + NICD cell line. As such, it is unlikely 
that SPANX mediates the NICD-induced cell cycle arrest detailed in Chapter 4. Very 
little is known about the role of SPANXA1/2 on tumour cell proliferation. However, 
CTA expression has been associated with poor prognosis in a number of cancers, 
which would be consistent with a positive correlation of SPANXA1/2 with cell 
proliferation (Yang, et al., 2015). However, as aforementioned, many factors can effect 
proliferation and further experiments would be required to investigate a potential 
relationship between proliferation and SPANX expression. 
 
6.8.3 The knockdown of SPANXA1/2 reverses NICD-mediated changes in cell 
morphology 
 
 The knockdown of SPANXA1/2 was found to increase cell area, reduce cell 
roundness and increase the percentage of elongated cells in the population. In 2016, 
Hsiao et al. showed that the expression of SPANXA was able to supress epithelial to 
mesenchymal transition (EMT) in lung adenocarcinoma by inhibiting c-JUN / SNAI2 
signalling. Consistent with data in this study, the group found that the increased 
expression of SPANXA was able to markedly change cell morphology from 
mesenchymal- to epithelial- like, i.e. less elongated and more rounded. Furthermore, 
as detailed in Chapter 5, SNAI2 was found to be decreased as a result of increased 
NICD expression. Overall, this data provides preliminary evidence to suggest that 
SPANXA may also be able to supress EMT by inhibition of c-JUN/SNAI2 signalling 
in SCCHN. Further, NOTCH1 may act as an upstream regulator of this signalling 
(Hsiao, et al., 2016). Further experiments would be required. These findings are 
inconsistent with the role of NOTCH1 as a positive regulator of SNAI2 (Niessen, et 
al., 2008; Ambler & Watt, 2010).  
 In addition, the expression of SPANX B in colorectal tumours has been 
associated with the induction of MET as measured by the induction of epithelial 
markers and downregulation of mesenchymal markers. In corroboration, microarray 
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data found vimentin to be one of the top downregulated genes in response NICD 
expression (Yilmaz-Ozcan, et al., 2014). As such, it would be of interest to investigate 
potential relationships between NOTCH and SPANX expression with EMT/MET in 
future experiments.  
 
 6.8.4 SPANXA1/2 expression is associated with increased cell migration 
 
 Scratch wound data suggests that the expression of SPANXA1/2 is associated 
with increased cell migration. This finding is inconsistent with the role of SPANXA 
as a suppressor of EMT (Hsiao, et al., 2016). However, it is important to note that 
wound closure is not a direct measure of metastatic potential. Although cells may be 
more motile in vitro, they may not have the ability to invade through the extracellular 
matrix or enter a mesenchymal state. Conversely, SPANXC/D have been associated 




 This study provides evidence to suggest a positive correlation between 
NOTCH1 and SPANXA1/2 expression, whereby a fold change in NOTCH1 is 
reflected by a 2x fold change in SPANXA1/2.  
 SPANXA1/2 was found to potentially increase cell proliferation, consistent 
with its proposed role tumorigenesis (Yang, et al., 2015). This is inconsistent with the 
role of NICD in cell cycle arrest. Therefore, if findings prove to be correct, other 
NICD-mediated changes in gene expression must able to out-compete the inducing 
action of SPANXA1/2 to dictate the final cell proliferation phenotype in SJG6.  
 NICD-mediated changes in cell morphology observed in SJG6 were reversed 
by SPANXA1/2 knockdown. Further, SNAI2 expression was increased. Collectively, 
findings suggest NICD expression may be able to suppress EMT in SCCHN via 
SPANX-mediated inhibition of c-JUN/SNAI2 expression (Maine, et al., 2016). 
Moreover, a decrease in vimentin provides further basis for investigating the potential 
role of SPANXA1/2 expression on EMT/MET in future experiments. SPANXA1/2 
expression was also found to increase cell migration, consistent with the role of 
SPANXC/D in metastatic progression (Yang, et al., 2015; Maine, et al., 2016). 
This study begins to investigate the relationship between NOTCH1 and 
SPANXA1/2 in SCCHN. More extensive studies are required. However, preliminary 
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data provides evidence to warrant further investigation into the potential role of 
NOTCH mediated SPANX signalling in SCCHN cell behaviour and in particular in 
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Chapter 7 
Investigating the Role of NOTCH1 in SCCHN in vivo 
 
 
Although in vitro studies can provide valuable information on cancer cell behaviour, 
they are limited as they do not recapitulate the tumour microenvironment. Cancer cell 
genomics and cell behaviour are influenced by both the mechanics of the 3D tumour 
architecture and the interaction of cancer cells with the stroma. This chapter begins 
to investigate the effect of NOTCH1 expression on tumour development in vivo using 
a xenograft model.  
 
 
A suspension of 100,000 SJG6 Blank or SJG6 + NICD cells were injected into 
the dorsal tongue of immunocompromised mice and tumours were allowed to develop 
over 60 days (Goldie, et al., 2012). A cohort of 7 mice (pooled from two experiments) 
was used for SJG6 Blank and SJG6 + NICD. Unfortunately, one SJG6 + NICD mouse 
did not recover from surgery, so analysis was performed on the remaining 6. In 
addition, one SJG6 Blank mouse did not form a tumour. A smaller cohort of 2 mice 
was injected with PBS as a control for the process of injecting a liquid volume into the 
tongue.  
Notably, a further experiment was performed in which 50,000 cells were 
injected and mice were harvested after 30 days; however, no tumours formed. 
Although immunocompromised, the NSG mice still produce neutrophils and 
monocytes capable of clearing tumour cells (The Jackson Laboratory, 2017). It is 
possible that 50,000 cells is below the threshold required to overcome the murine 
model’s innate immune system in order to successfully form a tumour. Successful 
xenograft formation has been recorded in more than 80% of mice injected with 10,000 
SCC13 cells (an established facial SCC line) and approximately 40% of mice injected 
with 1,000 SCC13 cells (Benaich, et al., 2014). However, the cell threshold required 
for tumour formation will be specific to the cell line. For example, a cell line with a 
higher proportion of CSCs will have a lower threshold than a highly differentiated cell 
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line. It is also possible that 30 days was too short for effective tumour development. A 
study into xenografts established from gastric cancer biopsies taken from different 
patients revealed a range of latency periods, from 11-160 days (Zhu, et al., 2015).  
This chapter highlights preliminary results from the two experiments that did 
yield tumours and provides the basis for further study into the role of NICD in SCCHN 
in vivo. Plans for continuation of the study are detailed in Chapter 8.  
  
 
7.1 The Expression of NICD Resulted in Increased Weight Loss in 
Xenograft Hosts 
 
 The weight of mice was monitored for the duration of the experiments. Figure 
7.1 shows the week-by-week changes for mice injected with SJG6 Blank cells, SJG6 
+ NICD cells and PBS. Due to the young age of the mice (6 weeks), the average weight 
of all three groups increased during the first 5 weeks of the experiment. Between 5 and 
10 weeks, weight plateaued. Until week 10, weight changes were similar between the 
three groups. However, between weeks 10 and 12, the average weight of mice injected 
with SJG6 + NICD significantly decreased by approximately 15%. To note, due to 
ethical concerns, two mice of this cohort were culled at day 58, 48hrs sooner than the 
experimental end point of 60 days (hereby referred to as Xenografts A and D of SJG6 
+ NICD).  
 Dissection of the mouse lymph nodes showed that they were clear of secondary 
growths. RT-qPCR of the lymph node tissue also confirmed an absence of mCherry 
and human markers. Further, flow cytometry did not identify mCherry or EpCAM (an 
epithelial cell marker) in the blood. The primary tumours made up the sole focus of 



































7.2 SJG6 + NICD Cells gave rise to Significantly Larger Tumours 
than SJG6 Blank Cells  
 
 On day 60, the mice were sacrificed and tongues collected. Tumours were 
visible by eye and macroscopic imaging in tongues that had been injected with SJG6 
Blank and SJG6 + NICD cells. No tumours had formed in the PBS controls.  
 Of the 7 mice injected with SJG6 Blank, 6 developed tumours. The tongues 
were frozen in OCT and a cryostat was used to create serial sections from different 
points along the width of the tumours. The absence of a tumour in the 7th SJG6 Blank 
mouse was confirmed by H&E staining of 8 µm serial sections (Figure 7.2). All mice 
injected with SJG6 + NICD developed tumours. Tumour area was measured using 
FIJI. Tumours derived from SJG6 + NICD were found to be significantly larger than 







Figure 7 1: Average weight of mice injected with either SJG6 Blank cells (orange), SJG6 + NICD cells 
(pink) or PBS (green) over a 60 day period. *The SJG6 + NICD cohort weighed significantly less than 
the SJG6 Blank cohort and PBS control at day 60. Student’s t-test < 0.05. n = 7 for SJG6 + NICD. n= 
6 for SJG6 + Blank. n=2 for PBS control. 
  




















7.3 Enhanced NICD Expression was Diminished by Day 60 but 
Increased SPANXA1/2 Remained  
 
 The cells of 50 µm sections were lysed, RNA was extracted and reverse 
transcription was performed.  The resultant cDNA was analysed by RT-qPCR for the 
expression of human NOTCH1 (primer specific for the NICD domain), mCherry and 
SPANXA1/2 (Figure 7.4). 
 Xenografts derived from SJG6 Blank and SJG6 + NICD showed no significant 
difference in NICD expression. However, 4/6 SJG6 + NICD xenografts were recorded 
to have a higher expression of SPANXA1/2 than the highest expressing xenograft of 
SJG6 Blank (25, 46, 105 and 267 fold respectively). Xenografts derived from SJG6 + 
NICD also presented with significantly reduced mCherry expression compared to 
SJG6 Blank xenografts. Potential explanations for these findings are considered in the 
discussion of this chapter.  
 Tumour sections of 10 µm were processed for immunohistochemistry. 
Unfortunately, NICD and SPANXA1/2 staining was unconvincing. Both NOTCH1 
and SPANXA1/2 proteins are conserved in mice, which may go some way to explain 
the high background and unspecific staining (Kouprina, et al., 2004). In addition, there 
is high conservation between the four human NOTCH receptors. Further experiments 
will be required to investigate the protein expression levels of NOTCH1 and 
SPANXA1/2 in vivo, as detailed in Chapter 8.  
 
Figure 7 2: 100,000 SJG6 Blank cells were injected into the tongues of 7 mice in a xenograft 
experiment. One mouse did not form a tumour. (a) Macroscopic image of said tongue (b) 
Representative H&E image from serial sections confirming the absence of a tumour. 
  




















































Figure 7 3: A suspension of 100,000 SJG6 Blank cells (ai), SJG6 + NICD cells (aii) or a PBS control 
(aiii) was injected into the dorsal tongue of immunocompromised mice. Tumours were allowed to 
develop for 60 days before mice were sacrificed and tongues were collected. Scale bar = 3mm. (b) FIJI 
was used to measure tumour area. ***Student’s t-test < 0.005. 
  













7.4 Preliminary Assessment of H&E Staining Provides Evidence to 
suggest that Tumours Derived from SJG6 + NICD may have 
Increased Comedo Necrosis and Fewer Keratin Pearls than those 
Derived from SJG6 Blank 
 
 Xenograft sections of 8 µm were used for H&E analysis. A representative stain 
from the approximate middle of each tumour is displayed in Figure 7.5. A common 
feature of SCCHN is keratin pearls, i.e. keratin structures made up of concentric layers 
of SCC cells (Jaimes, et al., 2012).  Apparent keratin pearl structures can be observed 
in the histological sections (arrows). Tumours derived from cells expressing NICD 
were found to have fewer keratin pearl structures than those derived from empty vector 
control cells. However, immunostaining for keratin markers would be required to 
confirm the structures are in fact keratin pearls. This observation is based on 
pathological descriptions and images presented by AAMC MedPics under the path 
Dermatological Disease; Squamous Cell Carcinoma; H&E stain as well as published 
literature (Das, et al., 2015; UCSD School of Medicine, 2018). 
NICD-expressing xenografts were also found to have increased areas of what 
histologically presents as comedo-type necrosis, i.e. dead cell build up within the 
tumour body. This observation is based on pathological descriptions and images 
presented in the Atlas of Genetics and Cytogenetics in Oncology and Haematology 
(Rousseau & Badoual, 2011). Again, immunostaining for dead cell markers would be 
required to confirm this observation. 
 
Figure 7 4: RT-qPCR analysis of NOTCH1, mCherry and SPANXA1/2 expression in xenografts derived 
from SJG6 Blank and SJG6 + NICD. Results normalised to PBS controls. n=3. ** Student’s t-test 
calculated at <0.01. 
  




































Figure 7 5: H&E staining of xenografts derived from SJG6 Blank (i) and SJG6 + NICD (ii). Arrows = 





Figure 7 6: Higher magnification H&E staining of representative pathological features considered to 
be comedo necrosis (a) and keratin pearls (b) in xenografts derived from the two SJG6 cell lines.  
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7.5 No Significant Difference in Tumour Cell Proliferation was 
recorded between Xenografts Derived from SJG6 + NICD and SJG6 
Blank   
 
 Mice were injected with EdU 2hrs prior to harvesting. The EdU incorporated 
into proliferating cells, which were then fluorescently labelled using the EdU Click IT 
kit in 10 µm sections. Cell nuclei were stained with DAPI and FIJI was used to 
calculate proliferating cells as a percentage of total tumour cell number in a 
representative image from each xenograft. No significant difference was recorded 
between the percentages of proliferating cells in xenografts derived from SJG6 + 
NICD and SJG6 Blank. In all tumours, proliferating cells were localised to the tumour 
front (Figure 7.7).  
 
 
7.6 Xenografts Derived from SJG6 + NICD show Reduced 
Differentiation Compared to those Derived from SJG6 Blank 
 
 Immunostaining for the epithelial differentiation marker, Transglutaminase 1, 
was performed on a representative xenograft section of 10 µm from each xenograft 
(Figure 7.8). FIJI was used to measure areas of differentiation as a percentage of total 
tumour area. Xenografts derived from SJG6 Blank displayed significantly larger areas 
of differentiation than those derived from SJG6 + NICD. Both cell lines formed 
tumours consistent with the histology of moderate- to well- differentiated SCCs. 
Differentiated tissue formed towards the centre of the tumour, behind the proliferating 
cells of the margin. In tumours presenting with what appeared to be large areas of 
comedo necrosis, differentiated layers formed around the inner mass of predicted dead 





























































Figure 7 7: EdU analysis of xenografts derived from SJG6 Blank and SJG6 + NICD. Mice were injected 
with EdU 2hrs prior to harvesting.  (a) Percentage of proliferating cells. (b) Representative staining of 
SJG6 Blank (i) and SJG6 + NICD (ii). EdU = red. DAPI = blue. Scale bar = 1mm.  
  




















































Figure 7 8: Transglutaminase 1 analysis of xenografts derived from SJG6 Blank and SJG6 + NICD. 
(a) Transglutaminase 1 positive staining as a percentage of total tumour area. (b) Representative 
immunohistochemistry staining of xenografts derived from SJG6 Blank (i) and SJG6 + NICD (ii). Green 
= Transglutaminase 1. Blue = DAPI. Scale bar = 1mm. 
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7.7 No Significant Difference in Angiogenesis was recorded between 
Xenografts Derived from SJG6 Blank and SJG6 + NICD  
 
 Immunostaining for the endothelial cell marker CD31 was performed on 
xenograft sections of 10 µm (Figure 7.9a-c). CD31 stains blood vessel walls and is a 
well-established marker of angiogenesis (Albelda, et al., 1991). In Figure 7.9, white 
arrows indicate the invasion of blood vessels into the tumour as well as potential 
micro-vessels within the xenograft. SJG6 Blank – Xenograft A presented with a more 
developed tumour vasculature than all other tumours. However, no striking difference 
in angiogenesis was observed between the remaining xenografts derived from SJG6 
Blank compared to SJG6 + NICD. Quantification would be required for confirmation. 
However, staining of the two experiments was performed on different days and, 
consequentially, different image settings were used. The same image settings must be 
used for accurate quantification. This will make up part of planned future work and 
will be discussed further in Chapter 8. 
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Figure 7 9a: Analysis of angiogenesis in xenografts A-B: Immunohistochemistry staining of xenografts derived from SJG6 Blank and SJG6 + NICD. Left-hand image = 10x. 
White box indicates region of interest shown at 40x in right-hand image. Green = CD31. Blue = DAPI. White arrows = areas of angiogenesis. Scale bar = 0.5mm. 
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Figure 7 9b: Analysis of angiogenesis in xenografts C-D: Immunohistochemistry staining of xenografts derived from SJG6 Blank and SJG6 + NICD. Left-hand image = 10x. 
White box indicates region of interest shown at 40x in right-hand image. Green = CD31. Blue = DAPI. White arrows = areas of angiogenesis. Scale bar = 0.5mm. 
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Figure 7 9c: Analysis of angiogenesis in xenografts E-F: Immunohistochemistry staining of xenografts derived from SJG6 Blank and SJG6 + NICD. Left-hand image = 10x. 
White box indicates region of interest shown at 40x in right-hand image. Green = CD31. Blue = DAPI. White arrows = areas of angiogenesis. Scale bar = 0.5mm. 
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7.8 Discussion  
 
7.8.1 SPANXA1/2 remains up-regulated after loss of NICD expression 
 
 At 60 days, mRNA expression of NICD was not significantly different between 
xenografts derived from SJG6 Blank and SJG6 + NICD. As commonly seen in 
lentiviral-transduced cell populations, the SJG6 + NICD line is not made up of 100% 
transfected cells. This is in part due to FACS purity, as well as gene silencing and loss 
of cells with unstable genome integration. The high percentage of transfected cells 
(approximately 80%) is maintained in culture by supported growth on J2 3T3 feeders. 
However, the microenvironment in vivo introduces selective pressures. It is predicted 
that cells expressing NICD in the xenografts were at a selective disadvantage and 
therefore substantially reduced in the population over the 60 day incubation. This 
finding is supported by the mirrored reduction in mCherry expression recorded in 
SJG6 + NICD compared to SJG6 Blank. It is also consistent with in vitro data showing 
reduced proliferation of SJG6 + NICD compared to the empty vector control when 
removed from feeder layers and assessed over 24hrs as well as microarray data that 
associated NICD expression with a decrease in proliferation.  
 This data is consistent with previous studies that have associated NICD 
expression with cell cycle arrest in oral and tongue SCC lines (Duan, et al., 2006; 
Pickering, et al., 2013). However, it opposes several studies associating the loss of 
NOTCH1 expression with reduced proliferation (Yao, et al., 2007; Yoshida, et al., 
2013; Sun, et al., 2014). Duan et al. provided evidence to suggest that the 
downregulation of Wnt / β-catenin signalling may act as a mechanism for cell cycle 
arrest in cell lines showing an anti-proliferative effect in response to NOTCH1 
expression in SCCHN (Duan, et al., 2006). Consistent with this, microarray data 
provided evidence to suggest a down regulation of the Wnt / β-catenin signalling 
pathway in SJG6 + NICD. This data acts to further highlight the highly context 
dependent role of NICD in cancer.  
 Interestingly, despite the depletion of the NICD-expressing cell population, 
SPANXA1/2 expression in 4/6 xenografts derived from SJG6 + NICD was higher than 
that of the highest expressing SJG6 Blank xenograft. This data suggests that, once 
initiated, the NICD-mediated increase in SPANXA1/2 expression is maintained in the 
absence of NICD. As it is predicted that NICD-expressing cells are negatively selected 
  
149 | P a g e  
 
in the population, it is hypothesised that NICD induces SPANXA1/2 expression in 
neighbouring cells rather than, or as well as, cell autonomously.   
 Consistent with in vitro data, large fold increases (25, 46, 105 and 267) were 
recorded in SPANXA1/2 expression in SJG6 + NICD derived xenografts. The wide 
range of fold changes potentially suggests a delayed reduction in SPANXA1/2 
expression as a result of NICD-loss. This is further supported by the absence of 
SPANXA1/2 in 2/6 SJG6 + NICD expressing xenografts.  
 Collectively, this data provides evidence to suggest that NICD is able to initiate 
an exaggerated and more stable increase in SPANXA1/2 expression in cells in 
SCCHN. As NICD expressing cells are lost from the population, it is predicted that 
induction of SPANXA1/2 expression must be non-cell-autonomous. However, further 
experiments comparing NICD and SPANXA1/2 expression over a series of time points 
and at the single-cell level would be required to confirm this hypothesis. This is further 
detailed in Chapter 8. To date, there are no studies associating NOTCH1 and 
SPANXA1/2.  
 
7.8.2 Xenografts derived from SJG6 + NICD were significantly larger than those 
derived from SJG6 Blank despite no significant difference in the proportion of 
proliferating cells 
 
 At experimental day 60, xenografts derived from SJG6 + NICD were 
significantly larger than those derived from SJG6 Blank. Although gel food was 
provided to the mice, it is predicted that the weight loss recorded in the SJG6 + NICD 
mouse cohort could be related to tumour size causing difficulty eating. 
Interestingly, despite the larger tumour volume, the percentage of proliferating 
cells was not found to be increased in SJG6 + NICD tumours. It is important to note 
that EdU data is a snapshot of proliferation in the 2hrs prior to harvesting the 
xenografts. Therefore, variation in proliferation earlier in tumour development could 
account for the difference in tumour size. However, both in vitro and microarray data 
suggest a reduced proliferation in SJG6 + NICD cells compared to the blank vector 
control. Together with the predicted reduction of SJG6 + NICD cells in the xenograft, 
it is unlikely that hyper-proliferation would have occurred earlier in tumour 
development.  
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7.8.3 The difference in tumour size recorded between xenografts derived from 
SJG6 Blank and SJG6 + NICD may be related to cell death and differentiation 
 
 H&E staining revealed variation in the histology of all tumour samples. This 
may be as a result of the difficulty in ensuring the accurate injection of 100,000 cells 
in the small volume of 30µl. As all SJG6 + NICD xenografts were larger than SJG 
Blank xenografts over two separate experiments, it is unlikely that potential 
inaccuracies influenced comparative findings between the two cell lines. However, it 
may account for the range of histology observed. Another potential reason for 
histological discrepancies between tumours derived from the same cell line is where 
in the tongue the cells were injected and whether the needle could have moved to 
secondary locations. All cells were injected into the dorsal tongue using the same 
technique. However, the total mouse tongue is approximately 1cm long and 0.5cm 
wide. As such, it is difficult to ensure consistency between injection locations. 
Nevertheless, H&E staining revealed more of what appeared to be keratin 
pearls in xenografts derived from SJG6 Blank than SJG6 + NICD. This finding was 
further supported by Transglutaminase 1 staining, which revealed a lower 
differentiated tumour percentage in SJG6 + NICD xenografts. This data is consistent 
with in vitro data that recorded increased differentiation in the SJG6 Blank cell line. 
There is little known about the role of NOTCH1 on keratin pearl formation. However, 
this finding is inconsistent with the role of NOTCH1 as a promotor of differentiation 
in normal keratinocytes and oral SCC cells (Lowell, et al., 2000; Rangarajan, et al., 
2001; Nickoloff, et al., 2002; Nicolas, et al., 2003; Sakamoto, et al., 2012; Ravindran 
& Devaraj, 2012).  
As discussed in Chapter 3, it is predicted that SJG6 + NICD cells transformed 
with high levels of NICD underwent differentiation prior to forming the stable cell 
line. Therefore the SJG6 + NICD cell population is predicted to be made up of cells 
expressing lower, or wild type, levels of NICD. A colony formation assay comparing 
SJG6 + NICD cells with high mCherry expression (and therefore high NICD expression) 
to those with low mCherry expression was performed. Consistent with the differentiation 
hypothesis, the cells with higher NICD expression formed much fewer colonies (Figure 
3.7d). RT-qPCR also confirmed that the NICD mRNA expression in the SJG6-NICD line 
was approximately 65% of that recorded in two SCCHN lines wild type for NOTCH 
pathway genes (discussed in depth in section 3.5.4). Consistent with this finding, and as 
discussed in Chapter 4, Kagawa et al. showed that NICD expression could switch from 
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being a driver of cellular senescence to an active promotor of differentiation (Kagawa, 
et al., 2015).  
Histology observations based on pathological descriptions and images 
presented in the Atlas of Genetics and Cytogenetics in Ocology and Haematology, 
suggest that xenografts derived from SJG6 + NICD present with larger areas of 
comedo necrosis when compared to those derived from SJG6 Blank (Rousseau & 
Badoual, 2011). These findings are consistent with microarray data that associated 
NICD expression with increased cell death. The expression of NOTCH1 has also been 
positively associated with apoptosis in laryngeal and oesophageal SCC cell lines (Lu, 
et al., 2008; Jiao & Li, 2012). Comedo necrosis is often associated with basaloid SCCs, 
a highly aggressive and rapidly growing tumour type (Rousseau & Badoual, 2012). 
This data is consistent with the larger tumour volume recorded in SJG6 + NICD 
derived xenografts. As aforementioned, further experiments are required to investigate 
the nature of the advanced tumour growth.  
 The histological difference resulting from reduced differentiation and 
predicted increase in comedo necrosis in xenografts derived from SJG6 + NICD 
compared to SJG6 Blank may go some way to explaining the difference in tumour 
volume. Comedo necrosis forms when tumour cells undergo necrosis and die. The 
dead cells often attract other components, such as calcium, and form a ‘plug’. 
Conversely, keratin pearls are made up of tightly packed concentric circles of 
keratinized SCC cells. Therefore, the tumour area occupied by the same number of 
cells would be different. Further experiments would be required to confirm the 
pathological differences. This is explored further in Chapter 8. 
  
7.8.4 Despite significantly larger tumour areas, xenografts derived from SJG6 + 
NICD did not show more developed vasculature when compared to those derived 
from SJG6 Blank  
 
 Immunostaining showed Xenograft A of SJG6 Blank was the only tumour to 
present with a more developed vasculature. In combination with microarray data, that 
demonstrated reduced VEGF in response to NICD expression and predicted a general 
decrease in angiogenesis, this data is consistent with that of Sun et al. The group 
reported a reverse correlation between NOTCH1 and VEGF expression in oesophageal 
SCC (Su, et al., 2009). The remaining xenografts derived from SJG6 Blank and SJG6 
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+ NICD were found to have similar levels of angiogenesis. However, a key trigger of 
angiogenesis is a hypoxic environment, therefore, the significantly larger SJG6 + 
NICD xenografts would be expected to have increased angiogenesis (Liu, et al., 1995).  
 In the previous section, it was hypothesised that the larger tumour size in 
xenografts derived from SJG6 + NICD could be as a result of increased comedo 
necrosis. An alternative possibility is that the comedo necrosis was a consequence of 
tumours becoming too large without adequate angiogenesis. Further experiments 




 It is predicted that cells expressing NICD were at a selective disadvantage 
when transferred to an in vivo environment and were therefore lost in the xenografts 
by day 60. Despite the loss of NICD, a large fold increase (up to 267x) of SPANXA1/2 
was recorded in 4/6 SJG6 + NICD derived tumours compared to those derived from 
SJG6 Blank. It is therefore put forth that the expression of NICD is able to initiate an 
exaggerated and longer-lived increase in SPANXA1/2 in SCCHN. As NICD 
expressing cells are predicted to be lost from the population, it is also projected that 
induction of SPANXA1/2 expression must be non-cell-autonomous. 
 At the time of measurement, no difference in proliferation was recorded 
between SJG6 Blank- and SJG6 + NICD- tumours. However, SJG6 + NICD tumours 
were found to be significantly larger than those derived from SJG6 Blank. It is 
suggested that this may be due to histological variance. Observational studies provide 
evidence to suggest that xenografts derived from SJG6 Blank may harbour more 
tightly packed keratin pearls and less narcotic build-up, in the form of comedo 
necrosis, than those derived from SJG6 + NICD.  
However, this theory assumes that tumour size is a result of cell death. A 
potential alterative is that cell death occurs as a direct consequence of tumour size. 
Despite the significantly larger tumour areas of SJG6 + NICD- compared to SJG6 
Blank- xenografts, there was no recorded difference in angiogenesis; in fact, one SJG6 
Blank xenograft presented with a more developed vasculature. Therefore, cell necrosis 
may be as a result of hypoxia in the NICD tumour centre.  
Collectively, these findings indicate that NICD expression gives rise to larger 
local tumours with reduced cell proliferation, differentiation and survival. This chapter 
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provides preliminary data on the role of NICD in an oral SCC cell line in vivo. Due to 
time constraints, the role of NICD on EMT/MET was not explored in in vivo samples. 
This would be of interest in future experiments. In addition, it would be of interest to 
compare findings with xenografts from a SCCHN cell line wild type for NOTCH 
pathway members. Various avenues of investigation can be built upon these findings 





































This chapter collates and summarise the findings of the thesis as a reflection of the 
initial aims. Findings are considered within the scope of current literature and future 






The aim of this thesis was to investigate the role of NOTCH1 in SCCHN. A panel 
of 16 low passage oral SCC lines was available for the study. Whole exome sequencing 
data were obtained in collaboration with BGI, and Sanger sequencing confirmed the 
presence of two truncating mutations in the SJG6 cell line. Chapter 3 validates the 
lentiviral rescue of SJG6 via the transduction of the NICD. Chapter 4 compares the 
original and rescued cell line to investigate the role of NOTCH1 expression on 
clonogenicity, proliferation, morphology, differentiation and cell migration in vitro. 
Chapter 5 details the findings of a microarray to investigate how the rescue of 
NOTCH1 in SJG6 alters gene expression in the whole transcriptome. Notably, fold 
changes identified in the SPANX family (co-increased with NICD) were 3 x greater 
than those of any other gene. Chapter 6 investigates the effect of SPANXA1/2 knock-
down in the rescued SJG6 line. The cell proliferation, morphology, differentiation and 
migration assays developed in Chapter 4 were performed to investigate whether 
SPANXA1/2 played a role in mediating any NICD-induced phenotypes. Finally, 
Chapter 7 details xenograft experiments investigating the role of NOTCH1 in SCCHN 
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8.2 Conclusions and Future Directions  
 
This section will collate the results from each chapter of the thesis and consider 
how the findings have contributed to the understanding of the role of NOTCH1 in 
SCCHN. Specifically, the aims set out in the introduction of this thesis were to 
investigate the effect of NOTCH1 expression on the following cellular functions:  
 
 Tumour Growth 
 Differentiation 
 Migration and invasion 
 Angiogenesis 
 




 EdU assays provided evidence to suggest that the expression of NICD in SJG6 
gave rise to cells with a reduced proliferative potential in vitro. This finding was 
supported by microarray data. Analysis of the differentially expressed gene set 
between SJG6 Blank and SJG6 + NICD identified 5 cellular and molecular functions 
associated with cell proliferation that were predicted to be significantly reduced as a 
result of NICD expression. In addition, 3 of these networks were associated with 
reduced proliferation in the skin, epithelium and breast cancer cell lines. Finally, 
NICD-expressing cells were lost from a murine xenograft by day 60, suggesting they 
were at a selective disadvantage. 
These findings are consistent with several studies which ectopically introduced 
NICD into tongue, oral and oesophageal SCC cell lines (Duan, et al., 2006; Pickering, 
et al., 2013; Kagawa, et al., 2015). In addition, the inhibition of NOTCH1 in 
oesophageal epithelial progenitor cells has been shown to prevent differentiation and 
give rise to clonal expansion representative of field change (Alcolea, et al., 2014). 
Conversely, NOTCH signalling has been associated with a stem-like phenotype in oral 
and tongue SCC cell lines (Lee, et al., 2012; Upadhyay, et al., 2016). However, both 
of those studies looked at the effect of activating NOTCH signalling in lines wild type 
for NOTCH1, whereas this study considered the effect of rescuing NOTCH1 in lines 
with inactivating mutations. It is therefore predicted that the effect of NOTCH 
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signalling is highly dependent on timing and signal strength. Further, studies that have 
inhibited or knocked-down NOTCH1 in mice and tongue oral SCC lines have also 
shown reduced proliferation (Yao, et al., 2007; Yoshida, et al., 2013; Sun, et al., 2014). 
NOTCH1 is a key regulator of many cellular processes and is known to influence 
numerous signalling pathways. It is therefore possible that the complete knockdown 
of NOTCH1 and the constitutive expression of NICD could both result in reduced 
proliferative potential by two distinct mechanisms. 
 The expression of NICD has also been associated with G0-G1 cell cycle arrest 
and cellular senescence (Duan, et al., 2006; Pickering, et al., 2013; Kagawa, et al., 
2015). Morphological observations of senescent cells in SCCHN are conflicting. In 
this study, the expression of NICD in vitro gave rise to a smaller and more rounded 
cell population. This morphology is consistent with a description by Pickering et al. of 
senescence in oral SCC lines (Pickering, et al., 2013). However, Duan et al. recorded 
a more elongated cell population in response to NICD expression. The group suggested 
that this may be reflective of senescence, cell cycle arrest or apoptosis, but no 
validating experiments were performed. In addition, Kagawa et al. described the 
senescent cell morphology as flat and enlarged in oesophageal cell lines.  
There is evidence to suggest that the downregulation of Wnt / β-catenin 
signalling may act as a mechanism for cell cycle arrest in cell lines showing an anti-
proliferative effect in response to NOTCH1 expression in SCCHN (Duan, et al., 2006; 
Pickering, et al., 2013). Of note, in normal mouse epidermis, the deletion of β-catenin 
was not found to alter proliferation or differentiation of keratinocytes (Posthaus, et al., 
2002). The CSL and p16 signalling pathways have also been associated with NOTCH-
mediated cellular senescence in oesophageal cell lines (Kagawa, et al., 2015).  
Microarray analysis showed a down-regulation in the Wnt / β-catenin 
signalling pathway and an upregulation of CSL and downstream signalling molecules 
in response to NICD expression. The p16 pathway was unchanged. However, these 
results would need to be confirmed experimentally.  
In the skin, NOTCH induces cell cycle arrest via the induction of p21. 
Consistent with findings that suggest NICD enhances senescence in SCCHN, 
microarray data identified a 1.21 expression fold increase in p21 in response to NICD 
rescue (Rangarajan, et al., 2001; Mammucari, et al., 2005).  
Moreover, of the 3150 genes found to have greater than a 1.2 fold change 
difference in microarray analysis, 68 were found to be histones or histone regulators 
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(2.2%). Further, 62 of the 68 genes were found to be downregulated (91%). Histone 
gene expression is cell cycle regulated. Histone protein synthesis is restricted to the S-
phase of the cell cycle, coupled to DNA replication. During DNA replication, histones 
are essential for packaging DNA into chromosomes (Pogo, et al., 1966; Meshi, et al., 
2000). As such, a decrease in histone related genes is consistent with in vitro and 
microarray data correlating NICD expression with cell cycle arrest in SCCHN.   
Interestingly, the knockdown of SPANXA1/2 in the SJG6 + NICD cell line 
reverted changes in cell morphology i.e. cells became larger and less round. It is 
therefore possible that SPANXA1/2 may play a role in NOTCH-mediated cell 
senescence.  
Both SPANX and NOTCH1 have been associated with the maintenance of 
CSCs. Microarray and SPANXA1/2 knockdown data has confirmed a positive 
correlation between the expression of both genes (Upadhyay, et al., 2015; Wilson, et 
al., 2016; Shahin, et al., 2017). Further experiments would be required to ascertain if 
SPANXA1/2 and NOTCH1 are mutually exclusive regulators of CSCs or whether a 
common mechanism exists. However, this observation was not supported by in vitro 
data. A colony formation assay was used to assess the ability of single cells to undergo 
numerous rounds of self-renewal. The expression of NICD was found to give rise to 
reduced clonogenicity. Further, NICD expressing cells were lost from xenografts and 




 Evidence suggests that the knockdown of NOTCH1 and the constitutive 
expression of NICD can both lead to reduced proliferative potential in SCCHN cell 
lines. To further understanding of this potential dual function of NOTCH1, it would 
be interesting to inhibit NOTCH1 in cell lines wild type for NOTCH pathway members 
and compare cell behaviour to NICD-rescued NOTCH1 null cell lines.   
 Further, NICD expression in SJG6 has been suggested to induce cellular 
senescence, in line with current literature (Duan, et al., 2006; Pickering, et al., 2013; 
Kagawa, et al., 2015). Moreover, the senescent-like morphology was reversed by the 
knockdown of SPANXA1/2. In order to confirm the senescent phenotype, comparative 
β-galactosidase staining should be performed on both cell lines.  
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 If senescence is confirmed, it would be of interest to genetically target aspects 
of the Wnt / β-catenin signalling pathway as well as CSL and p21 to further understand 
the mechanism of NICD-mediated cellular senescence in SCCHN.  
 A number of studies have associated the expression of both NOTCH1 and 
SPANX family members with CSCs. A positive correlation was confirmed between 
the genes but colony formation assays suggested the expression of NICD gave rise to 
cells with reduced clonogenicity. Further analysis of the colony formation potential of 
the cell lines via serial passaging would be required.   
Further, in order to confirm that cells expressing NICD were at a selective 
disadvantage in the xenografts, the loss of NICD over the 60 day incubation period 
would have to be confirmed. RT-qPCR and immunohistochemistry analysis of NICD 
expression in xenografts collectedly weekly would provide a more dynamic picture of 
cell behaviour.  
The ‘big bang’ model of tumour growth describes how a cancer develops as a 
single uniform expansion of a large number of intermixed clones (Sottoriva, et al., 
2015). Each clonal unit is made up of a mixture of dividing and differentiating cells, 
and will compete for dominance within the cancer (Jones, et al., 2007; Keats, et al., 
2012). It would be of interest to investigate the effect of NICD expression on the 
clonogenicity of the SJG6 line by performing a lineage tracing experiment i.e. marking 






 As discussed in Chapter 3, it is predicted that SJG6 + NICD cells transformed 
with high levels of NICD underwent differentiation prior to forming the stable cell 
line. A colony formation assay comparing SJG6 + NICD cells with high mCherry 
expression (and therefore high NICD expression) to those with low mCherry expression 
was performed. Consistent with the differentiation hypothesis, the cells with higher NICD 
expression formed much fewer colonies (Figure 3.7d). This is consistent with the known 
role of NOTCH1 as a promotor of terminal differentiation in normal epithelium 
(Lowell, et al., 2000; Rangarajan, et al., 2001; Nickoloff, et al., 2002). In addition, the 
downregulation of NOTCH1 was found to inhibit terminal differentiation and give rise 
  
159 | P a g e  
 
to an immature epithelium in mouse skin (Nicolas, et al., 2003; Sakamoto, et al., 2012). 
Further, in oral SCC, poorly- and moderately- differentiated tumours have also been 
associated with low NOTCH1 expression (Ravindran & Devaraj, 2012).  
 The stable SJG6 + NICD cell population is therefore predicted to be made up 
of cells expressing lower, or wild type, levels of NICD. RT-qPCR also confirmed that 
the NICD mRNA expression in the SJG6-NICD line was approximately 65% of that 
recorded in two SCCHN lines wild type for NOTCH pathway genes. The SJG6 + NICD 
cell line was found to show decreased expression of Transglutaminase 1 (an epithelial 
differentiation marker) in vitro and in vivo and decreased keratin pearl formation in 
vivo compared to the empty vector control. These findings are consistent with work 
performed by Kagawa et al., who showed that in certain contexts NICD expression 
could switch from being a driver of cellular senescence to an inhibitor of 
differentiation in oesophageal SCC lines. However, inconsistent with microarray 
findings in Chapter 5, this checkpoint was associated with the reduced expression of 
p16 (Kagawa, et al., 2015). These findings suggest other mechanisms may be actively 
involved in mediating the effect of NOTCH1 on differentiation in SCCHN.  
Alcolea et al. investigated the conditional knock-out of NOTCH1 in a small 
percentage of oesophageal progenitor cells in a mouse model. The group demonstrated 
that within one year, the NOTCH1 knock-out cells had replaced the normal epithelium 
and entered a new state of homeostasis (Alcolea, et al., 2014). It is predicted that 
following differentiation of NICD-high expressing cells, the SJG6 + NICD line 
acquired a new steady state of proliferation and differentiation. Moreover, the 
expression of NICD has been found to inhibit differentiation in neighbouring cells 
(Bray, 2006). It is therefore possible that the presence of NICD-high expressing cells 
in the originally transduced cell population inhibited differentiation in the remaining 
cells and influenced the eventual steady state. However, this is highly speculative and 
more work is required before conclusions can be drawn.  
 
Further Experiments  
 
 A colony formation assay was performed to confirm the reduced clonogenicity 
of cells with high NICD expression post-FACS. In order to certify that these cells 
underwent terminal differentiation, it would be necessary to perform live cell imaging 
on the cultures for the weeks immediately following mCherry selection. The IncuCyte 
  
160 | P a g e  
 
Zoom would allow hourly monitoring with minimal disturbance to culture conditions. 
Further, RT-qPCR, Western Blot and immunohistochemistry analysis of 
differentiation markers at the RNA and protein levels respectively could be performed 
every 24hrs. As it is predicted that the differentiated cells eventually detach from the 
adherent culture, it would also be interesting to perform RT-qPCR analysis on any 
cells pelleted from the culture media. In order to assess whether the NICD high 
expressing cells were influencing differentiation in the remaining cell population, it 
would be informative to split the populations based on mCherry expression 
immediately after transduction and seed the cells both separately and in co-culture for 
comparison.  
 It would also be of further interest to investigate potential mechanisms that may 
be involved in mediating the effect of NOTCH1 on differentiation in SCCHN. IPA 
analysis of microarray data did not highlight any known molecular or cellular functions 
or networks associated with differentiation. However, microarray data provides a solid 
base and key resource for further exploration.   
Finally, Transglutaminase 1 was used to stain for differentiated cells. 
Transglutaminase 1 is an intermediate differentiation expression marker in normal 
epithelium, i.e. it is expressed in the granular and spinous layers. In future experiments 
it would be of interest to stain for earlier (such as Keratin 1 and 10) and later (such as 
filaggrin) markers of differentiation in vitro and in vivo in order to establish a more 
thorough picture of the whole differentiation process in both SJG6 cell lines.  
 




In tongue and laryngeal SCC, NOTCH1 protein expression has been positively 
correlated with both lymph node metastasis and the depth of tumour invasion (Joo, et 
al., 2009; Zhang, et al., 2011; Dai, et al., 2015). Moreover, strong NICD expression 
has been recorded in cells located at the invasive tumour front of oral SCCs (Yoshida, 
et al., 2013). In corroboration, functional studies have confirmed that the 
downregulation of NOTCH1 in SCCHN results in reduced invasive and metastatic 
phenotypes (Yu, et al., 2012; Yoshida, et al., 2013; Dai, et al., 2015; Li, et al., 2015; 
Jing, et al., 2016). Further, a reduction in cell migration was recorded in 
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hypopharyngeal SCCHN as a result of ADAM10 mediated downregulation of 
NOTCH1 (Jing, et al., 2016). 
As previously discussed, EMT is a developmental process in which epithelial 
cells lose cell-cell adhesions and polarity and acquire migratory mesenchymal 
phenotypes. This process is often re-activated in cancer and is associated with cell 
invasion. Mesenchymal to epithelial transition (MET) is the reverse process and allows 
metastatic cancer cells to seed at distant sites (Birchmeier, et al., 1996).  
Studies by Yoshida et al. suggest that the expression of NOTCH1 contributes 
to the maintenance of TNF-mediated invasion in oral SCC, which functions via the 
transcriptional regulation of SNAI2 and TWIST (Casas, et al., 2011). During EMT, 
TWIST is known to induce SNAI2 which supresses the epithelial phenotype; TWIST 
and SNAI2 then work together to promote EMT and metastasis. High NOTCH1 
expression has also been recorded in CSCs. The plasticity of CSCs to be able to 
undergo EMT/MET has been correlated with enhanced chemo-resistance (Capaccione 
& Pine, 2013; Biddle, et al., 2016).  
Furthermore, in order to undergo metastasis, cells must first detach from the 
primary tumour and degrade the basement membrane and surrounding ECM. MMPs 
are a family of enzymes involved in the degradation of ECM and are commonly up-
regulated in cancers. There is evidence to suggest that NOTCH1 is able to mediate 
metastasis via the regulation of MMP2 and MMP9 in lingual SCC (Yu, et al., 2012). 
Collectively, this data suggests a key role for NOTCH1 in EMT, metastasis and tumour 
invasion in SCCHN.  
Surprisingly, in vitro data in this study suggests that the expression of NICD 
reduces cell migration in SCCHN. This finding was supported by microarray analysis 
of the differentially expressed gene set between SJG6 Blank and SJG6 + NICD, i.e. 
six cellular and molecular functions associated with tumour cell invasion were 
predicted to be significantly reduced as a result of NICD expression. Further, in 
opposition to the above mentioned literature, microarray data analysis confirmed a 
decrease in the expression of MMP9 and SNAI2. Microarray analysis also showed a 
decrease in VEGF, a key gene in angiogenesis. The presence of EMT markers has been 
associated with pro-angiogenic protein expression. Both EMT and angiogenesis are 
key promoters of carcinogenesis and there is evidence to suggest that the same factors 
that promote EMT may also drive endothelial cells towards an angiogenic phenotype 
(Holderfield & Hughes, 2008; Ribatti, 2017). As such, findings provide evidence to 
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suggest NICD expression may give rise to reduced cell migration and EMT in the 
SJG6 line.  
As aforementioned, the expression of SPANXA1/2 was found to significantly 
increase in response to NICD. Interestingly, the knockdown of SPANXA1/2 reversed 
morphology changes recorded in the rescued SJG6 + NICD line i.e. cells become 
larger, less elongated and more rounded. In section 8.2.1, this morphology was 
postulated to be associated with cell cycle arrest. However, this change in morphology 
is also consistent with findings of Hsiao et al., who showed that expression of 
SPANXA was able to alter the morphology of lung adenocarcinoma from 
mesenchymal- to epithelial- like. SPANXA has been shown to supress EMT in lung 
adenocarcinoma by inhibiting c-JUN / SNAI2 signalling. As aforementioned, SNAI2 
was found to be decreased as a result of increased NICD expression in the SJG6 line. 
Together, this data provides evidence to suggest that increased NOTCH1 expression 
could supress EMT in SCCHN by upregulating SPANXA1/2 expression that in turn 
inhibits c-JUN/SNAI2 signalling (Hsiao, et al., 2016).  
In corroboration, the expression of SPANX B has been associated with the 
spontaneous differentiation of a colorectal cell line and the progression of these cells 
into MET. Conversely, the reversal of differentiation was shown to give rise to a 
downregulation of SPANX B and the induction of EMT markers (Yilmaz-Ozcan, et 
al., 2014). These findings are also consistent with in vitro and in vivo data showing 
increased differentiation in the SJG6 + NICD cell line. Moreover, microarray data also 
showed a decrease in vimentin, a key mesenchymal marker, in response to NICD 
expression (Leader, et al., 1987).  
Notably, the knockdown of SPANXA1/2 did not reverse the decreased 
migration recorded in the NICD-rescued line. In fact, the knockdown of SPANXA1/2 
gave rise to a further decrease in cell migration, suggesting that SPANXA1/2 may 
enhance cell migration by mechanisms distinct from its relationship with NOTCH1. 
Collectively, in vitro and microarray data in this experiment provide evidence to 
suggest that the expression of NOTCH1 in SCCHN may give rise to a decrease in cell 
migration. This is inconsistent with current literature (Joo, et al., 2009; Zhang, et al., 
2011; Yu, et al., 2012; Yoshida, et al., 2013; Dai, et al., 2015; Li, et al., 2015; Jing, et 
al., 2016).  
The up- and down- regulation of SPANX in other cancers has been shown to 
promote MET and EMT respectively (Yilmaz-Ozcan, et al., 2014; Hsiao, et al., 2016). 
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SPANX knockdown experiments were shown to reverse NICD-mediated cell 
morphology changes consistent with mesenchymal phenotypes. This provides 
preliminary evidence to suggest that NOTCH1 may promote MET via SPANXA1/2 
in SCCHN. Interestingly, literature has shown NOTCH to promote EMT via TNF-α 
mediated upregulation of SNAI2 (Casas, et al., 2011). Conversely, SPANX A has been 
shown to induce MET via the downregulation of c-Jun / SNAI2. It is therefore possible 
that NOTCH1 is able to promote both EMT and MET via the regulation of SNAI2 
expression by two distinct mechanisms. This hypothesis would be consistent with the 
association of NOTCH1 with distant metastases as successful metastasis requires the 
ability of cells to undergo both EMT and MET. This theory is also consistent with the 
increased expression of NOTCH1 recorded in CSCs which show highly effective 
EMT/MET plasticity (Capaccione & Pine, 2013; Biddle, et al., 2016). It is important 
to note that this hypothesis is highly conjectural. However, it provides an interesting 




 The next step would be to investigate the role of NOTCH1 expression on 
tumour migration and invasion in vivo. Xenografts derived from SJG6 Blank and SJG6 
+ NICD failed to form any metastases. As such, it would be preferable to increase the 
incubation period to allow more time for metastasis to occur. However, following the 
same experimental set-up, incubation time could not be increased as tumour size at 
day 60 required the culling of two mice on ethical grounds. A smaller starting cell 
number could be injected into the mice. However, it is worth noting that 50,000 cells 
were too few for successful tumour formation. Alternatively, it is possible to surgically 
remove the majority of the primary tumour to allow increased time for secondary 
growths to develop (Sano & Myers, 2009). RT-qPCR of resultant circulating tumour 
cells and lymph node metastasis can then be assessed for key genes such as MMP2 
and 9, TNF-, SNAI2, TWIST and SPANXA1/2.  
 Further, immunohistochemistry staining to NOTCH1 and SPANXA1/2 in the 
primary xenografts needs to be optimised. The localisation of NOTCH1 and 
SPANXA1/2 proteins in the tumour may provide valuable information into their role 
in migration and invasion in SCCHN.  
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 In order to investigate the potential role of NOTCH1 and SPANXA1/2 in 
EMT/MET, staining for validated epithelial (CDX2, claudin-4 and E-cadherin) and 
mesenchymal (vimentin, fibronectin and transgelin) markers in in vitro and in vivo 






 Microarray analysis of the differentially expressed gene set between SJG6 
Blank and SJG6 + NICD identified 9 cellular and molecular functions associated with 
angiogenesis that were predicted to be significantly reduced as a result of NICD 
expression. In addition, microarray analysis associated the expression of NICD with a 
decrease in VEGF, a direct stimulant of angiogenesis. Further, in vivo, Xenograft-A of 
SJG6 Blank was the only tumour to present with a more developed vasculature. 
Notably, a key trigger of neo-vascularisation is a hypoxic environment (Liu, et al., 
1995). However, even though xenografts derived from SJG6 + NICD were 
significantly larger than those derived from SJG6 Blank, there was no difference in the 
levels of angiogenesis.   
This data is consistent with studies that have shown an increased micro-vessel 
density in response to NOTCH1 expression in oral SCC lines (Joo, et al., 2009; Troy, 
et al., 2013). Findings also replicate work performed by Sun et al., who confirmed a 
negative correlation between NOTCH1 and VEGF in oesophageal SCC (Su, et al., 
2009). However, the opposite has also been shown in oral SCC (Joo, et al., 2009; Troy, 
et al., 2013). 
 
Further Experiments  
 
 Quantification is required to confirm that there is no difference in the extent of 
angiogenesis in xenografts derived from SJG6 Blank and SJG6 + NICD (excluding 
the previously noted Xenograft-A of SJG6 Blank). CD31 staining of all xenografts 
under identical conditions and subsequent imaging using the same image settings will 
need to be carried out. FIJI software can then be used to assess CD31 positive staining 
as a percentage of total tumour area.  
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 However, the extent of angiogenesis was relatively immature in all xenografts. 
It would therefore be of interest to extend the incubation period to allow a more 
developed vasculature to form. As discussed in the previous section, the incubation 
period cannot be extended without reducing the starting cell population. However, as 
a key trigger for angiogenesis is hypoxia, and the maximum tumour volume for the 
mouse model has been reached, a more developed vasculature may not be achieved. 
One option may be to implant into the cheek.  
 Although the mouse model is beneficial as it allows orthotopic xenografts to 
be performed, zebrafish models have strong advantages for the study of angiogenesis. 
Specifically, zebrafish are transparent in the early life stages. As such, the vasculature 
endothelial cells can be fluorescently labelled so tumour neovascularisation can be 
visualised in real time (Zhao, et al., 2015).  
Alternatively, tumour formation in mice with a conditional deletion of 
NOTCH1 in the tongue could be assessed (Conti, et al., 2015). Current work by Dr 
Inês Sequeira, a post-doc in the lab, has confirmed the successful derivation of oral 
tumours in mice via the introduction of 4-nitroquinoline-1-oxide (4NQO) into the 
drinking water (Kanojia & Vaidya, 2006). 
 In addition, a co-culture of SJG6 Blank and SJG6 + NICD with Human 
Umbilical Vein Endothelial Cells (HUVEC) would provide a simple and direct 
functional comparison of angiogenesis in the two cell lines in vitro. The sprouting of 
HUVEC cells is a well-established method of studying neo-vascularisation (Jaffe, et 
al., 1973; Skovseth, et al., 2007).  
 




 Investigating the effect of NOTCH1 on cell death in SCCHN was not part of 
the original aims of this thesis. However, microarray analysis of the differentially 
expressed gene set between SJG6 Blank and SJG6 + NICD identified 7 cellular and 
molecular functions associated with cell survival that were predicted to be significantly 
reduced as a result of NICD expression. In addition, xenografts derived from SJG6 + 
NICD presented with what histologically appeared to be large areas of comedo-type 
necrosis i.e. dead cell build up within the tumour body (Rousseau & Badoual, 2011). 
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 These findings are consistent with research associating NOTCH1 expression 
with apoptosis in laryngeal and oesophageal SCC cell lines (Lu, et al., 2008; Jiao & 
Li, 2012). Conversely, the knockdown of NOTCH1 in laryngeal SCC has also been 
shown to induce apoptosis (Dai, et al., 2015).  In addition, there has also been evidence 
to suggest that the curcumin-mediated downregulation of NOTCH1 induces cell death 
alongside the downregulation of Nuclear Factor- κB (NF-κB) in oral and oesophageal 
SCC (Liao, et al., 2011; Subramaniam, et al., 2012). Notably, NF-κB was not found to 




 Xenografts derived from SJG6 + NICD require staining for a dead cell marker 
to validate that the observed central mass is indeed dead cells. To my knowledge there 
are no specific markers for comedo-necrosis. However, the dead cells often attract 
other components, such as calcium, which can be stained for. Further, comedo-
necrosis is associated with an altered basal lamina and a more disorganised 
collagenous network (Halls, 2017). Further analysis at 40x magnification and the 
opinion of a trained histologist may provide more clarity. 
 In vitro assays can also provide a quicker and more readily reproducible 
comparison of the effect of NICD expression on cell death in SCCHN.  Hayes et al. 
established an assay to compare the response of cell lines to staurosporine-induced 
apoptosis that could be utilised (Hayes, et al., 2016).  
 
8.2.6 Future Directions  
 
 Beyond the original thesis aims, this study has highlighted some potential 
novel research avenues. Firstly, microarray analysis provided evidence to suggest that 
SERPINE1 may act as a key mediator of the effect of NOTCH1 expression on cell 
proliferation, migration and invasion, cell death and angiogenesis in SCCHN. NICD 
expression has previously been linked to the inhibition of SERPINE1 in thyroid cancer 
(Yu, et al., 2016). SERPINE1 has also been associated with increased cell migration 
in SCCHN (Pavón, et al., 2015). In addition, the expression of SERPINE1 in the 
tumour microenvironment has been shown to promote amoeboid cell behaviour 
associated with cell migration in the metastatic process (Cartier-Michaud, et al., 2012). 
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Largely, however, very little is known about the role of SERPINE1 in SCCHN or the 
relationship between SERPINE1 and NOTCH1.  
 Microarray analysis of the differentially expressed gene set between SJG6 
Blank and SJG6 + NICD also showed that of the 3150 genes found to have greater 
than a 1.2 fold change difference, 2.2% were found to be histones or histone regulators. 
Moreover, 91% of said genes were found to be downregulated. Histone variants have 
been identified in SCCHN and modifications have been associated with CSC plasticity 
(Le, et al., 2014; Song, et al., 2014; Vardabasso, et al., 2014).  To my knowledge, the 
potential relationship between NOTCH1 and histones is novel. Given the potential 
genome wide effect of histone alterations, this could be a promising avenue for further 
understanding the role of NOTCH1 in SCCHN. However, analysis of histone 
regulators in further SCCHN cell lines would first be required to ensure it is not a cell 
line dependent association.  
Finally, microarray analysis also identified a fold change increase in 
SPANXA1/2 expression 3x greater than any other gene in response to NICD. The 
expression of SPANX has been linked to poor prognosis in SCCHN (Yang, et al., 
2015). However, very little is known about the functional consequence of 
SPANXA1/2 expression SCCHN. The relationship between NOTCH1 and 
SPANXA1/2 expression is also novel. SPANXA1/2 is a potentially interesting gene 
for targeted therapeutics as it is largely tumour-specific and naturally induces an 
immunogenic response (Almanzar, et al., 2009). This thesis has begun to explore the 
relationship between SPANXA1/2 and NOTCH1 in SCCHN. However, assessment of 
immune response is not possible using NSG mice as they are immune-compromised 
to allow for effective xenograft formation. An assessment of human tissue samples for 
NOTCH1, SPANXA1/2 and immune cells would be required to assess potential 
relationships.  
SCCHN is a highly heterogeneous cancer. As such, it is essential that 
experiments validated using SJG6 are carried out on numerous cell lines with known 
genetic backgrounds. It would also be of interest to investigate whether the knock-
down of NOTCH1 in SCCHN cell lines wild type for NOTCH pathway members gave 
rise to corroborative results. The genetic landscape of a tumour will alter the action of 
single genes. For example, SJG6 is known to harbour mutations in other NOTCH 
pathway members which could influence the effect of NICD expression. In addition, 
microarray analysis showed that NICD is able to alter the expression of a number of 
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key oncogenes and tumour suppressors in SJG6. Of the top 20 altered genes, the 
expression change in 9 would suggest a tumour suppressor role for NOTCH1 in 
SCCHN, whereas the expression change of 4 would indicate an oncogene function. 
Further research would be required to see how these genes work together in SCCHN 
to alter phenotype. One possibility is that the expression changes in individual genes 
compete with each other and the ‘winning’ genes govern the resultant changes in cell 
behaviour. Alternatively, a single change in cell behaviour, such as EMT, could be 
responsible for expression changes in all genes.  
There are a number of conflicting studies assessing the role of NOTCH1 in 
SCCHN. A better understanding of the consequence of genomic differences, mutation 
combinations and disparate microenvironments on the action of NOTCH1 is required 
to best ascertain whether it is a viable therapeutic target in SCCHN. It is hoped that 
this work will provide a foundation for further exploration. 
 
 
8.3 Concluding Statement 
 
 Collectively, the findings of this thesis have provided evidence to suggest that 
the expression of NOTCH1 in SCCHN gives rise to the following cell behaviours: (1) 
reduced clonogenicity, (2) reduced proliferation, (3) increased differentiation in 
response to high NICD expression, (4) reduced cell migration and invasion, (5) 
increased cell death and (6) reduced angiogenesis. Together, these findings suggest a 
tumour suppressor role for NOTCH1 in SCCHN. However, considered within the 
framework of current literature, it is clear that NOTCH signalling is highly complex 
and context dependent.  
SERPINE 1 was highlighted as a potential regulator of NICD-mediated 
changes in cell behaviour. A high number of histone related genes were also found to 
be down-regulated in response to increased NICD expression. 
This study identified SPANXA1/2 as the most up-regulated gene in response 
to NICD expression. The fold change increase of SPANXA1/2 was 3x that of any other 
gene. In order to investigate the functional consequence of SPANXA1/2 expression, a 
shRNA system was used to knockdown SPANXA1/2 in the NICD-rescued cell line. 
Preliminary findings provide evidence to associate the expression of SPANXA1/2 
with increased cell proliferation, increase cell migration and changes in cell 
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morphology. Current literature suggests that changes in cell morphology may be 
associated with the inhibition of EMT and the induction of MET. However, data is 
preliminary and further studies are required. 
Ultimately, it is hoped that this research has contributed to understanding of 
the heterogeneity of SCCHN, specifically to the complex role of NOTCH1 signalling, 
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